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ABSTRACT 
 
Recently, there has been an explosion of interest in developing biopharmaceutical 
therapeutics for the treatment of life altering conditions. The main issue with the utilization of 
biopharmaceutical therapeutics is the mode of administration. The Oral Ghost Drug Delivery 
(OGDD) device could potentially enable the administration of these peptide therapeutics via 
the oral route and significantly extend the application of these advanced therapeutic 
compounds.      
 
The OGDD device is a drug delivery platform that can permits the oral administration of 
peptide therapeutics at a targeted location within the gastrointestinal tract. The OGDD is 
composed of four entities: the non-responsive shell component, peptide therapeutic loaded 
EDTA-mPEG trimethyl chitosan mini-pellet, Avicel®-EDTA-mPEG in situ hot melt dispersion 
mini-pellet, pH responsive acrylamide-methacrylic acid hydrogel trigger mechanism. The 
peptide therapeutic loaded EDTA-mPEG trimethyl chitosan was optimized with a Box-
Behnken design with the peptide insulin. For ethical and moral reasons, salmon calcitonin 
was substituted for insulin during the in vivo assessment of the OGDD. The Avicel®-EDTA-
mPEG in situ hot melt dispersion mini-pellet and the pH responsive acrylamide-methylacrylic 
acid hydrogel trigger mechanism was characterized with a textual analyzer with respect to 
swelling properties in biorelevant dissolution fluid, USP dissolution fluid and isolated 
gastrointestinal fluid. This analysis illustrates the impact of physiologically similar dissolution 
fluid will not only impact the release or solubilisation of drug compounds but also the 
physical behaviour of the drug containing matrix. In addition small molecular weight drug 
compounds from biopharmaceutical classification system (BCS) I, II and III. The release of 
these compounds from the hydrogel is not only impacted by the BSC class but also the 
physical response of the drug matrix to these environments. Differential scanning calorimetry 
was utilized for both the hydrogel and hot melt dispersion components of this device.  
 
The oral administration of salmon calcitonin from the OGDD device was assessed in the 
porcine model. The in vitro-in vivo correlation for the oral administration of salmon calcitonin 
within different dissolution fluids and isolated porcine gastrointestinal fluids was conducted. 
The biorelevant dissolution fluid of the canine model generated a closer in vivo-in vitro 
correlation in comparison with USP and human biorelevant dissolution fluids. The utilization 
of the OGDD device as a platform for the oral administration of peptide therapeutics was 
achieved and the device is extremely customizable in a mathematically deterministic 
manner.  
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CHAPTER ONE 
An Oral Ghost Delivery Device for Macromolecules 
 
1.1. An introduction to macromolecules and their application as therapeutic agents 
 
Macromolecules, such as peptides and proteins, are any relatively large compounds that are 
composed of uniquely distinct monomers (Brander et al., 2009; Bennet et al., 2009; Amidi et 
al., 2010; Karsdal et al., 2011). These monomers can be substituted with alternative 
monomer types to form an entirely new macromolecule. Proteins and peptides can be 
considered the most elegant examples of macromolecule compounds that contain uniquely 
combinations of amino acid monomers. Nucleic acids that form the DNA macromolecule is 
often considered the blue print to life but it is the peptide and protein macromolecules that 
imbues purpose and function to these blueprints. Medical and biological scientists have 
progressively unlocked the unique function of proteins and peptides which has lead to the 
exploitation of these macromolecules for medical intervention purposes.   
 
Over many years, proteins and peptides have been exposed to selective pressures that 
optimize the functionality and robustness of these compounds to generate some of the most 
potent compounds. An extreme example of this is botulism toxin from the bacterium 
Clostridium botulinum (Montecucco and Molgó, 2005; Kukreja and Singh, 2009). Botulism 
toxin is a protein that is extremely efficient at blocking acetylcholine release between 
neurons and is the most potent acute toxin described. It has been shown to have a human 
median lethal dose of 1.3-2.1ng/kg (intravenous administration) and 10-13ng/kg (inhalation 
administration) (Arnon et al., 2001). Ironically, this toxin is utilized as a protein therapeutic for 
US Food and Drug Administration (FDA) approved treatments of cervical dystonia, 
strabismus, severe primary auxiliary hyperhidrosis, blepharospasm, achalasia, migraine, 
bruxism and hemifacial spasm (Brin et al., 1999; Eisenach et al., 2005; Shukla and Sharma, 
2005; Felber, 2006; Naumann et al., 2008; Ranoux et al., 2008). Peptides have also been 
exploited for the treatment of chronic conditions such as type I diabetes (insulin) and 
osteoporosis (calcitonin) (Cui et al., 2009; du Plessis et al., 2010; Cheng and Lim, 2010; 
Chaudhury and Das, 2011). Protein or peptide macromolecules that have been exploited for 
medical intervention purposes are often referred to as peptide or protein therapeutics as an 
indication that the specific function of the macromolecule has been determined and is 
effective at the treatment of a specific ailment. An issue arising in tandem with the 
progressive development of peptide or protein therapeutics is the delivery of these large 
molecules in a manner that is accommodating for the patient. 
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1.2. Currently described strategies for oral delivery of macromolecular therapeutics 
 
The oral administration of macromolecular therapeutics is most preferable by patients 
because of the convenience and comfort associated with this mode of drug delivery (Chen et 
al., 2013). In addition, for some macromolecular therapeutics such as insulin, oral absorption 
within the small intestine has been suggested to be more representative of the natural 
physicological distribution of the therapeutic within the systemic circulation than 
subcutaneous adminstration (Rekha and Sharma, 2013). Insulin is secreted into the hepatic 
portal vein in response to an increase in blood glucose levels and transported to the liver 
(Rekha and Shama, 2013). Parenteral administration of insulin will initially bypass the liver 
which may negatively impact the body’s natural response to insulin (Still, 2002; Federwisch 
et al., 2002; Rekha and Shama, 2013). The administration of insulin that more closely 
represents the innate physiologically means of distributing insulin to the liver may enhance 
the effectiveness of auxiliary biochemical pathways that can control blood glucose levels. 
The main challanges of orally administering peptide therapeutics is (i) by-passing the acidic 
gastric environment, (ii) circumventing the gastric peptidase enzymes, (iii) mucus barriers 
that exist within the gastrointestinal tract (GIT) and (iv) permeating intact peptide 
therapeutics through the GIT epidermis and into the systemic circulation (Torres-Lugo et al., 
2002; Cui et al., 2009; Sajeesh et al., 2010a; Huang et al., 2011; Rekha and Sharma, 2013). 
There are three main formulation approaches that have been employed to achieve an 
effective oral administration of peptide therapeutics. 
 
The first approach is the development of nanoparticle based systems that enhances oral 
delivery of peptide therapeutics by possessing a high surface area to volume ratio (Rekha 
and Shama, 2013). An example of this approach can be reviewed in Foss et al. (2004) 
whereby the researched utilized methacrylic acid grafted poly(ethylene glycol) to generate 
nanospheres that were pH responsive. The nanospheres were administered to rats and to 
lower blood glucose levels for 6 hours (Foss et al., 2004). The main issue with this study was 
that the dosage form was administered in gelatine capsules to a 200g rat which has a very 
low representation with respect to a human model. There are many other examples of this 
approach which can be reviewed in Reis et al. (2008), Cui et al. (2009), Sonaje et al. (2009) 
and Makhlof et al. (2011). The second approach is the administration of microparticles that 
may convey increased functionality with respect to drug delivery applications (Rekha and 
Shama, 2013). For instance, Lowman and co-workers, administered insulin loaded in 
polymethyacrylic grafted polyethylene glycol microparticles that prevented the release of 
insulin within the gastric environment but also facilitates the effective penetration within the 
mucosal layer in the intestinal environment (Lowman et al., 1999). A major drawback was 
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once again the microparticles were administered to 200 g rats in a gelatine capsule which 
rapidly degrades in the stomach (Lowman et al., 1999). The stomach of the human model 
has a far greater volume than the rat model and the stomach has an extremely thick mucus 
layer (Kerss et al., 1982; Copeman et al., 1994; Jordan et al., 1998; Lowman et al., 1999). 
The thick mucus layer of the stomach may easily entrap microparticles and reduce the 
effective absorbed dosage. A further example of the microparticle approach can be reviewed 
in Sajeesh and co-workers, whereby two functional groups were utilized to achieve an 
effective oral insulin absorption (Sajeesh et al., 2010a,b). Lastly, lipid based approaches 
have been attempted because it has been indicated that these systems have low acute 
toxicity and high biocompatibility properties (Torchilin, 2005; Almeida and Souto, 2007; 
Rekha and Shama, 2013). An example of this approach is where solid lipid nanoparticles 
were administered to rats and achieved in vivo absorption of orally administered insulin 
(Zhang et al., 2006). Additional examples of oral administration of insulin can be reviewed in 
Table 1.1. This table contains some examples of drug delivery systems that were assessed 
in vivo. The gap is that of upscaling to a larger in vivo model as many of these drug delivery 
solutions were suspensions. A suspension may not achieve the desired response in larger 
animal models due to the increased volume of distribution.  
 
 
Table 1.1 Summany of drug delivery systems for the oral administration of insulin  
Authors Year 
Published 
Drug 
delivery 
system 
Status Significant results Specific 
further 
steps 
required 
Sarmento et al. 2007 Insulin loaded 
alginate/chitosan 
nanoparticles 
Further 
development 
is required 
Particles had a 
mean size of 750nm 
Lowered basal 
glucose levels by 
more than 40% over 
18 hours in diabetic 
rats 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
Lin et al. 2007 Insuline loaded 
chitosan/ 
poly(γ-glutamic 
acid) 
nanoparticles 
Further 
development 
is required 
Particles had a 
mean size of 110-
150nm 
Transiently opens 
tight junctions 
Lowered basal 
glucose levels for 10 
hours in rats 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
Yin et al. 2009 Insulin loaded 
trimethyl 
chitosan-
cysteine 
nanoparticles 
Further 
development 
is required 
Particle size 100-
200nm 
Trimethyl chitosan-
cysteine increased 
transport of insulin 
and resulted in a 
35% decrease in 
glucose level after 8 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
4 
 
hours within rats 
He et al. 2012 Insulin loaded 
Poly(ester 
amide) 
microspheres 
Further 
development 
is required 
Reduce basal 
glucose level by 
49.4% within 5 
hours until an 8 hour 
period had elapsed 
within rats 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
Xong et al. 2013 Insulin loaded 
Pluronic P85/ 
poly(latic acid) 
vesicles 
Further 
development 
is required 
Vesicle diameter 
was 178nm 
Basal glucose level 
decreased after 2.5 
hours following oral 
administration in 
mice 
Basal glucose level 
remained stable at 
31.8% of initial 
blood glucose level 
for 14 hours 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
Chuang et al. 2013 Insulin loaded 
EGTA-
conjugated 
poly(γ glutamic 
acid) 
and chitosan 
nanoparticles 
Further 
development 
is required 
Significantly 
increased 
paracellular 
permeability 
Insulin present in 
heart, aorta, renal 
cortex, renal pelvis 
and liver after 
administration to 
rats 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
Mukhopadhyay 
et al. 
2014 Insulin loaded 
N-succinyl 
chitosan 
grafted 
polyarylamide 
hydrogel 
Further 
development 
is required 
pH sensitive with 
respected to the 
tested USP gastric 
and USP intestinal 
dissolution media. 
Bioavailability of 
insulin was ~4.43% 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
Nielsen et al. 2014 Insulin 
coadministered 
with 
penetratin 
Further 
development 
is required 
Half-life of insulin 
increased from 
24.9min to 90.5min 
in the presence of L-
penetratin and D-
penetratin 
Upscaling 
of the 
dosing into 
larger in 
vivo models 
 
  
1.3. Rationale and motivation for this study 
 
An innovative small intestinal targeted drug delivery device may overcome the limitations of 
the oral delivery of peptide therapeutic, therefore enhancing patient compliance, efficacy and 
reducing toxicity. This may be achieved with a combination of strategies that limits 
presystemic enzymatic degradation, site specific targeting within the small intestine, the use 
of permeation enhancers and mucoahesives across a synergistic platform. Chronic 
administeration of peptide therapeutics (such as calcitonin and insulin) is usually delivered 
as subcutaneous or intramuscular injections at a high dosing frequency (three times a week 
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to three times a day). Some of these macromolecules often require daily dosing which is 
painful and inconvenient for the patient. The proposed Oral Ghost Drug Delivery (OGDD) 
device may be taken orally once or twice a day, depending on the type of peptide 
therapeutic and the condition that is being treated. The OGDD protects the peptide 
therapeutic from the harsh gastric environment and releases the peptide therapeutic at a 
targeted location within the small intestine. In addition, the OGDD device provides a platform 
for the oral administration of peptide therapeutics in a manner that promotes successful 
absorption in a multi-approach strategy without the utilization of highly variable suspensions 
and within a large animal model.  
 
The comparison between isolated fasted state fluids from the GIT tract of Large White the 
pig model would aid significantly in generating a tighter correlation between the pig model, 
human biorelevant fluids and USP dissolution fluids. Acquired data from these comparisons, 
correlations and basic chemical profiling could be used in future for in vitro oral drug 
dissolution studies that would reduce development time and reduce the potential in vivo 
failure of an oral drug delivery system. In addition, the in silico analysis of the dissolution and 
disintegration behaviours could be used to generate disintegration kinetics of novel 
excipients that would assist in formulating enhanced in vivo relevant mechanisms. 
 
1.4. The Oral Ghost Delivery Device for the delivery of macromolecules within the 
therapeutic peptide class of drugs 
 
The Oral Ghost Drug Delivery (OGDD) device comprises a non-responsive non-degradable 
shell component was produced from United States Food and Drug Administration (FDA) 
approved plastic, Polystone® M. Polystone® M is a very had plastic with low water retention 
and is utilized within surgical implants during knee and hip operations. This plastic has 
demonstrated a biocompatibility that can be maintained within the body for an extended 
period of time. Due to these properties, Polystone® M is is an ideal material as it provides 
structure to the OGDD and has previously demonstrated biocompatibility. A dynamically 
equilibrating stimuli responsive hydrogel was placed within the base of the shell component. 
The stimuli responsive hydrogel was utilised to displace the peptide-loaded trimethyl 
chitosan chloride mini-pellet and the ethylenediaminetetraacetic acid (EDTA) in situ hot melt 
dispersion mini-pellet from the OGDD device. A peptide-loaded trimethyl chitosan chloride 
mini-pellet (TMC:Cl MiPe) was utilised as the drug carrier within the drug delivery system. An 
EDTA in-situ suspension mini-pellet was utilised to release EDTA within the targeted delivery 
site to transiently inhibit zinc-peptidase enzymes and reduce mucus viscosity by chelating 
zinc and calcium divalent ions respectively. A Eudragit® cap was utilised to facilitate the 
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release of the mini-pellets within the target location and to facilitate the generation of a 
positive pressure within the OGDD device. The positive pressure enabled the mini-pellets to 
be released within the small intestine at approximately the same time and at relatively the 
same location (throught the synergistic degradation of the Eudragit® cap and the displacing 
force of the pH sentive hydrogel). The design of the OGDD device is shown in Figure 1.1.  
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Figure 1.1: Schematic of the Oral Ghost Delivery Device (OGDD) components and mechanism of 
action within the GIT. The Eudragit
®
 cap (1) becomes soluble as the pH increases within the GIT tract. 
The dynamically equilibrating hydrogel (2) dramatically increases in volume in response to increasing 
pH of the GIT tract. The increase in volume of the dynamically equilibrating hydrogel displaces the 
EDTA in situ suspension mini-pellet (3) and the peptide-loaded trimethyl chitosan mini-pellet (4) at 
close relative position along the small intestine. EDTA is released from the mini-pellet and the peptide 
therapeutic is released from the trimethyl chitosan mini-pelle, thereafter absorption takes place in the 
jejunum-ileum region of the small intestine (5). 
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Figure 1.2: The assembly of the Oral Ghost Delivery Device with size dimensions 
 
1.5. Aim and Objectives of this study 
 
The aim of this study was to develop an Oral Ghost Drug Delivery (OGDD) device that 
enabled effective targeted oral delivery of macromolar therapeutic, which are primarily 
peptide therapeutics. Additionally, an in vitro/ex vivo/in vivo correlation of orally administered 
peptides namely salmon calcitonin will be evaluated with respect to USP dissolution fluid, 
biorelevant dissolution fluid and isolated gastrointestinal fluids from large White Pig model. 
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9 
 
The following objectives are outlined for the aim:    
 
1) Synthesis and characterization of a pH responsive superporous hydrogel  
2) Conduct release studies with a number of drugs for BCS I, II, III from hydrogel 
3) Synthesis and characterization of methoxypolyethylene glycol-
ethylenediaminetetraacetic acid-Avicel® in situ hot melt dispersion mini-pellets  
4) Synthesis and characterization of therapeutic peptide loaded EDTA-mPEG trimethyl 
chitosan mini-pellets utilizing a Box-Behnken design and formulation characterization 
5) Engineer a non-biodegradable non-responsive shell component from FDA approved 
food-grade plastic to facilitate the release of the mini-pellet dosage forms at the 
desired GIT location 
6) Assemble and conduct in vitro analysis of the Oral Ghost Drug Delivery device 
7) Conduct preclinical animal studies within Large White pigs for in vitro/ex vivo/in vivo 
pharmacokinetic analysis  
 
1.6. Overview of the thesis 
 
Chapter 1 introduces the issues associated with the current mode of administration of 
macromolecular therapeutics and the rationale for the study.  A brief background and 
introduction of the Oral Ghost Delivery Device design and conception is summarised. The 
aims and objectives of the study are outlined.  
 
Chapter 2 is an extension of Chapter 1 whereby an in-depth literature review focuses on the 
currently known aspects of orally administered therapeutic peptide delivery through the 
utilization of permeation enhancers to achieve enhanced absorption within the small 
intestine. The in-depth literature analysis of the permeation enhancers and strategies utilised 
for this drug delivery system is reviewed. 
 
Chapter 3 describes the development of the metal chelator component of the OGDD device 
that overcomes some of the zinc-dependent peptidase and mucus viscosity issues 
associated with the oral administration of peptide therapeutics. A number of EDTA-mPEG in 
situ hot melt dispersion mini-pellet formulations are investigated in order to achieve the most 
desirable formulation properties.  
 
Chapter 4 describes the development of the pH responsive hydrogel that facilitates the 
displacement of loaded mini-pellet solid dosage forms from the Oral Ghost Drug Delivery 
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device within the targeted small intestinal environment. An indepth physicochemical and 
physicomechanical characterisation of the pH responsive hydrogel within representitive 
dissolution fluids and ex vivo performance was evaluated. 
 
Chapter 5 describes the development of the peptide-loaded trimethyl chitosan mini-pellet 
formulations that are loaded into the Oral Ghost Delivery Device. A Box-Behnken factorial 
design coupled with physicomechanical and dissolution studies was utilised to generate an 
optimised formulation for the peptide drug carrier. This formulation overcame additional 
issues associated with oral administration of peptide therapeutics such as intraluminal loss 
of peptide from peptidase enzymes and non-specific targeting within the GIT. 
 
Chapter 6 describes the development of the final components, the non-responsive non-
degradable shell component and the Eudragit® cap. A finalised OGDD device was 
assembled and administered to the Large White pig model. A comparative in vivo study of 
the orally administered Oral Ghost Delivery Device with respect to intramuscular 
administration of salmon calcitonin was undertaken and descibed. These components 
facilitate the engineered mechanism for the delivery of the mini-pellet solid dosage forms to 
the targeted location of the jejunum and ileum of the small intestine. 
 
Chapter 7 provides the conclusions and recommendations of the study. These conclusions 
and recommendations describe the scientific direction that could be utilized to further 
enhance the OGDD device for therapeutic applications. 
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CHAPTER 2 
Orally Administered Therapeutic Peptide Delivery: Enhanced Absorption Through the 
Small Intestinal Wall Utilising Permeation Enhancers 
 
2.1. Introduction 
 
Peptide therapeutics are relatively small molecules (fifty or less amino acids or a maximum 
molecular weight of 5000Da) which may contain a specific sequence of amino acids joined 
together by peptide bonds resulting in a highly specific secondary structure, but absent of 
tertiary structure, that induces a rapid and highly specific beneficial response (Johnson, 
2005; Sato et al., 2006; Giuliani et al., 2007; Oyston et al., 2009; Tshala-Katumbay, 2010). 
Peptide therapeutics are currently one of the most advanced pharmacologically active 
compounds which may replace many traditional small molecule drug compounds as 
technological advances and economically feasible production methodologies are 
implemented within the industrial setting. Additionally, innovative and novel means that allow 
peptide therapeutics to be conveniently administered to patients in an acceptable manner 
need to be sought after in order to achieve an optimal pharmaceutical product that would 
significantly enhance medical treatment. The main focus of this review is therefore to provide 
a critical overview of peptide therapeutics and the means by which they may be desirably 
administered orally. 
  
2.1.1. Macromolecular therapeutics 
  
Presently, over 60 peptide therapeutics (PTs) are available and hundreds are in clinical 
development (Degim and Celebi, 2007; Vlieghe et al., 2010; Agyei and Danquah, 2011). The 
contemplation of the extraordinary amount of research and development invested into PTs, 
highlights their assured existence within the market place (Loffet, 2002; Bray, 2003; Guzman 
et al., 2007; Stevenson, 2009; Vlieghe et al., 2010). This is evidenced by an estimated PTs 
market value of US$15.7 billion in the year 2013 (Pichereau and Allary, 2005). Moreover, in 
the year 2004, peptides, proteins, and antibodies had an estimated sales value of US$40 
billion which accounted for 10% of the total pharmaceutical sales in that year (Decaffmeyer 
et al., 2008; Vlieghe et al., 2010). PTs are tremendously valuable therapeutic agents which 
are composed of a very specific sequence of amino acids. The composing amino acid 
sequence within PTs determines the three dimensional structure of these compounds and 
therefore influences the specific extracellular receptor that the peptide therapeutic physically 
interacts with (Oyston et al., 2009). The composing amino acid sequence also determines 
the charge that the peptide therapeutic exerts, thus influences the extracellular receptor that 
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the peptide therapeutic chemically interacts with (Yeaman and Yount, 2003). The charge 
and the three dimensional structure of PTs is extremely crucial for a desired therapeutic 
outcome to transpire. Any interference with the sensitive make-up of a peptide therapeutic 
will render the entire macromolecule inactive. PTs are considered to have many advantages 
over established small molecule therapeutics but also have many distinctive disadvantages 
(Vlieghe et al., 2010). 
 
The core issues surrounding the use of PTs in daily treatment is the prohibitive expense of 
these agents, their availability and sensitivity to degradation. The price of PTs and the 
availability of PTs can be considered as related issues since even readily available 
therapeutic agents may be expensive due to the unrefined material requirements or vast 
processing measures. PTs may clearly be prohibitively expensive if their availability is 
restrictive. A classical example is the production of recombinant human insulin by 
Escherichia coli (E. Coli) (insulin was firstly commercially available as animal insulin) in 1982 
under the trade names Humulin® in USA and Humuline® in Europe (Ferrer-Miralles et al., 
2009). Insulin was originally acquired from the pancreas of pigs and cattle in abattoirs but 
since 1982, diabetics have progressively purchased recombinant human insulin derived from 
E. Coli (Ferrer-Miralles et al., 2009). A 3mL vial of Humuline® with a concentration of 
100IU/mL can cost between US$40 and US$70 as of July 2010, which is considerably less 
expensive when compared to the difficulty incurred in acquiring insulin derived from the 
pancreas of cattle or pigs. Even though infinite potential amounts of recombinant human 
insulin can be produced from E. coli, the purification and isolation processes from massive 
vats of E. coli, adds some substantial overheads. Another example is enfuvirtide that took up 
to 8 months to synthesise and 106 steps to increase the scale of its production to a multi-
tonne per year operation (Bray, 2003; Vlieghe et al., 2010). Enfuvirtide has been used as a 
drug model to reduce the large scale production cost of peptides to less than US$1 per 
amino acid residue, therefore the potential cost of peptide drugs could be decreased 
significantly in the future (Bray, 2003; Vlieghe et al., 2010). This is a demonstration of the 
biotechnology industry filling the ever growing need for a peptide therapeutic at an 
economical feasible level. The advantages and disadvantages of peptide therapeutics with 
respect to recombinant proteins, small drug molecules and antibodies are showen in Table 
2.1. 
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Table 2.1 Advantages and disadvantages of peptide therapeutics over recombinant proteins, small 
drug molecules and antibodies. 
Advantages Reference 
Deeper infiltration into tissues 
Reduced immunogenic profile 
McGregor, 2008; 
Vlieghe et al., 2010 
  
Less cost of manufacture 
Higher activity ratio (activity per unit mass) than antibodies 
Reduced upstream patents which downstream firms have to acquire 
due to reduced intellectual property rigidity 
Greater stability than recombinant proteins and antibodies 
Ladner et al., 2004; 
Vlieghe et al., 2010 
  
Peptide therapeutics are the smallest functional element of a protein 
therapeutic macromolecule, therefore peptide therapeutics have 
greater efficacy, selectivity and specificity than small drug molecules. 
Hummel et al., 2006; 
Vlieghe et al., 2010 
  
Peptide therapeutics degrade to amino acids hence reduces the 
probability for drug-drug interactions which limits adverse effects. 
Loffet, 2002; Vlieghe et al., 
2010 
  
Less potential to amass in tissues and organs due to short half life 
thereby limiting the adverse effects. 
Vlieghe et al., 2010 
  
Small quantities of agonistic peptides are required to activate 
targeted receptors. 
Hruby, 2002; Vlieghe et al., 
2010 
 
  
Disadvantages Reference 
  
Potential of immunogenic reactions due to an extensive period of 
exposure or poor peptide therapeutic design. 
 
Restricted systemic transport in contrast to small drug molecules. 
 
Inadequate movement through biological membranes due to the 
general hydrophilic nature of peptide drugs. 
 
Rapidly cleared from the systemic circulation rapidly through 
hepatic and renal clearance. 
 
Extensively metabolised by excessive protease enzyme 
concentrations within the stomach, intestinal lumen and intestinal 
brush boarder. 
 
Limited absorption in the gastrointestinal tract therefore parenteral 
administration is often required. 
 
Peptide therapeutics has the potential to have distorted three 
dimensional structures due to pH variation, protease activity or ionic 
stress that may activate alternative receptors resulting in adverse 
effects. 
Guichard, 2004; Pichereau 
and Allary, 2005; Vlieghe et 
al., 2010 
  
Incredibly expensive to synthesise and/or produce depending on 
the molecular weight of the peptide drug. 
Guichard, 2004; 
Pichereau and Allary, 2005; 
Bray, 2003; 
Vlieghe et al., 2010 
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Parenteral administration of peptide therapeutics is extremely expensive with respect to 
orally administered therapeutic compounds. The injection needles, injection plungers and 
saline solution each require thorough sterilisation to prevent infections at the injection site or 
systemically. With the increase in PTs availability, a Drug Delivery System (DDS) which can 
administer these therapeutics without the experience of needle injections will become 
extremely important. An essential consideration for a DDS is to diminish the quantity of 
peptide therapeutic which is lost during the administration process so that the cost of the 
DDS can be minimised, thus allowing patients financial access to the DDS. A demonstration 
of the encompassing capacity in which PTs have been employed in diseased states and 
diagnostic purposes can be seen in the six examples listed under Section 2.1.2. 
 
2.1.2. Parenteral administration of peptide therapeutics 
 
PTs are currently administered primarily by the parenteral route though modes such as 
intramuscular injections (I.M.), subcutaneous injections (S.C.) and intravenous 
administration (I.V.). These modes of administration are used for PTs for the following 
reasons: 
 
 Guarantee that the complete PTs dose is delivered to the systemic circulation therefore 
ensuring that the therapeutic index is achieved. 
 Circumvent first pass metabolism so that the lowest amount of PTs is required, which 
reduces the cost of the therapeutic to the patient. 
 Circumvent pre-systemic metabolism in the stomach and intestine which also ensures 
that the lowest quantity of PTs is administred to attain the desirable therapeutic level. 
 
These reasons are extremely valid for administration of expensive PTs but as with any route 
of administration there are certain disadvantages as listed below: 
 
 Pain coupled with parenteral administration reduces patient compliance. 
 Inconvenience of using injections and I.V’s. 
 Expenditure encompassed in using sterilised needles, injection plungers, I.V. bags, saline 
and catheters. 
 
The advantages and disadvantages of parenteral administration have to be weighted 
carefully, especially if the PTs are intended for an extended period of time or even over a life 
time. This is often encountered in disease conditions such as osteoporosis, human 
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immunodeficiency virus (HIV) or type 1diabetes. These diseased states necessitate frequent 
administration of PTs ranging from three times a week to three times daily. More than 80% 
of the most lucrative pharmaceutics are administered via the oral route (Lennernäs and 
Abrahamson, 2005). 
 
One approach to augment the oral bioavailability of PTs is to modify the biologically 
synthesised peptide, such as salmon calcitonin, by adding functional groups or molecules 
that reduce proteolytic enzymes activity on a specific peptide (Cheng and Lim, 2010). 
Modification of these PTs may occur by PEGlyation where specific amino acids within the 
backbone of the peptide, are modified by the addition of polyethylene glycol (PEG) and this 
reduces the activity of proteolytic enzymes (Cheng and Lim, 2010). These engineered 
macromolecule therapeutics are often considered synthetic as they are manufactured in the 
laboratory. Below is a list of some interesting peptide therapeutics that demonstrates their 
wide activity: 
 
1) Corticorelin trifluoroacetate, known by the trade name Acthrel®, is a potent stimulator of 
adrenocorticotropic hormone (ACTH) which is released from the anterior pituitary. This 
synthetic peptide contains a 41 amino acid sequence and induces ACTH to stimulate 
cortisol production in the adrenal cortex. Acthrel® is produced by both Ferring Pharms 
and Biovail Pharms and is used in the diagnosis of ACTH-dependent Cushing’s 
syndrome as well as in the treatment of hypertension. 
2) Enalapril maleate, known by the trade name Vasotec®, is considered a long-acting 
angiotension converting enzyme (ACE) inhibitor drug. Vasotec®, a prodrug, is unique as 
this peptide therapeutic is administered orally and dependent on activation (via 
hydrolysis) in the gastrointestinal tract. In addition, Vasotec® has a sequence of 3 amino 
acids only but it is still capable of exerting a significant biological response.  
3) Enfuvirtide, known by the trade name Fuzeon®, is a fusion inhibitor peptide drug aganist 
the HIV-1 virus. Fuzeon® binds to the gp120 receptor on the HIV-1 protein coat which 
prevents the HIV-1 virus from fusing with CD4 receptors on mammalian cells. Fuzeon® 
has a 36 amino acid sequence and is produced by Roche. Enfuvirtide is used together 
with HAART therapy to further reduce the viral load in HIV-1/Aids. 
4) Human calcitonin, know by the trade name Cibacalcin®, is a polypeptide hormone drug. 
Human calcitonin is used to reduce osteoclastic osteolysis in the bone and to reduce 
mineral removal from bone. Human calcitonin also promotes renal excretion of calcium 
thus contributing to the reduction of pain symptoms in skeleton joints. Human calcitonin 
has a 32 amino acid sequence and is primarily administered via intramuscular or 
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subcutaneous injections. Cibacalcin® is produced by Novartis Pharma and is used in 
adults for postmenopausal osteoporosis, Paget’s disease and hypercalcaemia. 
5) Bivalirudin trifluoroacetate hydrate, known by the trade name Angiomax®, is an 
intravenously administered synthetic peptide drug. Bivalirudin trifluoroacetate hydrate 
works in the cardiovascular system by specifically and reversibly inhibiting thrombin 
activity, thus acting as an anticoagulant. Angiomax® has a 20 amino acids sequence 
and is produced by Nycomed Pharma. Bivalirudin trifluoroacetate is used in patients 
with unstable angina undergoing percutaneous transluminal coronary angioplasty or 
percutaneous coronary intervention. 
6) Ziconotide acetate, known by the trade name Prialt®, is an intrathecal administered 
synthetic peptide. Ziconotide acetate is a central nervous system drug which has a 25 
amino acids sequence. Ziconotide acetate is an interesting peptide drug because it is 
administered using a programmable implantable micro-infusion device with a variable 
rate of dosing. Ziconotide is produced by Elan Pharm and is used in patients to elicit 
relief of severe chronic pain which is refractory to other treatment methods.  
 
Recently “bioidentical” hormones, which can also be modified in laboratories, have entered 
the marketplace. Bioidentical hormones are plant derivatives that have been chemically 
modified to have the same three dimensional structures as naturally synthesised hormones 
(Chervenak, 2009). A large number of these bioidentical hormones are not FDA approved 
but many women are using them with the hope that they may avoid the potential side effects 
of FDA approved hormonal therapeutics (Boothby et al., 2004; Hickey et al., 2005;  
MacLennan, 2008). Any further discussion on the “bioidentical” hormones falls outside of the 
latitude of this literature review but it should be appreciated that these “bioidentical” 
compounds do not count towards an FDA approved peptide therapeutic market.  
 
The exploitation of polymers (such as chitosan, polyacrylic acid, poly(methyl acrylic) acid, 
cellulose, and many more) is another approach that has been demonstrated to be a budding 
solution to this quandary. Polymers, according to many researchers, are exceedingly 
adaptable with unique influence over biological membranes and in biological environments. 
An elaborate description of chitosan and trimethyl chitosan will be provided in detail as these 
polymers not only demonstrate mucoadhesive properties but also permeation enhancing 
activities (Mourya and Inamdar, 2009). Drug delivery systems using polymers have been 
shown to enhance the therapeutic outcome significantly but presently drug delivery systems 
which are based on chitosan polymers have not been approved by the FDA. Currently there 
are only two chitosan products namely Celox and Bandage, that have been approved for use 
in humans but they are not under the drug delivery systems category (Baldrick, 2010). Celox 
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is a chitosan based device which is used for the treatment of bleeding (Ranfeild, 2006) while 
Bandage, under the trade name HemCon® and QuikClot® (available in the USA and Europe), 
are devices which rapidly clot blood in open wounds (Barnard and Millner, 2009). 
 
2.1.3. Potential problems associated with the administration of peptide therapeutics 
via the oral route and possible solutions 
 
There are many potential problems with the oral administration of peptide therapeutics which 
can be unique to the PT itself or PTs in general which are separate from pharmaceutical 
excipients. The delivery of PTs via the oral route requires a number of important 
considerations that will be discussed fully throughout this literature review for which major 
focus will be within a pharmaceutical scientist’s perspective. The first factor that all 
pharmaceutical scientists should generally consider is the absorption of PTs from 
gastrointestinal tract. The second factor is the movement of PTs through the mucus layer 
that lines the gastrointestinal tract. The third factor that should be under consideration is the 
potential means to circumvent the proteolytic enzymes that exist in the stomach and the 
small intestine. A pharmaceutical scientist must also chose the animal model that most 
closely represents a human system in order to obtain data that closely predicts the 
behaviour of a PT delivery system in the human gastrointestinal tract. Finally a 
pharmaceutical scientist should consider approval bodies such as the United States Food 
and Drug Agency (FDA) and the European Medicines Agency (EMEA) by designing a drug 
delivery system with components that have a well established toxicity profile. Each of these 
considerations will be discussed and potential solutions suggested.  
 
2.2. The biochemical, anatomical and physiological makeup of the small intestine 
 
The small intestine is habitually depicted as a continuous tube-like organ that is divided into 
three distinct regions namely duodenum, jejunum and ileum. The primary function of the 
small intestine is the uptake of nutrients (fat, monosaccharides, amino acids, di and tri 
peptides and vitamins), whereas the colon is the major site for fluid and electrolyte 
absorption (Paranjpe and Sinko, 2002). The total surface area of the small intestine is 
approximately 200m2, including the columnar epithelial cell layer (Deli, 2009). The lower 
parts of the small intestine i.e. jejunum and ileum, are considered to be the major locations 
of drug absorption, because of the leaky paracellular tight junctions reflected by the low 
transepithelial electrical resistance, as compared to the other parts of the gastrointestinal 
tract (Ward et al., 2000). 
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The digestive role of the small intestines is one of the central factors which considerabley 
reduce the oral bioavailability of PTs. This occurs principally in the small intestine lumen 
fluid. An in-depth comprehension of the small intestine lumen fluid would allow 
pharmaceutical scientists to design drug delivery systems that functions more cost-
effectively in the small intestines. A pharmaceutical scientist should contemplate that the 
physiological nature of the small intestine is highly reliant on the diet of an individual, the 
age, disease state and the genetic input of that individual. A typical example is where it has 
been reported that a change in pH within the small intestines of an individual was measured 
a week apart and found to diverge extensively, even though the diet of that individual had 
not changed within that week (Ibekwe et al., 2008). The intestinal lumen fluid was 
considered to be ubiquitous in the small intestines until magnetic resonance imagery was 
used to demonstrate that the intestinal lumen fluid exists in what has been referred to as 
“fluid pockets” (Schiller et al., 2005). The average volume of fluid in the small intestines is 
319mL but each fluid pocket contained a volume of 12mL in the fasted state (Schiller et al., 
2005). The average volume during the fed state was 156mL where each fluid pocket 
contained a volume of 4mL only (Schiller et al., 2005). This is exceptionally important for 
researchers who intend to design DDS whilist considering the volume of fluid in the small 
intestine or the pH environment of the small intestine. Preferably, a DDS should be able to 
perform in the intestinal fluid volume found within fluid pockets, therefore preventing sporadic 
drug release from a DDS as the DDS moves through the small intestine, thus reducing 
peptide therapeutic absorption and causing the plasma levels of the peptide therapeutic to 
fluctuate. 
 
A pressing issue that has been reported is the inaccurate global representation of all the 
components in the small intestinal lumen fluid during in vitro dissolution testing (McConnell 
et al., 2008). Hank’s bicarbonate buffer has been demonstrated to model the ionic 
composition of the jejunal lumen fluid and Kreb’s bicarbonate buffer has been demonstrated 
to model the ionic composition of the ileal lumen fluid (Fadda and Basit, 2005; Ibekwe et al., 
2006). Drug dissolution profiles for Eudragit® S-coated mesalazine tablets were evaluated in 
phosphate buffer medium, Hank’s bicarbonate buffer and Kreb’s bicarbonate buffer (Fadda 
and Basit, 2005). The drug dissolution profiles that were generated from these medium types 
showed that Eudragit® S-coated mesalazine tablets release drug much more rapidly in 
phosphate buffer than in Hank’s bicarbonate buffer or Kerb’s bicarbonate buffer (Fadda and 
Basit, 2005). Hank’s and Kreb’s buffer medium also demonstrated to have the same 
buffering capacity as the small intestinal lumen fluid and consequently was concluded to be 
a more accurate representation of in vivo drug dissolution profiles (Ibekwe et al., 2006; 
Fadda and Basit, 2007). An accurate correlation between in vitro data and in vivo data 
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should be obtained in order for in vitro data to be used as a prediction of in vivo outcomes. 
Therefore, a pharmaceutical scientist should choose the medium in which a DDS has the 
highest degree of representation with respect to in vivo conditions. Phosphate buffers are 
used by a pharmaceutical scientist as a rapid means of obtaining a drug dissolution profile 
that is characteristic of the average intestinal pH environment. Phosphate buffers should 
therefore be used primarily as a screening tool when an optimised DDS is in the progress of 
being developed. Hank’s and Kerb’s bicarbonate buffers should then be used on the 
optimised DDS to generate a drug dissolution profile that is a closer representation of in vivo 
conditions. 
 
A novel or innovative DDS is often compared to a market gold standard or the leading 
market competitor. Phosphate buffers simulating physiological conditions are analysed for 
the market gold standard to generate a drug dissolution profile rapidly and then used again 
to compare the novel or innovative DDS. The drug dissolution profile of the innovative DDS 
can then be optimised with respect to the marketed gold standard. Both the market gold 
standard and the innovative DDS should then be tested in alternative buffers that model the 
intestinal lumen fluid more closely. Furthermore the volume of buffer available to the 
marketed gold standard or the novel DDS should be limited during dissolution studies, so 
that in vivo behaviour within fluid pockets may be characterised (McConnell et al., 2008). 
The pharmaceutical scientist can then decide how to change the DDS if intestinal fluid 
pocket volumes do not achieve the desired output. 
 
The simulated intestine lumen fluid for in vitro testing can be further refined for the fasted 
state and the fed state (Jantratid et al., 2008). The fasted state may correspond to a medium 
known as Fasted State Simulated Intestinal Fluid (FaSSIF) whereas the fed state can be 
represented by a medium known as Fed State Simulated Intestinal Fluid (FeSSIF) (Jantratid 
et al., 2008). FaSSIF and FeSSIF which have bile salts and phospholipids incorporated into 
the medium gives a superior representation of in vivo conditions with respect to Hank’s or 
Kerb’s bicarbonate buffer (Vertzoni et al., 2005; Jantratid et al., 2008). An assessment of the 
fasted and fed state should also be conducted since the volume and composition of the 
intestinal fluid during the fed and fasted state have been shown to differ (Schiller et al., 
2005). Currently there is no piece of lab equipment or methodology that will predict the 
behaviour of a DDS in vitro with an accuracy that can correlate well with in vivo behaviours 
(McConnell et al., 2008; Jones and Grainger, 2009; Hsiao, 2011). Therefore a 
pharmaceutical scientist should try conducting a number of drug dissolution procedures 
using different medium volumes, pH conditions and compositions. This may characterise as 
fully as possible the in vivo behaviour of a DDS targeted at the small intestine. 
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The small intestine is one of the most active sites in the body for biochemical processes. The 
small intestine is composed of six different cell types in the epithelium layer that enhance the 
exchange of nutrients and mediate immunological processes. Protease enzymes secreted 
from the pancreas into the small intestine has a paramount influence on the bioavailability of 
PTs (Vlieghe et al., 2010). The total proteolytic enzyme load in the luminal fluid of the small 
intestine can reach gram quantities (Vlieghe et al., 2010). These proteolytic enzymes are 
secreted by the pancreas and include enzyme species such as α-chymotrypsin, trypsin, 
pancreatic elastase, carboxypeptidases A, B, D, N and U (Woodley, 1994). The brush border 
along the intestinal epithelium also contains a high number of proteolytic enzymes that 
rapidly degrade PTs (Vlieghe et al., 2010). The brush border secretes a great number of 
different peptidase species that include dipeptidyl-peptidase IV, prolyl tripeptidyl-peptidase, 
angiotensin-converting enzyme, leucyl-aminopeptidase, aminopeptidase M, aminopeptidase 
A, and neprilysin (Woodley et al., 1994). Should PTs manage to escape all of these 
peptidase species but then be endocytosed by the epithelia cells that line the small intestine, 
the PTs will get degraded by lysosomal enzyme species such as leukocyte elastase, 
cathepsins B and cathepsins D (Vlieghe et al., 2010). 
 
2.2.1. The importance of intestinal mucus in the design of an oral peptide therapeutic 
drug delivery system 
 
Mucus is a semi-permeable barrier that lines the small intestine as well as other organs 
along the gastrointestinal tract (Cone et al., 2009). Mucus permits an exchange of nutrients, 
water, gases and other compounds between the intestinal lumen and the blood stream 
through the small intestine epithelium layer (Cone et al., 2009). Notably the small intestine is 
covered in the thinnest mucus layer along the gastrointestinal tract which is exceptionally 
important for the proper functioning of the small intestine and a very attractive factor for a 
pharmaceutical scientist to consider (Varum et al., 2010). Mucus is constantly secreted by 
specialised epithelial cells (Goblet cells) which prevent many bacteria and fungi from gaining 
access to the intestinal epithelium wall (Cone et al., 2009). Due to nearly 10L of mucus 
secreted each day into the gastrointestinal tract, PTs absorption through the gastrointestinal 
tract is highly restricted (Powell, 1987; Cone et al., 2009). In addition, mucus is an extremely 
viscous material (non-Newtonian property), therefore causing further retardation in peptide 
diffusion through the mucus layer. Mucoadhesive polymers are used to concentrate a drug 
load at a relatively small portion of the gastrointestinal tract and allow a concentration 
gradient to form in the localised area. With a higher concentration of localised drug, the 
pharmaceutical scientist aims to overcome the mucus release per second gradient. A 
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graphical illustration of the ideal location within the gastrointestinal tract to target peptide 
therapeutic delivery is shown in Figure 2.1.  
 
 
 
Figure 2.1: Graphical illustration theoretical profile of ideal location within the gastrointestinal tract to 
target peptide therapeutic delivery (adapted from Cone, 2009).  
 
The mucus secretion in the gastrointestinal tract has been estimated to be at an average 
rate of between 1μm and 100μm per second (Powell et al., 1987; Cone, 2009). Within an 
individual in good health, the average thickness of mucus should remain consistent but vast 
ranges have being observed from 0μm to 300μm along the gastrointestinal tract (Powell et 
al., 1987; Cone, 2009). This is a substantial issue with respect to oral drug delivery systems 
based on mucoadhesive polymers because of the following aspects: 
 
 If the oral DDS does not encompass an extremely refined and accurate target location 
within the gastrointestinal tract, the oral DDS will fail to deliver the drug load efficiently. 
 If the oral DDS releases the drug load in a region where the mucus layer is too thick for 
the design, the drug load will not penetrate the mucus layer efficiently.  
 If the oral DDS releases the drug load in a region where the mucus layer is too thin for 
the design, the coadhesion between the DDS, the intestinal epithelium and the mucus 
layer could be too weak causing the DDS to fail. 
 
The stomach offers the least desirable target for the delivery of PTs. The mucus thickness, 
from the epithelium layer, in the human stomach has been estimated to be on average 
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180μm (range 50-450μm) (Kerss et al., 1982; Sandzen et al., 1988; Coperman et al., 1994; 
Cone 2009) and the gastric pH is as low as 1.2 to 1.7. Since the mucus layer is so thick, it is 
problematic for peptide therapeutics to move through this semi-permeable layer and reach 
the epithelium layer of the stomach. Furthermore, the low pH of the stomach causes PTs to 
undergo acidic catabolism and therefore their breakage to amino acids. 
 
The small intestine has the thinnest layer of mucus throughout the entire human 
gastrointestinal tract, which appeals to many pharmaceutical researchers as the target site 
for most oral peptide drug delivery systems (Varum et al., 2010). The thinner mucus layer in 
the small intestine permits the most effective opportunity for second generation 
mucoadhesive polymers that not only adhere to the mucus layer but also to the epithelium of 
the small intestine (Serra et al., 2009). Thus, providing the most prolonged direct interaction 
with the small intestine epithelium that may afford a more effective application of permeation 
enhancers. The colon has the second most thick mucus layer of 110-160μm (Kerss et al., 
1982; Sandzen et al., 1988; Coperman et al., 1994; Cone, 2009; Varum et al., 2010) but also 
an astronomical population of enteric bacteria live on the mucus layer. The combination of 
the thick mucus layer and the presence of enteric bacteria make the colon an undesirable 
target for delivery of PTs.  
 
The assembly of the peptide therapeutic delivery system should also take into consideration 
that a reserve of unhydrated mucus is stored in Goblet cells which can be rapidly released in 
the case of toxic or irritating elements that makes contact with the intestine (Cone et al., 
2009). Therefore the DDS should use the least toxic components possible to prevent the 
rapid release of mucus that will obstruct the movement of the PTs from the intestine lumen 
through the mucus layer to the epithelium. A unique property of the mucus structure is the 
unstirred layer, also known as the glycocalyx, which adheres tightly to the surface of the 
epithelium layer. This layer is between 10nm to 500nm in the gastrointestinal tract and 
remains present on the epithelium layer even when the mucus layer is removed by chyme 
(Szentkuti and Lorenz, 1995; Strugala et al., 2003; Cone et al., 2009). This unstirred layer is 
a considerable challenge to the dispersion of PTs as this layer is more compacted in 
comparison to rest of the mucus layer. The effect this layer has on the movement of PTs 
must be minimised, so as to allow PTs to diffuse towards the epithelium surface of the 
intestine more rapidly. A pharmaceutical scientist could consider a chemical means to 
reduce the viscosity of the glycocalyx since physical means (the presence of chyme) do not 
seem to have a significant effect on this layer of mucus.  
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Mucus contains two main negatively charged functional groups which are carboxyl and 
sulphate groups (Cone et al., 2009). The sulphate groups form disulphide bonds which 
causes mucin to fold into its three dimensional structures. The sulphate groups have 
become a recent target in the design of thiolated polymers (Cevher et al., 2008). The 
thiolated polymer interacts covalently with sulphate functional groups on mucin which 
prolongs the mucoadhesiveness of the thiolated polymer. The potential problem with this 
thiolated polymer is that the polymer could interact with the cysteine amino acids in PTs 
which could result in PTs becoming inactive or worse immunogenic. Sulphate functional 
groups are generally incorporated into proteins and peptides to facilitate the formation of 
covalent disulphide bonds that link peptide strands together or to the peptide strand itself 
(Figure 2.2). An example of this potential interaction can be seen in salmon calcitonin which 
has 32 amino acids, two of which are cysteine amino acids that forms a disulfide bridge 
(Cheng et al., 2008). Therefore thiolated polymers may not only interact with the mucin 
proteins within mucus but also with PTs, potentially resulting in misfolding of these PTs. A 
pharmaceutical scientist should consider a polymer that has the least potential to interact 
with PTs but maintains balanced mucoadhesion (a polymer should adhere to the mucus 
layer but not reinforce the mucus layer).  
 
 
Figure 2.2: Three dimensional representations of two cysteine amino acids. There is a sulphur bond 
present between the cysteine amino acids. 
 
2.2.2. Tight junctions: a barrier as well as a target 
 
Tight junctions (TJ) are highly regulated orifices that limit toxic substance absorption and 
regulate the passage of ions between epithelial cells through a process known as 
paracellular transport (Brandner, 2009). Pharmaceutical scientists that wish to use 
paracellular transport should consider the dimensions of the peptide therapeutic because the 
diameter of tight junction orifices range between 30-50Å (Rubas et al., 1996; Morishita and 
Peppas, 2006). Tight junctions are often considered ridged structures with two functions: a 
barrier function and a fence function (Brander, 2009). Evidence is increasing being 
discovered that implicates tight junctions as dynamic structures that are responsive to many 
stimuli (Kondoh et al., 2008; Steed et al., 2010). Paracellular transport of PTs is very 
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important because presently this transport mechanism is the only means by which PTs can 
be absorbed in an undigested state (Kavimandan and Peppas, 2008). Pharmaceutical 
scientists use permeation enhancers (i.e. β-cyclodextrin) and recently polymers (i.e. 
chitosan) to increase the bioavailability of drug molecules therefore lessen the amount of 
drug required to achieve a desired therapeutic index (Ammar et al., 2008). Permeation 
enhancers are substances that facilitate the transient breakdown of the barrier function 
within tight junctions (Furuse and Tsukita, 2006). Furthermore, the small intestinal epithelium 
has the lowest trans-epithelial electrical resistance (TEER) throughout the body that can be 
practically observed by the highest absorption of salmon calcitonin from the jejunum and 
ileum in comparison to the stomach or large intestine (Shah and Khan, 2004).  
 
PTs, such as insulin, may be transported intracellular from the small intestinal lumen to the 
systemic circulation via the epithelial cells but will likely undergo degradation due to 
exposure to intracellular metalloproteinase enzymes (Bennett et al., 2009). The intracellular 
degradation of therapeutic agents has lead to the development of pro-drugs. Pro-drugs are 
engineered therapeutic agents that become biologically activated after being exposed to the 
gastrointestinal tract (Vlieghe et al., 2010). Large PTs that are engineered to be 
administered as pro-drugs are difficult to develop and expensive to manufacture. Large 
peptide pro-drug therapeutics has a great number of cleavage sites for proteolytic enzyme 
activity when exposed to the highly variable gastrointestinal environment. Peptide pro-drug 
therapeutics may also be lost, because the absorption of these large macromolecules may 
be challenging to achieve at a therapeuticaly relevant level. Thus, large PTs that are 
administered in their native form within a DDS may offer more potential to be effective than 
the development of large peptide pro-drug therapeutics. 
 
Tight junctions serve as exceptionally beneficial targets for facilitating the oral absorption of 
native PTs because they act as a direct link between the lumen of the intestine and the 
systemic circulation. The structural components within tight junctions function dynamically 
within the cytoplasm of cell, the external environment of the cell and other extracellular 
proteins (Brander, 2009). The central components that make up tight junction membrane 
proteins are claudins, occludins and junctional adhesion molecules (JAMs). These 
components are coupled to the cytoskeleton of the cell through tight junction plaque proteins 
(Brandner, 2009). Tight junction plaque proteins (ZO-1, ZO-2, ZO-3, cingulin, symplekin, 
aPKC, Par3, and Par6) mediate the connection between the tight junction membrane 
proteins and the cell cytoskeleton (Brandner, 2009). In order to open these tight junctions 
and allow PTs to permeate through these orifices, an appreciation of the tight junction 
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biological function as well as the extensive intracellular signalling biochemistry and structure 
is essential. 
 
2.2.3. Main components of tight junctions  
 
The main components of tight junctions are highlighted in Figure 2.3. Occludin was the first 
transmembrane proteins within tight junctions to be identified (Furuse et al., 1993). These 
proteins have been demonstrated to regulate the permeability properties of tight junctions 
and in particular the regulation of size-selective diffusion (Balda et al., 1996; McCarthy et al., 
1996; Balda et al., 2000). Occludins have been characterised as integral membrane protein 
that loops four times through the phospholipid layer of the epithelial cell (Furuse et al., 1993; 
Paris et al., 2008). The two extracellular domains of one occludin protein within a cell interact 
with two extracellular domains of one occludin protein in an adjacent cell (Figure 2.3). Tight-
junction plaque proteins ZO-1 (Furuse et al., 1994), ZO-2 (Itoh et al., 1999), ZO-3 (Haskins 
et al., 1998) and actin (Paris et al., 2008) interact with occludins as well as the cytoskeleton. 
Cingulin which interacts with actin and myosin also interact with occludin (Cordenonsi et al., 
1999). Phosphorylation of occludin on tyrosine using non-receptor kinase c-Yes, has been 
thought to maintain tight junction integrity (Paris et al., 2008). Occludin is also 
phosphorylated on serine/threonine residues which may be linked to some signalling 
cascades (Sakakibara et al., 1997).  
 
The disassembly of occludin from kinase c-Yes due to extracellular reduction of calcium 
causes the disassembly of the tight junction (Chen et al., 2002). The reduction of calcium 
from the tight junction with calcium chelation agents such as ethyleneglycoltetraacetic acid 
(EGTA) or ethylenediaminetetraacetic acid (EDTA) will be discussed as first generation 
permeation enhancers. Occludin which is phosphorylated on to the serine/threonine amino 
acids by casein kinase-2 (Andreeva et al., 2001; Smales et al., 2003) and atypical protein 
kinase C (aPKC) has a significant impact on the core polarity complex (Paris et al., 2008). It 
has been suggested that phosphorylation of serine/threonine on occludin maintains tight 
junction integrity (Paris et al., 2008). Therefore a possible permeation enhancer may be a 
reversible inhibitor of casein kinase-2 or aPKC that may reversibly decrease the tight 
junction integrity. Occludin is dephosphorylated by protein phosphatase 2A which inhibits the 
over phosphorylation of occludin (Paris et al., 2008). Thus an alternative tactic for opening 
tight junctions for peptide therapeutic delivery would be inducing dephosphorylation of 
occludin, by indentifying a substance which reversibly enhances the activity of protein 
phosphatase 2A.  
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Occludin has also been observed to interact with lipid kinases, such as phosphatidylinositol 
3-kinase (PI3K) (Sheth et al., 2003). Occludin associates with the p85 regulatory subunit of 
PI3K and during oxidative stress, PI3K-mediated tight junction disassembly may be induced 
(Sheth et al., 2003). Another permeation enhancer strategy could be suggested whereby 
oxidative stress is induced in the epithelial cell, thereby causing the tight junction to open but 
it should also be understood that many studies have reported that oxidative stress may 
induce the formation of oncogenes and therefore precancerous cells may form. These are 
just some of the examples of intracellular regulation mechanisms of occludin.      
 
Claudins are considered to be the major component of tight junctions with over 20 protein 
isotypes each having four transmembrane domains (Morita et al., 1999). Based on the 
charge on the two extracellular domains, Claudins have been reported to act as paracellular 
ion channels or paracellular ion barriers (Simon et al., 1999; Amasheh et al., 2002; Yu et al., 
2003). The different isotypes of claudins have been noted to be associated with a specific 
tissue type (Claudin 3, 4 and 7 are found in the small intestine), therefore a substance which 
can interact with these claudins transiently, could be incorporated into a drug delivery 
formulation and therefore aid in the absorption of therapeutic macromolecules (Gonzalez-
Mariscal et al., 2008). Claudins interact with tight junction plaque proteins ZO-1, ZO-1, multi-
PDZ domain protein-1 (MUPP1), and PATJ (Hamazaki et al., 2002). Each of these plaque 
proteins have the potential to mediate tight junction opening from within the cell. A schematic 
representation of the anatomical and biochemical elements at the small intestinal epidermis 
layer is shown in Figure 2.3. 
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Figure 2.3: A schematic representation of some anatomical and biochemical elements that form the 
small intestinal epidermis layer depicting the five transport mechanisms that are currently known to 
occur in the small intestine as: 1) passive diffusion transcellular transport (represented by a blue 
arrow); 2) active transcellular transport (represented by a  purple arrow); 3) carrier mediated efflux 
which results in the absorption of a compound from the intestinal lumen and its secretion into the 
intestinal lumen (represented as a green arrow); 4) active vesicle mediated transcellular transport 
(represented by a yellow line); and passive paracellular transport (represented by a red arrow) which 
is the most important transport mechanism for the absorption of peptide therapeutics in the oral route 
(Adapted from Gonzalez-Mariscal et al., 2008; Paris et al., 2008). 
 
2.2.4. Structure and components of tight junctions 
 
The contraction of the perijunctional actinomyosin ring and the protein kinase or 
phosphatase mediated changes during tight junction protein phosphorylation (Hochman and 
Artursson, 1994). Intracellular tight junctions (Figure 2.3) serve as the rate-limiting barrier for 
solutes crossing columnar epithelial cells by means of the route between the cells. As 
bridges, the gap junctions (Figure 2.3) regulate solute movement from the inside part of one 
cell to another. As gates, the tight junctions regulate solute movement from the luminal 
solution directly into the lateral intercellular spaces, bypassing the cells. As fences, the tight 
junctions or associated structures presumably also regulate the movement of membrane 
constituents from the apical cell membrane to the basolateral cell membrane. The cell-cell 
contact is mediated by cell adhesion protein molecules (CAMs) that participate in spatial 
organisation and establishment of cell polarity. Tight junctions seal adjacent epithelial cells in 
a narrow band just beneath their apical surface. Adherens junctions provide strong 
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mechanical attachments between adjacent cells. Gap junctions are intercellular channels 
(1.5-2nm diameter) (Figure 2.3). These permit the free passage between the cells of ions 
and small molecules (up to a molecular weight of about 1000Da). They are constructed from 
4 (sometimes 6) copies of a family of transmembrane proteins called connexions. Because 
ions can flow through them, gap junctions permit changes in membrane potential to pass 
from cell to cell. Desmosomes are localised patches that hold two cells tightly together. They 
are common in epithelia (i.e. skin). Desmosomes are associated with intermediate filaments 
in the cytoplasm.  
 
2.3. Permeation enhancers employed in the small intestine 
 
Permeation enhancers are substances that are used to aid the transport of substances (e.g. 
PTs) through a biological membrane such as the small intestinal epithelia by opening tight 
junctions. The efficiency of permeation enhancers is often measured as a reduction of 
transepithelial electrical resistance (TEER). The more effective a permeation enhancer is the 
more tight junctions or for a longer time period tight junctions are opened, thus the ions flux 
is increased through the biological membrane due to less resistance (Kondoh et al., 2008). 
An ideal permeation enhancer is a substance that reversibly opens tight junctions within a 
definite time period, precisely at a tissue layer, in an instantaneous and unidirectional way 
(Fasano, 2008). The permeation enhancer should not be toxic (e.g. irritate or damage the 
biological membrane), but should decompose quickly and be excreted rapidly when 
absorbed systemically (Fasano et al., 2008). The permeation enhancer should act as a 
“universal key” which can open tight junctions for a variety of PTs. Currently there are 
important disadvantages with many of the known permeation enhancers, especially first 
generation permeation enhancers, such as: low specificity with regard to the tight junction 
components or the epithelium layer, an influx into the systemic circulation of toxic 
metabolites or contaminates from the intestinal lumen may occur; and damage to the 
epithelial lumen may occur resulting in malabsorption of nutrients (Kondoh et al., 2008). 
Table 2.2 depicts permeation enhancers that have been tested in the small intestine to 
facilitate therapeutics absorption which have been divided into first and second generation 
TJ permeation enhancers. The first generation TJ permeation enhancers are those that do 
not target specific TJ components whereas second generation TJ permeation enhancers are 
the ones that target specific components in tight junctions (Kondo et al., 2008).  
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Table 2.2 Permeation enhancers that have been tested in the small intestine to facilitate therapeutic 
absorption. 
 
2.3.1. Ethylenediaminetetraacetic acid 
 
Ethylenediaminetetraacetic acid (EDTA) is classified as a zinc and calcium chelator 
(Bernkop-Schnürch and Krajicek, 1998; Deli, 2009). The reduction of calcium by EDTA leads 
to the activation of protein kinase C (PKC) thus increasing paracellular transport through 
tight junctions and adhesion junctions (Citi, 1992; Tomita et al., 1996). Since both tight 
junctions and adhesion junctions are opened, the diffusion of PTs would be significantly 
enhanced. EDTA has been reported to increase the transport of polyethylene glycol 4000 
(average molecular weight between 3400-4500g/mol) through Caco-2 monolayers (Tomita et 
al., 1994). Additionally EDTA may augment the swelling and distribution of mucus by 
chelating calcium ions that crosslink mucin peptides (Chen et al., 2009). This may aid the 
diffusion of PTs through the mucus layer, towards the epidermal layer of the small intestine.  
 
2.3.2. Sodium caprate 
 
Sodium caprate is a 10 carbon medium chain fatty acid (Deli, 2009). Sodium caprate 
activates phospholipase C by inducing the contraction of calmodulin-dependent actin-mycin 
filaments (Aungst, 2000; Kondoh et al., 2008). The contraction of calmodulin-dependent 
actin-mycin filaments causes the plaque protein ZO-1 and transmembrane protein occludin 
Permeation enhancer Generation Location of 
activity 
Reference 
ΔG (Zot fragment; 12 kDa) Second Duodenum Salama et al. 2005 
AT-1002 Second Duodenum Song et al. 2008 
Zot (45kDa) Second Jejunum and 
ileum 
Fasano et al. 1997; Fasano and Uzzau 
1997; Fasano et al. 1995 
Zonulin (47kDa) Second Jejunum and 
ileum 
Wang et al. 2000 
C-CPE Second Jejunum Masuyama et al. 2005; Kondo et al. 
2005; Kondoh et al. 2008 
Sodium caprate First Jejunum and 
ileum 
Kondo et al. 2005; Soderholm et al. 
1998; Kondoh et al. 2008 
Dimethyl-β-cyclodextrin  Jejunum Shao et al. 1994 
NO donors (NOC5, 
NOC12 and SNAP) 
First Jejunum and 
ileum 
Yamamoto et al. 2001; Kondoh et al. 
2008; 
Fetih et al. 2005, Fetih et al. 2006 
Oleic acid First Through out Kondo et al. 2008 
EDTA First Through out Kondo et al. 2008 
Occludin peptide Second Through out Kondo et al. 2008 
FSH-fusion occludin 
peptide 
Second Through out Kondo et al. 2008 
Trimethyl chitosan First Jejunum Du Plessis et al. 2010 
Bile Salts First Through out Kondo et al. 2008 
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to dissociate from the tight junction, thus allowing substances such as mannitol to access the 
paracellular permeation pathway (Lindmark et al., 1995; Lindmark et al., 1998).   
 
2.3.3. Bile salts 
 
Bile acids are included into pharmaceutical formulations by binding these compounds to 
sodium to form salts or by mixing with polyoxyethylated hydrogenated castor oil (Muranishi, 
1990). The exact mechanism in which bile salts increase the absorption of compounds such 
as polyethylene glycol 4000 is not known but it has been suggested to be most likely through 
paracellular transport (Meaney and O’Driscoll, 2000).  
 
2.3.4. Occludin peptides 
 
Occludin peptides are synthetic peptides that bind the extracellular domain of 
transmembrane protein occludin, thus inhibiting the interaction of occludin molecules on 
each side of the lateral membrane within tight junctions (Wong and Gumbiner, 1997). This 
induces the tight junction to open and does not affect other tight junction components such 
as ZO-1, ZO-2 and cingulin (Wong and Gumbiner, 1997). A short peptide of 14 amino acids 
that binds to the extracellular loop region of occludin could be a prototype for a new class of 
TJ modulators in intestinal epithelium (Tavelin et al., 2003). Occludin peptides may be 
digested in the stomach due to proteolytic enzymes and harsh pH environment before 
reaching the small intestine. Thus a DDS that has been designed to deliver PTs and use 
occludin peptides as permeation enhancer will have to protect both peptides. The DDS will 
also have to ensure that both peptides are co-localised, within a small region of the intestinal 
wall to ensure that a peptide therapeutic concentration gradient is set up at the same time 
when occludin peptide is opening the tight junction. The localised occludin peptides are 
depicted in Figure 2.4. 
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Figure 2.4:  Localisation of occludin peptides in confluent T84 cell monolayers which has undergone 
cation (Ca
2+
) depletion and elucidation using fluorescence microscopy (adopted from Nusrat et al., 
2006). FITC-conjugated streptavidin (green fluorescence) was used to determine the distribution of 
BAIT peptides after cation repletion and F-actin architecture (red fluorescence) was determined using 
Alexa 568-phalloidin. 
 
2.3.5. Clostridium perfringens enterotoxin 
 
Clostridium perfringens enterotoxin (CPE) is a toxin secreted by the gastrointestinal 
pathogen Clostridium perfringens (Hanna et al., 1992). CPE has been modified to act as a 
tight junction permeation enhancer by removing the cytotoxic N-terminal domain and 
manufacturing the receptor binding C-terminal (C-CPE) (Hanna et al., 1992). The receptor 
binding C-terminal has been reported to interact with the second claudin extracellular loop 
domain, therefore preventing two claudin proteins from adjunct cells interacting with one 
another (Fujita et al., 2000). The ability of C-CPE to reversibly enhance paracellular 
transport has been demonstrated to be 400 times greater than sodium caprate in the 
jejunum (currently used in pharmaceutical formulations) (Kondoh et al., 2005). Even though 
C-CPE is extremely efficient at decreasing tight junction integrity, this permeation enhancer 
is a peptide sequence and may be susceptible to extensive acid catabolism within the 
stomach (Sonoda et al., 1999). Furthermore, C-CPE is not readily available commercially 
and has not currently received FDA approval in any drug formulations with intent to deliver 
PTs orally.   
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2.3.6. Zonula occludens toxin 
 
Zonula occludin toxin (Zot) is a toxin secreted by the pathogenic bacterium species Vibrio 
cholera (Fasano et al., 1991). Zot is a peptide that reversibly opens tight junctions within the 
small intestine (Fasano et al., 2008). Zot activates protein kinase C α-dependent 
polymerisation of actin microfilaments that induces the opening of tight junctions (Fasano et 
al., 2008). Insulin and immunoglobulin G (IgG) have been administered with Zot on excised 
rabbit ileum and demonstrated significant absorption of these macromolecules (Fasano and 
Uzzau, 1997). Some of the benefits of Zot as a permeation enhancer are as follows (Fasano 
et al., 2008):    
 Zot is not cytotoxic and therefore does not negatively impact the viability of the intestinal 
epithelium. 
 Zot does not completely inhibit TEER, thus potential toxins may be limited from entering 
the systemic circulation. 
 Zot is a generation 2 permeation enhancer and interacts with specific intestinal receptors. 
 Zot does not have activity in tight junctions located in the small intestine which prevents 
harmful enteric bacterium from entering the systemic circulation and causing sepsis. 
 Zot has not been reported to cause systemic side effects when administered orally.  
 Zot is a rapid and reversible permeation enhancer within the small intestine that has a 
half life of 60 minutes. 
 
Zot, like occludin peptide and C-CPE, is a peptide that has not currently received FDA 
approval as a permeation enhancer for orally administered PTs. Zot peptides may also be 
significantly degraded within the stomach due to proteolytic enzymes and harsh pH 
conditions. For any DDS using Zot as a permeation enhancer, there will be a need to protect 
it from degradation. 
 
2.4. Chitosan and its derivatives as permeation enhancers 
 
Chitosan is a cationic polymer which is derived from chitin through three distinct chemical 
processes (George and Abraham, 2006). The most common commercially available chitin is 
derived from crab and shrimp (Roberts, 1992; Shepherd et al., 1997). The shells from crabs 
and shrimp were the first to be ground to produce chitin powder (George and Abraham, 
2005). The ground chitin was then deproteinised by treatment with alkali followed by 
demineralisation with an acid. Finally the deproteinised and demineralised chitin was 
deacetylated at high temperatures with an alkali solution to form α-chitosan (George and 
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Abraham, 2005). The average molecular weight and the degree of acetylation (percentage of 
primary amino groups in the chitosan backbone) are dependent on the length of duration of 
the chemical process (Roberts, 1992). Chitosan has been reported to be an extremely 
effective mucoadhesive agent in vitro (Gåserød et al., 1998). Mucoadhesivity of chitosan is a 
very important property with respect to drug delivery devices. The mucoadhesiveness of 
chitosan has been reported to improve its residence time thus improving the bioavailability of 
a loaded macromolecule therapeutic agent by providing an increased time window which the 
macromolecule therapeutic agent may achieve optimal absorption.   
 
2.4.1. The rationale for consideration of chitosan and its derivatives for orally 
administered drug delivery systems 
 
A great amount of interest has been shown in chitosan for drug delivery applications 
because of its reported potential for biocompatibility and biodegradability (Kean and Thanou, 
2010). Commercially available chitosan is said to be highly customisable since its average 
molecular weight can range between 10kDa to 1000kDa and the degree of deacetylation 
can range between 70% to 95% (George and Abraham, 2005). For this reason, chitosan can 
be refined to create novel drug delivery systems with very specific properties. The degree of 
deacetylation and molecular weight determines the solubility of chitosan within an aqueous 
environment at pH 7 (neutral pH that is relatively similar the pH of the small intestine). It has 
been observed that increased acetylation of the chitosan crystal structure increases its 
solubility with neutral aqueous environments hence chitosan in its native form will not 
dissolve at pH 7 whereas chitosan that has been half acetylated can easily dissolve at pH 7 
(Zhang et al., 2006; Sogias et al., 2010). One of the main properties which attract medical 
researchers to chitosan is the biological activity of chitosan. Chitosan has been reported to 
open tight junctions in the epidermal layer when the pH of the environment is under 6.5 
(Thanou et al., 2001; Yeh et al., 2011). Chitosan therefore can act as a functional 
component in environments such as the stomach and ocular fluid but presents a problem for 
the small intestine. The small intestine has a pH of 6.8 which is above the generally 
accepted pH of chitosan solubility hence chitosan cannot act as a permeation enhancer in 
the small intestine. In order to make chitosan soluble within neutral aqueous medium 
derivatives which can dissolve at higher pH values were synthesised such as trimethyl 
chitosan. Figure 2.5 and Figure 2.6 are three dimensional representations of chitosan and 
trimethyl chitosan, respectively. 
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Figure 2.5:  Three dimensional representation of chitosan which gives an indication of the optimised 
ring structure of each chitosan unit. Each functional group in the chitosan back bone is highlighted 
with a red ring. The functional groups include: a carboxyl and an amino group attached to a ring 
structure. The atomic radii of each atom in the chemical structure are represented as dotted spheres 
in the same colour as the source atom. The amino functional group has a positive charge (pKa ~6.5) 
and is the main functional group that lends chitosan its cationic property. 
 
2.4.2. The chemistry of chitosan and its derivatives 
 
Chitosan contains two units linked by a β 1 to 4 carbon bond; the first unit being 2-amino-2-
deoxy-D-glucose (D-glucosamine) and the second one being 2-acetamido-2-deoxy-D-
glucose (N-acetyl-glucose) (Figure 2.5). Chitosan contains many amino functional groups 
which causes chitosan to swell in response to decreasing pH (more acidic). Therefore 
chitosan would be a very good functional polymer in environments such as the stomach. But 
for the use of chitosan in the small intestine where the pH is 6.8, the amount of amino 
groups needs to be reduced; such that the pH at which chitosan swells is increased.  
 
2.4.3. Trimethyl Chitosan  
 
Trimethyl chitosan (TMC) is a chitosan derivative which has been partially quaternised at the 
2-carbon position, in order to make the chitosan backbone soluble in solutions with a pH 
greater than 6.5 (Verheul et al., 2009). Figure 2.6 shows a three dimensional representation 
of trimethyl chitosan. It has been reported in several in vitro and in vivo models that TMC has 
Carboxyl 
functional group 
Amino functional 
group 
Amino functional 
group 
35 
 
limited toxicity, possesses mucoadhesive properties and can increase the uptake of small 
drug molecules as well as proteins at various mucosal locations such as the small intestine, 
nasal passages and in the rectum (Thanou et al., 2000; Hamman et al., 2002; Van der 
Lubben et al., 2002; Di Colo et al., 2004; Amidi et al., 2006; Boonyo et al., 2007; Chen et al., 
2007; Chen et al., 2008; Sayin et al., 2008).  
 
 
 
 
Figure 2.6: Three dimensional representation of trimethyl chitosan with functional groups highlighted 
in red rings. The atomic radii of each atom in the chemical structure are represented as dotted 
spheres in the same colour as the source atom.  
 
TMC has recently been formulated in many pharmaceutical forms that range from 
nanoparticle to macroscopic forms that aim to deliver peptide therapeutics or gene 
therapeutics and chemotherapeutic compounds (Cafaggi et al., 2011; Guo et al., 2011; 
Martins et al., 2011; Vongchan et al., 2011). TMC has also been demonstrated in rats to be 
a potent intestinal absorption enhancer of PTs at neutral environments therefore an oral 
formulation of trimethyl chitosan that could be tested in humans may be relatively close to 
finalisation (Thanou et al., 2000; Thanou et al., 2001). TMC facilitates peptide therapeutic 
absorption by opening tight junctions thereby facilitating paracellular reversible diffusion of 
PTs from the intestinal lumen into the blood stream (Thanou et al., 2001). The advantage of 
reversible paracellular diffusion is that after the removal of the polymer from the epithelium 
surface paracellular orifices close, therefore reducing the potential for toxic metabolites or 
Three methyl functional 
groups attached to a 
nitrogen atom 
Hydroxyl 
functional group 
Amino functional 
group 
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pathogens from entering the systemic circulation (Thanou et al., 2001). The degree of 
quarterisation which that has been shown to optimally enhance peptide absorption across 
epithelium cells is 46%. This is partially important for an optimised oral pharmaceutical 
formulation that intends to use trimethyl chitosan since this degree of quarterisation reduces 
the requirement to determine the effect of variant degrees of quarterisation of trimethyl 
chitosan that would be used in pharmaceutical formulations (Hamman et al., 2003).  
 
Trimethyl chitosan has been reported by different authors to have contradictory properties 
(Jintapattabakit et al., 2008). An example is the TMC toxicity profile, where some authors 
have concluded that TMC is non-toxic (Thanou et al., 1999; Amidi et al., 2006; Florea et al., 
2006), whereas others have concluded that TMC is a toxic chitosan derivative (Kean et al., 
2005; Mao et al., 2005).  
 
Furthermore some authors have reported TMC as having enhanced mucoadhesion capacity 
with respect to the parent compound chitosan (Sandri et al., 2005) while other authors have 
reported reduced mucoadhesive properties (Synman et al., 2003; Synman et al., 2004). The 
contradictory variability of TMC may be due to the procedure of synthesis and the resulting 
unique TMC properties (i.e. chain length and degree of quarterisation). The mucoadhesivity 
and cytotoxicity of trimethyl chitosan have been thought to be the result of the interaction 
between the positively charged methyl groups and the negatively charged groups in mucin 
(Mao et al., 2005). Thus, a standardised fully described trimethyl chitosan should be 
developed so that other authors can accurately compare the properties of trimethyl chitosan 
and refine the chemical nature of this polymer to a form which has optimal functionality but 
minimal side effects. A standardised means to synthesis trimethyl chitosan could be based 
on Polnok and coworkers’ synthesis which is shown in Figure 2.7 whereby the methodology 
is relatively easy to perform and the degrees of deacetylation can be controlled through the 
various indicated steps (Polnok et al., 2004). In addition, the synthesis of trimethyl chitosan 
through this methodology could be optimised to produce a product that can be accepted by 
the FDA as a safe excipient. 
 
The charge density of TMC (as determined by the degree of quarterisation) is an important 
property with respect to effective absorption enhancement (Kotzé et al., 1999). During 
synthesis of TMC, the number of positive charges on the TMC backbone is increased by 
increasing the duration of the alkaline reaction or the strength of the alkaline used (Polnok et 
al., 2004). The expansion of TMC in alkaline solution is caused by the repelling force 
between the positive methyl functional groups (Domard et al., 1986). In addition, the thermal 
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stability of trimethyl chitosan with respect to native chitosan molecule and different counter 
ions that may be used in the synthesis of trimethyl chitosan has been compared. 
 
 
Figure 2.7: Schematic chemical process diagram of trimethyl chitosan using sodium hydroxide. Each 
coloured line represents a reaction process of 1 to 3 steps. 
 
The differential thermal analysis (DTG) has been determined for a series of different counter 
ions used in the synthesis of trimethyl chitosan and found to occur at lower DTG peak 
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temperatures (trimethyl chitosan chloride has a DTG peak of 238.2°C) compared to chitosan 
which has had a higher DTG peak of 306.4°C thus concluding that trimethyl chitosan variant 
has a lower thermal stability in comparison to chitosan (de Britto et al., 2011). The stability of 
trimethyl chitosan variants is an extremely important factor to consider with respect to 
pharmaceutical products since this stability is a general indication of the shelf life of that 
variant and therefore an indicator of how long it can remain intact as an active excipient in a 
pharmaceutical formulation.  
 
The methylation of the primary amine to the quaternary stage is accomplished by using a 
base to bind the acid that is being generated during the reaction and to avoid the protonation 
of the unreacted primary amino groups (Polnok et al., 2004). The increased degree of O-
methylation at hydroxyl groups has been reported to decrease the solubility of TMC in 
neutral solutions; therefore methodologies which minimise the degree of O-methylation are 
highly desired by researchers and pharmaceutical scientists (Snyman et al., 2002; Polnok et 
al., 2004). High levels of trimethyl substitution at amino groups (above 70%) has led to high 
levels of methyl substitution on hydroxyl groups found at position 3 and 6 on the chitosan 
backbone structure (Polnok et al., 2004). The degree of methylation will determine how often 
nitrogen will be bound to three methyl groups. An example is 60% trimethyl chitosan which 
indicates that six out of ten nitrogen atoms will be bound to three methyl groups instead to 
two hydrogen groups. The methyl groups are used to increase the overall positive charge of 
chitosan and therefore allow trimethyl chitosan to be soluble over a wider pH range. The 
methylation of chitosan enhances the mucoadhesivity of chitosan.  
 
Polnok and co-workers (2004) attempted to decrease the degree of O-methylation by using 
dimethylaminopyridine, a weaker alkaline solution (i.e. in comparison to sodium hydroxide). 
The degree of O-methylation at 3rd and 6th hydroxyl groups was found to have been 
significantly decreased in some instances but the degree of trimethylation was significantly 
decreased as well (Polnok et al., 2004). Therefore the use of dimethylaminopyridine would 
not have produced a degree of trimethylation at the amino group that would significantly 
enhance peptide absorption from the small intestinal lumen. Formulation scientists should 
continue the search for nucleophilic catalyst that will enhance trimethylation but reduce O-
methylation of chitosan so that synthesised trimethyl chitosan will have optimised peptide 
therapeutic delivery potential.  
 
The standard methods that have been used by these authors to produce TMC with sodium 
hydroxide are shown in Figure 2.7. The degree of quarterisation was reported to increase 
significantly with the number of reaction steps when using sodium hydroxide as the base 
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(Polnok et al., 2004). The green line in Figure 2.7 represents the three reaction steps which 
resulted in 77.6% degree of quarterisation whereas the blue line represents one reaction 
step which resulted in a 29.7% degree of quarterisation. The degrees of O-methylation at 3- 
and 6- hydroxyl groups also increased with the number of reaction steps (Polnok et al., 
2004). The green line in Figure 2.7 represents three reaction steps which resulted in 
degrees of O-methylation at 3- and 6- hydroxyl groups as 62.2% and 62.4%, respectively, 
whereas the blue line represents one reaction step which resulted in degrees of O-
methylation at 3- and 6- hydroxyl groups as 17.9% and 25.5%, respectively (Polnok et al., 
2004). 
 
Trimethyl chitosan has been used for the oral delivery of salmon calcitonin in the rat model 
(du Plessis et al., 2010). Trimethyl chitosan was compared to a novel patented DDS 
Pheroid™ (composed of essential and fatty acids of plant origin which has been emulsified 
in nitrous oxide saturated water). Salmon calcitonin was administered to the jejunum of the 
small intestine of rats at a concentration of 500IU/Kg, and then determining the absolute 
bioavailability using Equation 2.1:  
 
Absolute bioavailability      
A C  
A C  
 -  
Dose  
Dose  
  100                                                   (Eq. 2.1) 
Where:  
AUCEV is the area under the curve for extra vascular administration of salmon calcitonin. 
AUCIV is the area under the curve for intravenous administration of salmon calcitonin. 
DoseEV is the amount of salmon calcitonin that was administered extravascularly. 
DoseIV is the amount of salmon calcitonin that was administered intravenously. 
 
 
Pheroid™ vesicles and microspheres were able to achieve an absolute bioavailability of 
3.87% and 4.18%, respectively (du Plessis et al., 2010). TMC at a concentration of 0.5% 
(w/v) was able to achieve an absolute bioavailability of 6.52%, even though the authors did 
not indicate the molecular weight, the degree of quarterisation or the degree of O-
methylation at the 3- and 6- hydroxyl residues (du Plessis et al., 2010). It should be noted 
that TMC was injected directly into the jejunum of Sprague Dawley rats; therefore a limited 
amount of pre-systemic metabolism in the stomach and in the small intestine did not occur. 
Salmon calcitonin has also been reported to be absorbed most efficiently in the ileum and 
jejunum region of the small intestine (Shah and Khan., 2004). Noteworthy is that the rat 
model that has been used is a poor representative model for the human gastrointestinal 
tract. Thus, an absolute bioavailability could present a poor correlation in human subjects 
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exposed to the same formulation. A formulation scientist should, when possible, use a large 
model animal such as the pig in order to obtain better in vitro and in vivo correlations 
especially when using extremely small amounts of peptide therapeutic.  
 
2.4.4. Food and Drug Administration approval of chitosan and chitosan derivatives  
 
To date chitosan and chitosan derivatives have not been granted Food and Drug 
Administration (FDA) approval for use in drug delivery systems (Kean and Thanou, 2010). 
This is mainly due to the wide range of different substances which are collectively referred to 
as chitosan (different average molecular weights and different degrees of acetylation). The 
FDA will only approve a DDS composed of chitosan once it has demonstrated limited toxicity 
in humans. Currently chitosan has not been characterised fully in terms of in vivo 
degradation but chitosan has been reported to have decreased degradation when the 
degrees of deacetylation are increased (Xu et al., 2007; Yang et al., 2007). In vivo 
degradation of chitosan within humans has been attributed to three enzymes namely acidic 
mammalian chitinase and di-N-acetylchitobiase. In addition, commercially available chitosan 
that is derived from shelled fish that may present a problem in patients that have seafood 
sensitivity (Baldrick, 2010). Even though it has been reported throughout literature that 
chitosan is a non-toxic, biodegradable and biocompatible polymer (Thanou et al., 2001), the 
FDA has not yet approved the whole chitosan group as being safe (Thanou et al., 2001). 
The chitosan derivative, trimethyl chitosan, has been reported to decompose similarly to 
chitosan by lysozyme processes but the degradation of trimethyl chitosan was pH 
independent (Verheul et al., 2009).  
 
The oral absorption of chitosan from the small intestine to the systemic circulation is not 
generally characterised well which presents a further issue for the FDA with regards to the 
approval of drug delivery systems that are based on chitosan (Kean and Thanou, 2010). It 
has been generally accepted that chitosan cannot be absorbed orally and therefore it is 
unlikely to demonstrate biodistribution especially when considering its high average 
molecular weight (Kean and Thanou, 2010). Weight loss products that are based on 
chitosan are currently used because these products fall within the weight loss supplement 
classification; thus chitosan does not need to be FDA approved for these uses. The toxicity 
of chitosan is also classified according to the degree of deacetylation and the average 
molecular weight (Schipper et al., 1996; Schipper et al., 1999; Kean and Thanou, 2010). 
With increased degrees of deacetylation and molecular weight, toxicity of chitosan increases 
and the visa versa is also the case (Schipper et al., 1996; Schipper et al., 1999; Kean and 
Thanou, 2010). 
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2.5. Concluding remarks  
 
The optimisation of pharmaceutical formulations which are designed to deliver peptide 
therapeutics via the oral route should consider the highlighted features of that was 
discussed. An example of a peptide drug formulation that is an alternative to parental 
administration is the FDA accepted nasal formulation of salmon calcitonin that has a 
bioavailability of only 3% relative to a parentally administered salmon calcitonin. Hence, an 
oral formulation, for example, of salmon calcitonin that can achieve a bioavailability of 10% 
to 30% would be a significant, economically feasible option and more over, a far more 
agreeable administration method for the patient. Any particular pharmaceutical formulation 
should also attempt to overcome each challenge outlined in this chapter as a single unified 
entity so that a patient will be more inclined to follow the correct dosing schedule in order to 
achieve a reasonable therapeutic outcome. The journey begins by developing a none-
specific metal chelator solid dosage form that can restrict the divalvent cation load within a 
localized site. Ideally, the chelatory ability of the metal chelator should remain intact, so that 
maximal chelatory ability can occur at the site of action. If the chelator is already occupied by 
divalent cations, the compound cannot reduce the localized cationic load at the site of 
delivery. Therefore, cannot assist the process of oral absorption of the peptide therapeutic at 
the target site. 
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CHAPTER 3 
Physicomechanical Characterization and Optimization of EDTA-mPEG and Avicel®-
EDTA-mPEG In Situ Hot Melt Dispersion Mini-Pellets 
 
3.1. Introduction  
 
The development of an oral drug delivery device for therapeutic peptides that will allow 
patients to avoid the parenteral route of administration, will result in increase patient 
compliance (Amidi et al., 2010; Makhlof et al., 2011; Dünnhaupt et al., 2012; Pillay et al., 
2012). The Oral Ghost Drug Delivery (OGDD) device is a single dosage form that contains 
distinct entities and is administered as a single unit. The metal chelatory mini-pellet 
formulation assists with the synergistic enhancement of in vivo bioavailability of a therapeutic 
peptide. This Chapter evaluates the physicomechanical properties of the in situ melt 
dispersion of ethylenediaminetetraacetic acid (EDTA) and the effect of including Avicel® 
RC/CL type R-591 (Avicel®) has on these in situ melt dispersions to facilitate the 
development of a predictably customizable metal chelating containing entity. 
 
Hot melt dispersion is a process whereby a drug entity is homogenously incorporated within 
a polymeric matrix without the use of solvent. This comprises a polymeric material that can 
undergo stable melting and a drug that is thermostable at the melting point of the polymeric 
material. A hot melt dispersion is a single-step process (polymeric material is melted at 
required temperature and drug mass is added to the molten polymeric material under 
constant aggregation) and no solvents are required which is an economical advantage 
(Breitenback, 2002). 
 
A metal chelator such as EDTA has been utilized for oral delivery of peptide therapeutics 
because it has been proven that EDTA decreases the localized ionic concentration load 
thereby reducing mucus viscosity and transiently reducing optimal peptidase enzyme (i.e. N-
aminopeptidase) activity (Bernkop-Schnürch et al., 1997; Peppas and Kavimandan, 2006; 
Bravo-Osuna et al., 2007; Whitehead and Mltragotri, 2008). In addition, EDTA has been 
suggested to enhance permeation of peptide therapeutics through the small intestine 
(Peppas and Kavimandan, 2006). An example of this can be reviewed in the permeation of 
hexarelin through the rat distal intestine that achieved an apparent permeation of 2.5 
(significantly greater than sodium caprate and palmitoylcarnitine) and allowed for 91% of the 
peptide drug to be recovered from the rat ileum after 60 min in comparison to 55% of the 
peptide drug without EDTA present (Westberg et al., 2001). Methoxy polyethylene glycol 
2000 (mPEG) is known as a waxy polymer with a low melting temperature. mPEG assisted 
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in the compatibility of EDTA and enhanced the compressibility of EDTA. Avicel® functions as 
a water-dispersible organic hydrocolloid that is primarily used for suspensions and 
emulsions. Avicel® provides an emulsion or suspension with two primary attributes, namely a 
structured dispersion element and a protective element (Rudraraju and Wyandt, 2005; Zhao 
et al., 2011). Avicel® was incorporated to determine the effect of an additional excipient to 
facilitate drug release. Avicel® is a spray-dried mixture of carboxymethyl cellulose and 
microcrystalline cellulose (Rudraraju and Wyandt, 2005; Zhao et al., 2011). 
 
The physicomechanical properties of each EDTA-mPEG and Avicel®-EDTA-mPEG in situ 
hot melt dispersion mini-pellet formulations were statistically analyzed using regression 
curve fitting to correlate the change of a physicomechanical property with that of changing 
excipient weight concentration in a predictable manner. A specific physicomechanical 
property degree within a specific formulation can be utilized to calculate, from fitted 
regression curves, the degree of other measured physicomechanical properties such as 
matrix hardness, matrix resilience, primary disintegration rate, secondary disintegration rate, 
or total disintegration time.  
 
3.2. Material and methods 
 
3.3. Materials  
 
EDTA (≥99  pure) was purchased from Sigma-Aldrich, mPEG 2000 was purchased from 
Fluka Analytical, Avicel® RC/CL type R-591 (co-dried blend of microcrystalline cellulose and 
sodium carboxymethyl cellulose) was purchased from FMC, hydrochloric acid from CJ 
Chem, monobasic potassium phosphate (99.99% pure) and sodium hydroxide (≥98  pure) 
was purchased from Merck Chemicals. 
 
3.4. Methods 
 
3.4.1. Synthesis of EDTA-mPEG in situ hot melt dispersion powder formulations 
 
The in situ hot melt dispersion powder formulation of EDTA-mPEG were synthesized at the 
weight concentration ratios shown in Table 3.1. Avicel® was added to formulations 6-10 at a 
constant weight concentration of 33%w/w. The mPEG was first melted to 60°C (two 
thermometers were utilized, one in a 100mL beaker containing 50mL water and another in 
within the molten mPEG) were  by a calibrated hot plate magnetic stirrer. Once the solid 
mass of mPEG was melted, EDTA was added to the molten mPEG. The EDTA was 
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homogenously distributed within the molten mPEG. Once The EDTA-mPEG hot melt 
dispersion was then allowed to cool under constant stirring. The cool solid mass was then 
passed through a metal sieve with an aperture of 850μm to form a fine powder. 
 
Table 3.1. Component concentrations (in percent 
w
/w) within the 10 formulations 
 
Formulation  
Number 
EDTA  
(%w/w) 
mPEG  
(%w/w) 
Avicel® RC/CL R-591  
(%w/w) 
1 10 90 0 
2 20 80 0 
3 30 70 0 
4 40 60 0 
5 50 50 0 
6 6.7 60.3 33 
7 13.4 53.6 33 
8 20.1 46.9 33 
9 26.8 40.2 33 
10 33.5 33.5 33 
 
3.4.2. Attenuated Total Reflectance-Fourier Transform Infrared quantification of EDTA 
and Avicel® 
 
Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) quantification was 
performed on EDTA and Avicel® at different mass concentrations within potassium bromide 
(KBr) utilizing a Perkin Elmer Spectrum 2000 FTIR spectrometer with a single-reflection 
diamond MIRTGS detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK). Samples 
were prepared and placed on a diamond crystal and processed by universal ATR 
polarization accessory for the FTIR spectrum series at a resolution of 4cm-1. The samples 
were subjected to a pressure of 130psi between the scanning range of 4000-600cm-1 and 
were scanned to obtain a signal to noise ratio of 10. Beer’s Law (Equation 3.1) was utilized 
in order to generate a quantitative analysis of the concentration of EDTA and Avicel® which 
had been serial diluted within potassium bromide. 
 
                                                                                                                            (Eqn. 3.1) 
 
Where A is absorbance, ε is absorptivity, l is path length, and c is concentration. 
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A serial dilution of EDTA and Avicel® was prepared using KBr as the diluent. Accurately 
weighted EDTA and Avicel® samples were ground with KBr to produce uniform white powder 
samples of increasing weight concentration of each compound. Unique wavenumber peaks 
for EDTA and Avicel® was determined from the ATR-FTIR spectra. A corresponding 
absorbance at the respective wavenumber peak, for each serial dilution, was determined for 
EDTA and Avicel®. The absorbence of wavenumber peaks (n=3) were plotted and a linear 
regression curve was fitted. The curve gradient was used for determinating the absorptivity 
and path-length (Equation 3.2) as a single variable. The single variable (m) and the 
absorbance at the wavenumber peak was used within Equation 3.3 to determine the 
concentration of EDTA and Avicel® from a sample. 
 
                                                                                                                            (Eqn. 3.2) 
 
Where m is the gradient of calibration curve, ε absorptivity, and l is path-length. 
 
         
        
 
                                                                                                    (Eqn. 3.3) 
 
Where Cunknown is the unknown concentration, Aunknown is the absorbance of unknown sample 
at a specific peak, and m is the gradient of the calibration curve.  
 
3.4.3. Determination of EDTA loading using physical separation within deionized 
water 
 
The weight of entrapped EDTA through physical separation was determined and compared 
to the loaded EDTA weight within each in situ melt dispersion powder formulation. The in situ 
hot melt dispersion powder formulations were accurately weighed into three samples of 
500±0.5mg and dissolved with deionized water for a period of 1 hour (to ensure complete 
removal of mPEG from the solid phase). The solution of each sample was then separated 
through filtration utilizing glass filters (0.22μm pore size) and placed in an oven at 40°C 
overnight. The quantity of entrapped EDTA within each sample of the in situ hot melt 
dispersion powder formulations was determined by Equation 3.4. This was used to 
determine the relationship between the effective EDTA entrapment and the loaded EDTA 
concentrations within each in situ hot melt dispersion powder formulation. 
 
                                                                                                              (Eqn. 3.4) 
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Where, WEDTA is the weight of EDTA dry mass, WEDTA filter is the weight of the dry filter after 
EDTA was retained in the filter, and Wfilter is the weight of the dry filter before EDTA was 
retained within the filter. 
 
3.4.4. Thermal characterization of EDTA-mPEG in situ hot melt dispersion/Avicel®-
EDTA-mPEG formulations 
 
EDTA-mPEG in situ hot melt dispersion powder formulations and Avicel®-EDTA-mPEG in 
situ hot melt dispersion powder formulation samples (n=3) were subjected to Differential 
Scanning Calorimetry (DSC) analysis in a similar manner as previously reported (Prodduturi 
et al., 2005). Accurately weighed samples (10±0.4mg) were placed in a 40μL aluminium 
crucible pan. An open crucible system was produced by inducing a 0.2mm hole in the lid 
aluminium crucible pan, which was then hermetically sealed. The thermal profile of each 
component that makes up the mini-pellets were compared with the formulation powders to 
determine any change in thermal properties. DSC protocols were ran within a ramping 
temperature of 2, 5 and 10°C/min between the temperature range of 25-110°C (first run), 
respectively. Each sample was analyzed again at the same respective heating rate but the 
temperature range wad extended from 25 to 270°C (second run). The heat of fusion, onset 
of melting, melting peak temperatures and crystallization peak temperatures were 
determined for each EDTA-mPEG in situ hot melt dispersion powder formulations and 
Avicel®-EDTA-mPEG in situ hot melt dispersion powder formulations. 
 
3.4.5. Manufacture of EDTA-mPEG and Avicel®-EDTA-mPEG in situ hot melt 
dispersion powder into mini-pellets 
 
The EDTA-mPEG in situ hot melt dispersion powder formulations and Avicel®-EDTA-mPEG 
in situ hot melt dispersion powder formulations were accurately weighed into predetermined 
weight allotments. A modified punch and die tool was utilized to produce cylindrical mini-
pellets with a diameter of 4mm under a hydraulic pressure of 3.45MPa from each accurately 
weighed allotment. The length of the cylindrical mini-pellets varied depending on the amount 
of powders used and the compressibility of the formulation. Each mini-pellet which had a 
weight difference of ±0.5mg of the original allotment weight was discarded. The thickness of 
the minipellets varied according to the physical amount of the excipient that was utilized for 
each formulation. 
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3.4.6. Physicomechanical properties of EDTA-mPEG and Avicel®-EDTA-mPEG in situ 
hot melt dispersion mini-pellets 
 
The EDTA-mPEG and Avicel®-EDTA-mPEG in situ hot melt dispersion mini-pellets 
formulations were evaluated with respect to matrix resilience (MR), matrix hardness (MH) 
and deformation energy (DE). A calibrated textural analyzer (TA.XT plus, Stable 
Microsystems, Surrey, UK) fitted with a cylindrical steel probe (50mm diameter; for MR) and 
a flat tip steel probe (2mm diameter; for MH and DE) was utilized. The parameters utilised 
for the analysis is outlined in Table 3.2. All studies (n=3) were conducted at standard 
operating procedures (25°C, 1atm pressure). 
 
Table 3.2. Textural profiling parameters employed for physicochemical characterization of EDTA-
mPEG and and Avicel
®
-EDTA-mPEG in situ hot melt dispersion mini-pellet formulations  
 
Parameters MR*(%) MH* (N/mm) DE* (J) 
Pre-test speed 1mm/s 1mm/s 1mm/s 
Test speed 0.5mm/s 0.5mm/s 0.5mm/s 
Post-test speed 10mm/s 10mm/s 10mm/s 
Trigger type Auto Auto Auto 
Trigger force 0.05N 0.05N 0.05N 
Load cell 5Kg 5KG 5Kg 
Compression strain Variable N/A N/A 
Target mode Stain (40%) Distance Distance 
  *MR: matrix resilience 
  *MH: matrix hardness 
  *DE: deformation energy 
MR (%) was calculated by the percentage of the ratio between the area under the curve 
(AUC) of the peak to baseline (after the force was removed; AUC2-3) and the baseline to 
peak (before the force is removed; AUC1-2) from a Force-Time profile (Murphy et al., 2012). 
MH (in Newton per millimetre), and DE (in Joules) were both determined based on force-
distance profiles. In particular, MH was elucidated from the gradient between the initial force 
and the maximum force attained, and the DE from the AUC (Murphy et al., 2012). The MH, 
MR, and DE for each EDTA-mPEG and Avicel®-EDTA-mPEG in situ hot melt dispersion 
formulations were determined (n=3). The measurements for each formulation were plotted 
regression curve fitted to each set of formulations with respect to increasing mini-pellet 
weight.  
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3.4.7. Disintegration studies determined from EDTA-mPEG in situ hot melt dispersion 
mini-pellet formulations and Avicel®-EDTA-mPEG in situ hot melt dispersion mini-
pellet formulations 
 
The disintegration studies of the EDTA-mPEG and Avicel®-EDTA-mPEG in situ hot melt 
dispersion mini-pellet formulations were evaluated on a textural analyzer (TA.XT plus, Stable 
Microsystems). A speciality probe was attached to the textural analyzer which facilitated 
disintegration testing. Water soluble glue was used to attach the mini-pellet to the probe 
head. A reservoir of USP 36 simulated intestinal buffer (pH 6.8) was placed under the probe. 
The mini-pellet was lowered into the reservoir and as the mini-pellet came in contact with a 
magnetic gridded base plate, the distance from the magnetic gridded base plate to the 
surface of the probe head was captured. As the in situ hot melt dispersion mini-pellet 
formulation disintegrates within the simulated intestinal buffer, the probe was lowered and 
the distance moved over time was captured as a disintegration profile.  
 
The disintegration parameters (primary rate of disintegration, secondary rate of 
disintegration, and total disintegration time) for each EDTA-mPEG in situ hot melt dispersion 
mini-pellet formulation and Avicel®-EDTA-mPEG was evaluated in triplicate. The obtained 
data points (including standard deviations) were placed within a scatter plot and a regression 
curve was applied to these scatter points for each formulation with respect to increasing 
mini-pellet weights. The parameters utilized for textural disintegration analysis is outlined in 
Table 3.3. 
 
3.4.8. Scanning Electron Microscopy imaging of EDTA-MPEG and Avicel®-EDTA-
mPEG in situ hot melt dispersion mini-pellet formulations  
 
Scanning electron microscopy (SEM) imaging studies were performed (n=3) for each in situ 
hot melt dispersion mini-pellet formulation that had a total weight of 60mg. The surface 
structures at two locations were obtained per in situ hot melt mini-pellet formulation for 
comparative purposes. Each in situ hot melt dispersion mini-pellet formulation was mounted 
on a stub with silicon tape and sputtered coated with gold for 210s. Each mini-pellet was 
then placed in a F   Phenom™ Desktop Scanning  lectron Microscopy (The Netherlands, 
Eindhoven) and SEM images were aquired. The first image obtained was the edge of the in 
situ hot melt dispersion mini-pellet formulation and the second image was obtained in the 
inner central surface of the in situ mini-pellet formulation. 
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Table 3.3. Textural parameters employed for disintegration characterization of EDTA-mPEG in situ 
hot melt dispersion mini-pellet formulations and Avicel
®
-EDTA-mPEG in situ hot melt dispersion mini-
pellet formulations 
 
Mode Measure force in distance-time 
Option Hold until reset 
Pre-test speed 2.0mm/s 
Test speed 3.0mm/s 
Post test speed 10.0mm/s 
Force 10g 
Trigger type Auto - 3g 
Load cell 5Kg 
Tare mode Auto 
 
 
3.4.9. Statistical regression analysis  
 
The standard deviation of each obtained data measurement (n=3) was determined using 
Microsoft® Office Excel® 2007 (Build 12.0.4518.1014, Microsoft Corporation, USA). The 
obtained data measurements and the standard deviations were plotted within scatter plots 
using SigmaPlot V11.0 (Build 10.0.0.77, Systat Software Inc., Germany). Regression curves 
were fitted to the scatter plots and R2 values for each regression curve were determined 
using SigmaPlot V11.0. A Shapiro-Wilk test was utilized during the calculation of each 
regression curve to determine if obtained data measurements were normally distributed 
populations at an alpha level of 0.05 using SigmaPlot V11.0. In addition, a constant variance 
test (P=0.05) for each regression curve was determined to indicate if the dependent variable 
remained constant despite a dynamically changing value of the independent variable using 
SigmaPlot V11.0. The 95% confidence interval and 95% predicted confidence interval was 
determined for linear regression curves in quantitative ATR-FTIR analysis and physical 
separation of EDTA from in situ melt dispersion powder formulations was obtained using 
SigmaPlot V11.0. 
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3.5. Results and Discussion 
 
3.5.1. Determination of entrapped EDTA from EDTA-mPEG in situ hot melt dispersion 
powder formulations 
 
Quantitative ATR-FTIR analysis of EDTA and Avicel® was conducted by serial dilution within 
KBr which generated a linear standard regression curve (Khoshmanesh et al., 2012) (Figure 
3.1). The quantitative ATR-FTIR analysis was initially utilized as a non-destructive means to 
determine the entrapped EDTA weight concentration within each in situ melt dispersion 
powder formulation (Khoshmanesh et al., 2012). The absorbencies (n=3) of EDTA and 
Avicel® increased as the concentrations of these compounds increased within KBr. 
 
 
Figure 3.1: ATR-FTIR spectra of different standard EDTA concentrations (A): 10%
w
/w (red), 20%
w
/w 
(blue), 30%
w
/w (pink), 40%
w
/w (green) and 50%
w
/w (orange) used to generate the standard curve. ATR-
FTIR spectra of different standard Avicel
®
 RC/CL type R-591 concentrations (B): 10%
w
/w (light purple), 
20%
w
/w (gray), 30%
w
/w (green), 40%
w
/w (dark purple), and 50%
w
/w (blue) used to generate the 
standard curve. Each profile was obtained from 100 scans (SNR:10) between a range of 4000-600cm
-
1
 at a constant pressure of 130psi. 
 
The unique wavenumber peak of EDTA and Avicel® was determined at 1212 cm-1 and 
892cm-1, respectively. The determined absorbencies (n=3) at this wavenumber were plotted 
and the R2 adjusted value was determined to be 0.98 for each fitted linear regression curve. The 
determined absorbencies values remained within the 95% confidence interval and the 95% 
predicted confidence interval. The fitted linear regression curve passed the normality test 
KBR+10% EDTA 130psi 100scans 4000-600range
KBR +20% EDTA 130 psi 100 scans 4000-600 range
KBr+30% EDTA 130psi 100 scans 4000-600 range
KBr+40% EDTA 130psi 100scans 4000-600 range
KBR+50% EDTA 130psi 100 scans 4000-600range
Name
Sample 030 By Administrator Date Wednesday, February 22 2012
Sample 028 By Administrator Date Wednesday, February 22 2012
Sample 031 By Administrator Date Wednesday, February 22 2012
Sample 032 By Administrator Date Wednesday, February 22 2012
Sample 029 By Administrator Date Wednesday, February 22 2012
Description
4000 6003500 3000 2500 2000 1500 1000
0.71
-0.01
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0.10
0.15
0.20
0.25
0.30
0.35
0.40
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0.55
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0.65
cm-1
A
10% Avicel 130psi 100scans 4000-600 range S1
20% Avicel 130psi 100scans 4000-600 range S1
30% Avicel KBR 130psi 100 scans 4000-600 range_1
40% Avicel KBr 130psi 100scans 4000-600 range S2
50% aVICEL 130psi 100scans 4000-600 range S3
Name
Sample 045 By Administrator Date Monday, February 27 2012
Sample 044 By Administrator Date Monday, February 27 2012
Sample 040 By Administrator Date Friday, February 24 2012
Sample 041 By Administrator Date Friday, February 24 2012
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0.40
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A 
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1212cm-1 
892cm-1 
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Shapiro-Wilk at an alpha level of 0.05 and the constant variance test (P=0.05). The serial 
dilution of EDTA and Avicel® within potassium bromide produced highly predictable 
absorbencies.  
 
The concentration of EDTA could not be determined accurately because the mPEG had 
effectively coated EDTA. The ability of ATR-FTIR to detect EDTA within the mPEG melt was 
restricted because very little surface boundary of EDTA molecule was exposed. An example 
of this is the entrapment of a drug substance within the core of cyclodextrin (de Sousa et al., 
2008). The ability of ATR-FTIR to detect a drug substance within the cyclodextrin core is 
effectively reduced as the absorption and reflection of infrared light is a surface boundary 
phenomenon. The infrared light cannot penetrate into the cyclodextrin core or through the 
mPEG coating of EDTA that allows for the accurate determination of “internalized” 
compound concentrations. The concentration of Avicel® was difficult to determine within the 
in situ melt dispersion powder formulations because this compound is made of methyl 
cellulose which does not absorb strongly, relatively to EDTA and mPEG. 
 
The loaded concentration of EDTA within in situ hot melt dispersion powder formulations 
were determined by the physical separation of EDTA from the in situ hot melt dispersion 
powder formulations (Figure 3.2). The physical separation was conducted within deionized 
water because EDTA that is not chelated to any metal ion species is highly insoluble within 
deionized water whereas mPEG is highly soluble within deionized water. The slight 
predictable deviation, whereby the determined weight of EDTA was higher than the original 
loaded mass of EDTA, is due to entrapment of mPEG within the filter. The physical 
separation was conducted within deionized water because EDTA that is not chelated to any 
metal ion species is highly insoluble within deionized water whereas mPEG is highly soluble 
within deionized water. The slight predictable deviation, whereby the determined weight of 
EDTA was higher than the original loaded mass of EDTA, is due to entrapment of mPEG 
within the filter. The physical separation of EDTA from the in situ hot melt dispersion powder 
formulations allowed for accurate determination of loaded EDTA. 
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Figure 3.2: Scatter plot of Avicel
®
 RC/CL type R-591 (blue squares) (A) and 
ethylenediaminetetraacetic acid (B) concentration (in percent 
w
/w) against absorbance units at 892 cm
-
1
 and 1212cm
-1
, respectively. Scatter plot EDTA weight recovery (C) within increasing EDTA 
concentration (in %
w
/w) formulations. A linear regression curve was fitted to each scatter plot and a 
linear regression curve fitted. Each fitted regression curve has an R
2
 value, 95% confidence interval 
(blue line), 95% predicted confidence interval (red line) determined. 
 
3.5.3. Thermal Analysis of EDTA-mPEG in situ hot melt dispersion/Avicel®-EDTA-
mPEG formulations 
 
The development of an oral pellet dosage form usually requires the homogenous mixing of 
drug powder excipients and the drug or dissolving the powder excipient within a solvent, the 
homogenously mixing powder excipient solutions/suspensions with drug and then removal of 
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the solvents takes place to generate uniform mixtures (Gu et al., 1990; Breitenback, 2002; 
Sanganwar et al., 2010). The challenge with mixing drug polymers within a homogenous 
mixture is the variability that may cause slight deviations in drug concentrations within the 
powdered excipients but solvent mixing produces industrial polution and some drugs 
degrade when exposed to solvents. Melt dispersions allow a reduction in drug loss, a more 
homogenous distribution with respect to drug, as well eliminating the requirement of 
solvents.  
 
The heat of fusion, the onset of melting, or crystallization temperature and the peak melting 
or crystallization temperature for Formulation 1 and 5 in Figure 3.4 and 6 and 10 in Figure 
3.4. The crystailization events that occurred during the DSC analysis indicate that 
amorphous material underwent an enthopy event to become more ordered in response to 
heat energy input. Thus, knowing precisely where this may occur can assist formulation 
processes. The main component that would undergo crystallization within the Avicel®-EDTA-
mPEG would be Avicel® as this component already contains microcrystalline cellulose 
which may be induced to form additional crystallization upon exposure to heat energy.  The 
DSC results are represented for these formulations because the represent the most extreme 
weight concentrations of excipients that were utilized in this study. The DSC of the melt of 
dispersion formulations indicate that EDTA and mPEG formed a physical melt dispersion as 
the melting points for both compounds did not significantly change. The heating rate of 
2°C/min generally obtained the highest heat of fusion and the slower heating rate causes the 
sample to undergo the process of protracted melting. Interestingly, Formulation 1 which 
contains EDTA-mPEG (10:90) required 65.34% less heat of fusion energy than Formulation 
5 which contains EDTA-mPEG (50:50). The heat of fusion energy required to induce melting 
in Formulation 6, Avicel®-EDTA-mPEG (33:6.7:60.3), was determined to be 66.46% less 
than Formulation 10, Avicel®-EDTA-mPEG (33:33.5:33.5).  
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Figure 3.3: Differential Scanning Calorimetry of Formulation 1 (EDTA-mPEG (10:90) in situ hot melt 
dispersion powder and Formulation 5 (Avicel
®
-EDTA-mPEG (50:50) in situ hot melt dispersion powder 
(n=3).  
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Figure 3.4: Differential Scanning Calorimetry of Formulation 6 (Avicel
®
-EDTA-mPEG (33:6.7:60.3)) in 
situ hot melt dispersion powder and Formulation 10 (Avicel
®
-EDTA-mPEG (33:33.5:33.5)) in situ hot 
melt dispersion powder (n=3).  
 
3.5.4. Physicochemical properties of the EDTA-mPEG and Avicel®-EDTA-mPEG in situ 
hot melt dispersion mini-pellet formulations 
 
3.5.4.1. Matrix Hardness, Matrix Resilience and Deformation Energies studies 
 
The matrix hardness of a substance is determined at a point of indentation that stresses the 
local intermolecular bond strength which exists between the powdered granules of the pellet 
by measuring the amount of force per millimetre required to indent the surface of the pellet. 
56 
 
The greater the force required to cause an indentation within the pellet surface, the greater 
the bond strength between the powder granules (Ellison et al., 2008). The scatter plots and 
the fitted regression profile for each formulation are shown in Figure 3.5 and Figure 3.6. 
The Shapiro-Wilk test passed at an alpha level of 0.05 for each scatter plot and the variance 
constant test was passed (P=0.05) for each regression curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Matrix hardness, deformation energy and the matrix resilience regression plots for 
formulation 1 – 5. 
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Figure 3.6: Matrix hardness, deformation energy and the matrix resilience regression plots for 
formulation 6 – 10. 
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occurred in all formulations that were assessed. The matrix resilience for formulations which 
contained Avicel® (Formulations 6 and 10) was less than the formulations which did not 
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concentration of EDTA also had reduced matrix resilience. Deformation energy was 
determined to be constant throughout all the in situ melt dispersion formulations than were 
tested at ~0J. The in situ hot melt dispersion mini-pellets were highly resistant to plastic 
deformation even at high-strain degrees.  
 
3.5.4.2. Disintegration of EDTA-mPEG in situ hot melt dispersion mini-pellet and 
Avicel®-EDTA-mPEG in situ hot melt dispersion mini-pellets 
 
The time-distance profile was analyzed and the total time of disintegration, the primary rate 
of disintegration, the secondary rate of disintegration, and the pellet thickness was 
determined by the shape of the graph and formulation 1 to 5 in Figure 3.7 and formulation 6 
to 10 in Figure 3.8 (El-Arini and Clas, 2002). The total disintegration time increased with the 
increasing concentrations of EDTA within EDTA-mPEG in situ hot melt dispersion mini-
pellets. Additionally, total disintegration time increased significantly with the addition of 
Avicel®. Formulation 1 pellets had the fastest disintegration time but the weakest matrix 
hardness whereas Formulation 10 mini-pellets had the longest disintegration time. The effect 
that bond strength has on the total disintegration time can be observed when comparing 
formulations 1 to 5. The weight concentration of EDTA within Formulation 5 was five times 
greater than in Formulation 1, but the total disintegration time only increased 10 minutes.  
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Figure 3.7: Total disintergration time, primary disintergration rate, secondary disintergration rate and 
mini-pellet thickness regression plots for formulation 1 – 5. 
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Figure 3.8: Total disintergration time, primary disintergration rate, secondary disintergration rate and 
mini-pellet thickness regression plots for formulation 6 – 10. 
 
The primary disintegration rate (mm/s) is the breakdown of the in situ hot melt dispersion 
mini-pellet into granules per minute. The primary disintegration rate was determined to be 
the fastest in Formulation 5 pellets even though the bulk volume was the greatest whereas 
the primary disintegration rate was the slowest in Formulation 10. The presence of EDTA 
within mPEG induces faster primary disintegration because once the strong intermolecular 
bond is broken, the macrostructure of the in situ hot melt dispersion mini-pellet breaks down 
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to granules very rapidly. Whereas Avicel® reduces the primary rate of disintegration because 
the compound effectively eliminated void spaces that resulted in recued surface area which 
solvent attack may occur at cold weld spots within the macrostructure of the in situ hot melt 
dispersion mini-pellet. In combination, these compounds could be used to customize the 
disintegration rate of in situ hot melt dispersion formulations in a predictable manner. 
 
The secondary disintegration rate (mm/s) is the dissolution of in situ hot melt dispersion mini-
pellet granules. The secondary disintegration rate was determined to be the fastest when 
EDTA weight concentrations within in situ hot melt dispersion mini-pellets were at the lowest 
respective concentrations. This may be a benefit to the in situ hot melt dispersion mini-pellet 
formulations. For example, EDTA in these in situ hot melt dispersion mini-pellet formulations 
would benefit from a slow secondary disintegration rate as this allows the granules of these 
formulations to penetrate deeper into the mucosal layer and chelate divalent cations deeper 
within the mucosal layer (Singhal and Curatolo, 2004). The primary disintergration is the rate 
limiting step of releasing drug during the disintergration process because the solvent can has 
access only to a relatively small surface area of the mini-pellet. The formation of granules 
during the secondary disintegration, increases the surface area that the solvent can access 
and increases the release rate of the drug with respect to the primary disintegration phase. 
 
The successful industrial manufacture of a solid dosage form, such as the in situ hot melt 
dispersion mini-pellets, is dependent on the degree of compressibility a formulation may 
achieve (Singhal and Curatolo, 2004). The pellet thickness directly indicates the 
compressibility of the in situ hot melt dispersion mini-pellet formulations when compressed at 
the same force. For example, Formulation 10 had the greatest compressibility, but the 
entrapped EDTA weight concentration was not the highest of the tested formulations. 
Whereas Formulation 5 has the highest entrapped EDTA weight concentration but had a 
reduced degree of compressibility. An additional advantage of the higher compressibility of 
Formulation 10 is that the formulation weight could be adjusted to compensate for the 
reduced EDTA concentration with respect to Formulation 5 but maintain an almost equal 
volume. Therefore, Formulation 10 could achieve all the benefits of including Avicel® but 
maintains a relatively higher or similar EDTA payload to that of Formulation 5. 
 
3.5.5. Surface Morphology Analysis of EDTA-mPEG in situ hot melt dispersion and 
Avicel®-EDTA-mPEG in situ hot melt dispersion mini-pellet formulations 
 
The surface structure of the in situ mini-pellet formulations were viewed from the edge of the 
in situ hot melt dispersion mini-pellet and the center of the in situ hot melt mini-pellet using 
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SEM imaging, as seen in Figure 3.9. Formulation 1, which had the highest concentration of 
mPEG, had the most uniform surface structure whereas Formulation 5 that had the highest 
concentration of EDTA had a relatively heterogeneous surface structure. Formulations 6 and 
10 which contained Avicel® had microcracks in the surface structure which was not similar to 
those of Formulations 1. The surface structure of the formulation indirectly indicated the 
physicomechanical effect of including Avicel® and EDTA had on the macrostructure of the in 
situ hot melt dispersion mini-pellets. The SEM images of the melt dispersion formulations 
clearly indicated that the surface topography of EDTA-mPEG in situ hot melt dispersion mini-
pellets is significantly more uniform than those formulations which contain Avicel®. The 
mPEG may have compressed at the surface level to fill large void spaces but the ability of 
the mPEG to fill the void space decreases within the core macrostructure of the mini-pellet. 
 
3.5.6. The customization of EDTA-mPEG and Avicel®-EDTA-mPEG in situ hot melt 
dispersion mini-pellet formulations 
 
The focus of this study was determining the physicomechanical effect of Avicel® inclusion on 
EDTA-mPEG in situ hot melt dispersion mini-pellet formulations. Additionally, the 
predictability of physicomechanical properties could be accurately determined from 
regression curve fitting. This allows for a customizable system to be developed where the 
physicomechanical properties of the formulations is predictable. An example of this are 
shown in Table 3.4. The optimal hardness with respect to in situ hot melt dispersion mini-
pellet weight was determined from the second derivative of the fitted regression curve 
equation. The in situ hot melt dispersion mini-pellet matrix hardness, total disintegration time, 
primary rate of disintegration, secondary rate of disintegration, mini-pellet thickness and 
amount of loaded EDTA can be predicted. The prediction of physicomechanical properties of 
a formulation is not limited to optimal hardness but can be determined for any desired 
physicomechanical property. 
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Figure 3.9: Scanning Electron images of the EDTA-mPEG and Avicel
®
-EDTA-mPEG in situ hot melt 
dispersion mini-pellet formulations.  
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Table 3.4. The optimal pellet properties determined from regression fitted curves for formulation 1, 5, 
6 and 10 
 
Parameter Formulation 
1 pellets 
Formulation 
5 pellets 
Formulation 
6 pellets 
Formulation 
10 pellets 
Weight of optimal 
hardness (mg) 
36.284 38.8175 45.0556 36.2778 
Matrix hardness 
(N/mm) 
67.28 72.29 75.32 75.53 
Total disintegration 
time (s) 
967.717 1587.518 2062.359 4965.965 
Primary rate of 
disintegration (mm/s) 
-0.00283 -0.00629 -0.00486 -0.0013 
Secondary rate of 
disintegration (mm/s) 
-0.00287 -0.00262 -0.00206 -0.001 
Pellet thickness (mm) 2.051 3.079 2.396 1.592 
EDTA weight (mg) 3.63 19.41 3.02 12.15 
 
3.6. Concluding remarks 
 
The incorporation of Avicel® RC/CL type R-591 enhanced the physicomechanical properties 
of the in situ hot melt dispersion mini-pellet formulations of chelatory agent EDTA. In 
addition, the incorporation of Avicel® RC/CL type R-591 within the in situ hot melt dispersion 
formulation allowed for extended disintegration to occur. The physicomechanical properties, 
such as matrix hardness or total disintegration time, of these formulations were described 
using mathematical regression curve fitting. Desired physicomechanical properties, 
formulations were described using mathematical regression curve fitting. A desired 
physicomechanical property degree, within a specific in situ hot melt dispersion formulation, 
can mathematically predicts the degree of other physicomechanical properties to create a 
customizable formulation for a specific application. This would be extremely useful within the 
OGDD device where the properties of the drug-carrying entity or permeation-enhancing 
entity can be synergistically enhanced using a predictable customizable EDTA containing in 
situ hot melt dispersion mini-pellet formulation. The selection of the best in situ hot melt 
dispersion mini-pellet formulation could be simply selected from desired physicomechanical 
properties using mathematically determined regression curves to meet the needs of the 
OGDD device. 
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CHAPTER 4 
pH Responsive Hydrogel Formulations For The Oral Ghost Drug Delivery Device 
 
4.1. Introduction 
 
Targeted pH-responsive oral drug delivery, such as hydrogels, have been utilized to 
overcome the challenges in optimal drug absorption or reduction of side-effects (Calija et al., 
2013; Islam et al., 2013; Lopes et al., 2013; Pandey et al., 2013). The ability of these pH 
responsive hydrogels to respond to the gastrointestinal pH gradient has been determined 
within USP dissolution buffers (simulated gastric and simulated intestinal pH). Recently, new 
biorelevant dissolution fluids have been developed to accurately predict the solubility of 
drugs or account for a change in drug dissolution profiles of an optimized drug delivery 
system (Witzleb et al., 2012; Gómez et al., 2013; Sangwai and Vavia, 2013; Takács-Novák 
et al., 2013).   Biorelevant fluids have been suggested to simulate the physiological fluids 
within the GIT to a higher degree than USP dissolution fluids, especially for charged 
lipophilic compounds (Vertzoni et al., 2005; Fagerberg et al., 2010). Biorelevant dissolution 
fluids have been designed to obtain similar surface tension, pH buffer capacity, pH and 
osmolality that are present physiologically within the human GIT (Jantratid et al., 2009). In 
addition to human biorelevant dissolution fluids, canine biorelevant dissolution fluids have 
been designed to increase the in vitro and in vivo correlation of a drug entity profile during 
preclinical trial phases of drug development (Arndt et al., 2013). The beagle dog is often 
utilized during preclinical studies because this model animal is easy to utilize but an average 
male beagle dog can only achieve a body weight between 7 and 13Kg (Hu et al., 2011; 
Otabe et al., 2011; Liu et al., 2012).  A porcine model is favoured by some researchers as 
these animals have been suggested to have a very similar anatomical, physiological GIT 
features to that of humans, can eat a similar diet to humans and can easily achieve the 
same weight of an adult human (Davis et al., 2001; O’Driscoll and Griffin, 2008). 
 
This in vitro-ex vitro study was designed to evaluate a crosslinked acrylamide-methyacrylic 
acid (AAm-MAA) pH responsive hydrogel within drug delivery device. The study was 
designed to firstly, evaluate the polymerization of crosslinked AAm-MAA hydrogel 
formulations and remove any of the formulations that underperformed during the synthesis 
reaction. The dried AAm-MAA hydrogel formulations were then subjected to spectroscopic 
and thermal analysis to determine the degree of crossed linking of the AAm-MAA at different 
reacted concentrations. Additionally, the AAm-MAA hydrogel formulations were then 
subjected to performance evaluation within biorelevant dissolution fluids and isolated porcine 
fluids.  Finally, optimized hydrogel for the current application AAm-MAA hydrogel formulation 
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was observed through MRI studies within USP dissolution fluids. This study aims to 
demonstrate the impact that biorelevant dissolution fluids can have on the 
physicomechanical performance of a pH responsive hydrogel and compare this 
physicomechanical performance with the physicomechanical performance within isolated 
porcine fluids. Furthermore, this study also aimed to demonstrate that the altered 
physicomechanical performance of a pH responsive hydrogel within biorelevant dissolution 
fluids or isolated porcine gastrointestinal fluids may impact the dissolution profile of a variety 
of entrapped drugs for three formulations which were either relatively pH insensitive 
(expanded in acidic and neutral pH media), or contained an equal mass concentration of 
AAm-MAA or was very sensitive to pH (expanded only in neutral media).  
 
4.2. Materials and Methods 
 
4.3. Materials 
 
Acrylamide (≥98  pure, MW 71.08g/mol) was purchased from Fluka (Sigma-Aldrich, Buchs, 
Switzerland). Methacrylic acid (99% pure, 86.09g/mol) was purchased from Aldrich 
(Schnelldorf, Germany). Tetramethylethylenediamine (99% pure, 116.20g/mol) , ammonium 
persulfate (98% pure, 228.20g/mol), Pluronic F-127, N,N’-methylenebis(acrylamide) (99% 
pure, 154.17g/mol), sodium hydroxide (≥98  pure), sodium chloride (≥99  pure), 
hydrochloric acid (37%v/v), sodium deoxycholate (≥98  pure), maleic acid (99% pure), 
lysophosphatidylcholine (≥99  pure), sodium taurocholate (≥90  purity), sodium 
taurodeoxycholate (≥97  purity), sodium dihydrogen phosphate monohydrate (≥99  purity) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). dichloromethane (≥99.9  pure), 
sodium dihydrogen phosphate monohydrate (≥99  purity), acetic acid (99.99 ) and 
orthophosphoric acid (85%w/v, 99.99% pure) were purchased from Sigma-Aldrich (St. Louis, 
Missouri, USA).  Egg phosphoatidylchloline (97.5% pure) purchased from Lipoid GmbH 
(Ludwigshafen, Germany).  Acetonitrile (≥99.9  pure) and sodium oleate (≥99  pure) was 
purchased from Sigma (St. Louis, MO, USA) at UPLC grade.  
 
4.4. Methods 
 
4.4.1. Synthesis of the pH responsive hydrogel to be implemented in the oral ghost 
drug delivery device  
 
The synthesis of crosslinked acrylamide-methacrylic acid (AAm-MAA) hydrogel formulations 
was achieved through a modifed free radical polymerization (Hames, 1990). Aqueous 
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solutions of acrylamide and methacrylic acid were prepared (Table 4.1). Additionally, 
solutions of N,N’methylenebis(acrylamide) (B S), Pluronic F-127 (F127), N,N,N’,N’-
tetramethylenthylenediamine (TEMED) and ammonium persulfate (APS) were also prepared 
accordingly (Table 4.1). The monomer solutions were sequentially added to a glass polytop, 
followed by the crosslinker BIS, deionised water, and surfactant F127. Once the solution was 
homogenously mixed, free radical polymerization was induced with the addition of APS and 
TEMED at room temperature (Shibayama et al., 1999). Sodium hydrogen carbonate was 
immediately added to the polymerizing solution and allowed to generate carbon dioxide gas 
bubbles within the polymerizing solution for 60 seconds. The polymerizing solution was 
either poured into cylindrical moulds (0.4mm diameter) and allowed to cure overnight or 
poured between the cone and plate rheometer to measure the increase of viscosity with 
respect to time during the polymerization reaction. The hydrogel formulations nomenclature 
utilized throughout this study will correspond to the nomenclature utilized in Table 4.1. For 
instance, F1 (Formulation 1) will correspond to a hydrogel with a acrylamide concentration of 
100%w/v and methacrylic acid concentration of 0%
w/v. 
 
Table 4.1. The composition of the crosslinked acrylamide-methacrylic acid hydrogel formulations 
 
Formulation [AAm] 
(%w/w) 
[MAA] 
(%w/v) 
[MBA] 
(%w/v) 
dH2O [F127] 
(%w/v) 
[APS] 
(%w/v) 
[TEMED] 
(%w/v) 
NaH
CO3 
(mg) 
F1 100 0 2.5 - 10 20 20 100 
F2 90 10 2.5 - 10 20 20 100 
F3 80 20 2.5 - 10 20 20 100 
F4 70 30 2.5 - 10 20 20 100 
F5 60 40 2.5 - 10 20 20 100 
F6 50 50 2.5 - 10 20 20 100 
F7 40 60 2.5 - 10 20 20 100 
F8 30 70 2.5 - 10 20 20 100 
F9 20 80 2.5 - 10 20 20 100 
F10 10 90 2.5 - 10 20 20 100 
F11 0 100 2.5 - 10 20 20 100 
Volume added 
to final in situ 
gelling 
solution (mL) 
 
3 
 
2 
 
0.7 
 
3 
 
0.3 
 
0.25 
 
0.25 
 
*[AAm]: concentration of acrylamide 
*[MAA]: concentration of methacrylic acid 
*[MBA]: concentration of N,N’-methylenebis(acrylamide) 
*dH2O: deionised water 
*[F127]: concentration of Pluronic F-127 
*[APS]: concentration of ammonium persulfide 
*[TEMED]: concentration of N,N,N’,N’- tetramethylethylenediamine 
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4.4.2. Chemical structure analysis of the crosslinked AAm-MAA hydrogel formulations 
 
Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) analysis was 
performed on freshly prepared crosslinked AAm-MAA hydrogel formulations, dried 
crosslinked AAm-MAA hydrogel formulations, AAm, MAA, MBA, and pluronic F-127. A 
Perkin Elmer Spectrum 2000 FTIR spectrometer with a single reflectance MIRTGS detector, 
(PerkinElmer Spectrum 100, Llantrisant, Wales, UK) was utilized for analysis. 
 
 
Dried samples were prepared by milling and sieved through an 800μm aperture sieve to 
generate fine dried powder particles which could be easily compacted against the diamond 
crystal. Freshly prepared samples (that were in the semi-solid state) were cut into small 
pieces which could easily compact against the diamond crystal under 130psi pressure. 
Samples were placed on a diamond crystal and processed by universal ATR polarization 
accessory for the FTIR spectrum series at a resolution of 4cm-1. Each sample was analysed 
after 100 scans (SNR:10) at 130psi between 650-4000cm-1 range.  
 
4.4.3. Thermal characterization of crosslinked AAm-MAA hydrogel formulations 
 
Differential Scanning Calorimetry (DSC) analysis of crosslinked AAm-MAA hydrogel 
formulations (n=3) were conducted on a indium calibrated Differential Scanning Calorimeter 
(Mettler Toledo DSC1 STARe System, Switzerland) in a similar manner as reported 
previously (Prodduturi et al., 2005). Accurately weighed samples (10±0.4mg) were placed in 
a 40μL aluminium crucible pan. The thermal profile of each component which makes up the 
crosslinked AAm-MAA hydrogel and powdered samples of each AAm-MAA hydrogel 
formulation were analysed to determine any change in thermal properties. DSC protocols 
were run with a ramping temperature of 2, 5, and 10°C/min (first run), respectively. Each 
sample was analyzed again at the same respective heating rate but the temperature range 
was extended from 25 - 270°C (second run). The heat of fusion, onset of melting, melting 
peak temperatures and crystallization peak temperatures were determined for each 
crosslinked AAm-MAA formulation hydrogel. 
 
4.4.4. Viscosity analysis of the polymerizing crosslinked AAm-MAA formulation 
hydrogels 
 
The viscosity (η) of the polymerizing hydrogel formulations were determined at 10°C, 25°C 
and 40°C at shear rate 200s-1 using a Modular Advanced Rheometer (ThermoHaake MARS 
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Modular Advanced Rheometer, Thermo Electron, Karlsruche, Germany) equipped with a 
C35/1° Ti sensor. Measurements were performed employing the rheological parameters 
shown in Table 4.2.  
 
Table 4.2. Rheological parameters utilized for the analysis of gelation initiation within the crosslinked 
acrylamide-methacrylic acid hydrogel formulations 
 
Parameter Value 
Cone and plate gap 0.0051m 
Driver version 0.29 
Inertia 89051.00PA 
A-factor 1.721x10-6Kg.m2 
M-factor 57.01rad/s 
Temperature 10°C, 25°C, 40°C 
Damping 30.00 
 
The AAm-MAA monomer solution polymerization was induced with the addition of 
APS/TEMED, followed by the addition of sodium hydrogen carbonate for 60 seconds. After 
60 seconds, the solution was immediately placed between the cone and base plate of the 
rheometer. The viscosity of the polymerizing hydrogel formulations was measured on 1mL 
samples for 10800 seconds. The viscosity of the polymerizing hydrogel solutions was 
measured with respect to time. A solvent trap was utilized to minimize evaporation.  
 
4.4.5. Determination of the gel fraction of the crosslinked AAm-MAA hydrogel 
formulations 
 
The gel fraction percent was determined as previously described (Hwang et al., 2010). 
Briefly, the freshly synthesized crosslinked AAm-MAA hydrogel formulations were dried at 
50°C in an oven for 6 hours and weighed (W0), under vacuum. The crosslinked AAm-MAA 
hydrogel formulations were then placed within Millipore® water for 24 hours and dried in an 
oven at 50°C, under vacuum. This process was repeated three times to remove any 
uncrosslinked monomers from the hydrogel matrix. Thereafter the hydrogels were dried at 
50°C under vacuum, and placed once again in Millipore® water for 24 hours. The crosslinked 
AAm-MAA hydrogel formulations were dried and weighed once again (We). The gel fraction 
percent was determined according to Equation 4.1 (Yoshii et al., 1999; Ajji et al., 2005):  
 
                         
  
  
                                                                            (Eqn. 4.1) 
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Where W0 and We are the weights of the hydrogel samples at the respective conditions. 
 
4.4.6. Powdered X-ray Diffraction to determine the crystallity of the hydrogel 
formulations  
 
The powder XRD patterns were determined for the stimuli responsive hydrogel formulations 
utilizing a Miniflex diffractometer (Rigaku, Toyko, Japan) with CuK∞ (1.5406Å) radiation. The 
powdered samples were analysed over a 0° to 90° 2-Theta range. The X-ray diffraction 
patterns were collated with Rigaku software (Version 2.0). The crystallinity degree was 
determined against XRD reflection that obtained a FWHM degree above 4.0 (reflection 
marked as amorphous).    
 
4.4.7. Isolation of porcine small intestinal tissue and gastrointestinal fluids 
 
The Large White pigs utilized in this study were obtained according to the Guide for the Care 
and Use of Laboratory Animals that was approved by the Animal Ethics Screening 
Committee of the University of Witwatersrand (Ethics Clearance number: 2011/33/03). The 
gastrointestinal fluids isolated from the pigs were collected during the fasted state which was 
induced by restricting food for 12 hours (water was provided ad libitum). The gastric and 
small intestinal fluids were collected after euthanization. The stomach and small intestine 
were isolated and a small incision was made to perforate the respective organ wall.  
 
The pH and buffer capacity of the isolated gastric and small intestinal fluids (individual and 
pooled samples) were measured immediately (Arndt et al., 2013; Dressman et al., 1998). 
The pooled sample was maintained with an equal addition from each individual sample. To 
preserve the composition of the gastrointestinal fluid, the samples were immediately frozen 
in liquid nitrogen and maintained at -80°C (Arndt et al., 2013; Dressman et al., 1998). In 
order for distance-time studies and drug dissolution studies to be effectively preformed, 
removal of solid matter (food particles and ingested hay) from the samples was achieved by 
centrifugation at 5000rpm for 10 minutes at 10°C, followed by filtration of the supernatant 
through a 0.44μm Millipore Millex injection filter (Billerica, MA,  SA). 
 
4.4.8. USP 35 and biorelevant dissolution media utilized for the gravimetric swelling 
analysis and distance-time analysis  
 
The USP 36 simulated gastric fluid pH 1.2 (USP pH 1.2) and USP simulated small intestinal 
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fluid pH 6.8 (USP pH 6.8) were prepared according to the USP 36. The fasted and fed state 
biorelevant media (FaSSGF, FaSSIF V2, FeSSIF V2) for the human model was prepared as 
previously described (Jantratid and Dressman, 2009; Fotaki and Vertzoni, 2010; Klein, 
2010). The fasted and fed state biorelevant media (FaSSIFc, FaSSGFc pH 1.5, FaSSGFc 
pH 6.5) for the canine model was also prepared (Arndt et al., 2013). 
                                                                                                         
4.4.9. Gravimetric swelling analysis of the crosslinked AAm-MAA hydrogel in USP 
simulated gastrointestinal and biorelevant fluids  
 
Gravimetric swelling analysis of the crosslinked AAm-MAA hydrogel formulations was 
conducted as previously described, with a slight modification (Singh, 2007; Singh and Pal, 
2012; Némethyl et al., 2013). Briefly, dried crosslinked AAm-MAA hydrogel formulations 
(1cm length, 0.4cm diameter), were placed in the biorelevant fluids (FaSSGF pH 1.6, 
FaSSIF pH 6.5, FeSSIF pH 5.0, FaSSGFc pH 1.5, FaSSGFc pH 6.5, FaSSIFc pH 7.5), 
United States simulated gastrointestinal fluids (USP pH 1.2 and USP pH 6.8) and Millipore® 
water. The initial weight of each dried crosslinked AAm-MAA formulation hydrogel was 
determined at time zero. At predetermined time intervals (once every 30 minutes until 7 
hours after initial weighing and once again after 24 hours), the crosslinked AAm-MAA 
formulation hydrogels were patted dry with absorbent tissue paper and weighed. Once all 
the weights of the samples were obtained over the time interval, the percent of swelling was 
determined according to the following Equation 4.2: 
 
     
       
   
                                                                                                   (Eqn. 4.2) 
 
Where SP% is the swelling percent,    is the weight at time X and    is the weight at time 
0. 
 
A scatter plot was generated from the swelling percent (n=3) at specific time points. A 
regression curve was fitted to the scatter plot and the rate of swelling percent was 
determined with respect to time was determined from the gradient of the regression curve. 
Additionally, the area under the curve (AUC) was calculated for each profile. 
 
4.4.10. Distance-time studies of the crosslinked AAm-MAA formulation hydrogels 
 
The distance-time studies of the crosslinked AAm-MAA formulation hydrogels were 
evaluated on a textural analyzer (TA.XT plus, Stable Microsystems) using a modified 
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methodology for the evaluation of disintegration (El-Arini and Clas, 2002). A textural probe 
was utilized to capture the swelling distance-time profile. Water soluble glue was used to 
attach the crosslinked AAm-MAA hydrogel formulations to a probe head which magnetically 
attached to the probe shaft. The reservoir contained 5mL of dissolution fluid (FaSSGF pH 
1.6, FaSSIF pH 6.5, FeSSIF pH 5.0, FaSSGFc pH 1.5, FaSSGFc pH 6.5, FaSSIFc pH 7.5, 
USP pH 1.2, USP pH 6.8 or Millipore® water) or isolated porcine gastrointestinal fluids. The 
crosslinked AAm-MAA formulation hydrogel was lowered into the reservoir and as the 
crosslinked AAm-MAA hydrogel formulation comes in contact with the magnetic gridded 
base plate, the distance from the gridded base plate to the surface of the probe head is 
measured. The magnetic gridded plate is approximately 5cm in diameter with an etched grid 
pattern to facilitate the free movement of solvent under a placed dosage form. In addition, 
the magnetic gridded plate contains holes within intersections of the gridded pattern to 
enhance the free movement of solvent around the placed dosage form. The crosslinked 
AAm-MAA hydrogel formulation swells within the dissolution media or isolated porcine 
gastrointestinal fluid against a constant downward force of 0.01N exerted by the probe. The 
probe is moved upwards once the swelling force exerted by the hydrogel can overcome the 
constant downward force and this distance with respect to time is measured. The procedure 
was repeated in triplicate and the parameters utilized for this procedure is shown in Table 
4.3. 
 
Table 4.3. Parameters utilized to obtain the swelling distance-time profiles for crosslinked acrylamide-
methacrylic acid hydrogel formulations 
 
Mode Measure Force in distance-time 
Option Hold until reset 
Pre-test speed 2.0mm/s 
Test speed 3.0mm/s 
Post-test speed 10.0mm/s 
Force 10g 
Trigger type Auto-3g 
Load cell 5Kg 
Tare mode Auto 
 
 
Specific time points (once every 600 seconds for 10800 seconds) were selected and the 
corresponding distance moved by the probe was determined. These measurements (n=3) 
were placed within a scatter plot, and a regression curve was fitted to the scatter plot (data 
not shown). The distance-time was determined for each time point and plotted within a three 
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dimensional bar graph. The distance-time point at each time point was determined according 
to Equation 4.3: 
 
   
     
     
                                                                                                                 (Eqn. 4.3)    
                
Where DT is the distance-time, Dx and D0 is the distance moved at point x and at time point 
0, respectively. Tx and T0 is the corresponding time at point x and at time point 0, 
respectively.  
 
4.4.11. The porositometric characteristics of crosslinked AAm-MAA hydrogel 
formulation 6  
 
The surface area and porosity analysis was performed on the F6 with respect to time points 
120 minutes, 240 minutes and 1440 minutes within USP pH 1.2, USP pH 6.8 and Millipore® 
water utilizing a Porositometric Analyzer (Micrometritics ASAP 2020, Norcross, GA, USA). 
The porosity analysis was conducted for F6 only because this formulation was utilized for the 
finalized OGDD device and the time points were selected to demonstrate how the hydrogel 
initial swelling influences porosity and the porosity achieved after equilibration. This 
formulation demonstrated sensitivity to the pH environment and could withstand a 
compressive force.The F6 hydrogels were initially swelled within the aforementioned 
dissolution fluids, at the respective time points a sample hydrogel was removed and then 
flash frozen with liquid nitrogen at the respective time. The F6 samples were then lyophilized 
in order to remove the respective solvent but maintain the architecture of the hydrogel 
sample. The respective parameter settings utilized for the porosimetric analysis are shown in 
Table 4.4.  
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Table 4.4. Parameters utilized for the porositometric analysis of crosslinked acrylamide-methacrylic 
acid hydrogel formulations 
 
Parameter Rate/target 
Temperature ramp rate 10°C/min 
Target temperature 40°C 
Evacuation rate 50.0mmHg/s 
Unrestricted evacuation from 30mmHg/s 
Vacuum set point 500µmHg 
Evacuation time 60min 
Temperature ramp rate 10°C/min 
Hold temperature 30°C 
Hold time 900min 
 
Subsequent to complete degassing, the sample tube was transferred to the analysis port 
were the surface area, pore volume, and pore size was obtained in accordance with Barrett-
Joyner-Halenda (BJH) and Brunauer–Emmett–Teller (BET) theories. The BET gas 
absorption theory is conducted in a two-stage process (Sing et al., 1985). The BET equation 
was used in the linear form to determine the monolayer capacity based on Equation 4.4.  
 
 
       
 
 
  
   
 
      
  
    
                                                  (Eqn. 4.4) 
 
Where,    refers to the quantity of    absorbed at the relative pressure 
 
  
,   
  was the 
monolayer capacity and C was exponentially related to the enthalpy of absorption in the first 
absorption layer.  
 
The total and specific surface area was determined from the monolayer capacity using 
Equation 4.5 and Equation 4.6.  
 
          
                                                       (Eqn. 4.5) 
 
        
       
 
                                                              (Eqn. 4.6)  
 
Where         and         are the total and specific surface areas, respectively, of the 
adsorbent (of mass m) and L is the Avogadro constant. The surface area, pore volume and 
pore diameter is determined in triplicate and the results were plotted in bar graphs.  
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4.4.12. UPLC analysis of the drug compounds utilized in this within the pH responsive 
hydrogel 
 
The UPLC method utilized in this study was previously described (Serra et al., 2011). A 
Acuity High Strength Silica (HSS) T3 column (100mm x 2.1mm, 1.8μm) was utilized to 
isolate and separate theophylline, ciprofloxacin, indomethacin, metronidazole, 
sulfamethazole, sulpiride, zidovidine, 4-aminosalcylic acid and naproxen. The λ was set at 
271nm and the column was maintained at 25°C. Mobile phase A (0.2% acetic acid) and 
mobile phase B (acetronitrile) was utilized as a gradient method: 0-10min, 5-35% B; 10-
10.10min, 35-80% B; 10.10-11min, 80% B; 11-11.10min, 80-5% B and 11.10-12.50min, 5% 
B at a flow rate of 0.4mL/min. The area under curve (AUC) for each drug peak, over a wide 
range of concentrations (25mg/L, 20mg/L, 15mg/L, 10mg/L, 5mg/L, 2.5mg/L, 1.25mg/L and 
0.75mg/L) was determined in order to generate a standard curve for each drug. An internal 
standard of caffeine (20mg/L) was utilized throughout the study to validate the accurate 
retention time and AUC for each procedure. Each sample was dried within an ANSI HPLC 
2mL vial at 40°C for 12 hours and resuspended in 1mL of diluent (50%v/v 0.2% acetic acid in 
acetronitrile).   Replicate samples (n=3) containing the aforementioned model drugs at 3 
different concentrations (5mg/L, 10mg/L, 20mg/L) was analysed on three separate days to 
evaluate the accuracy and the within-day and between-day imprecision (C.V.)  An injection 
volume of 2μL was utilized throughout the study.  
 
4.4.13. Loading drug within crosslinked AAm-MAA hydrogel F6  
 
F6 was used as the platform to release the drugs (theophylline, metronidazole, zidovudine, 
indomethacin, sulfamethoxazole, ciprofloxacin, sulpiride, naproxen) that was loaded by 
equilibrium partitioning in a slightly modified manner as previously described (Schoener et 
al., 2012). These drugs have different Biopharmaceutical Classification System classes, thus 
not only does the pH responsiveness of the hydrogel affect release, but also the innate 
solubility of the drug compounds. The drugs were dissolved within nine solutions of 2%v/v 
DMSO/Millipore® water solutions (25°C, 100rpm) which contained a final concentrations of 
theophylline (0.003M), ciprofloxacin (0.17M), indomethacin (0.18M), metronidazole 
(0.007M), sulfamethazole (0.003M), 4-aminosalcylic acid (0.0014M), zidovudine (0.001M) 
sulpiride (0.003M) and naproxen (0.003M), respectively. F6, which had non-reacted 
monomers removed, were placed within the drug solutions and allowed to swell over a 
period of 24 hours. The hydrogels were dried within a vacuum oven for 24 hours at 40°C.  
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4.4.14. Determination of drug entrapment efficiency 
  
The estimated percentage of drug entrapment efficiency was determined before dissolution 
studies were undertaken. A hydrogel, which had been precisely cut into 1cm long cylinders, 
crushed into powder form (placed through a sieve of aperture 800μm) and weighed. The 
powder was then suspended in 100mL Millipore® water for 24 hours. A 5mL sample was 
withdrawn and filtered through a 0.44μm Millipore Millex injection filter (Billerica, MA,  SA). 
The filtered sample was placed within an ANSI HPLC 2mL vial and the drug concentration 
calculated utilizing the previously described UPLC method. This procedure was conducted in 
triplicate and the entrapment efficiency was determined according to Equation 4.7: 
 
                                 
                   
                        
                               (Eqn. 4.7)   
 
4.4.15. Dissolution studies from crosslinked AAm-MAA hydrogel formulation 6 within 
dissolution fluids and isolated porcine gastrointestinal fluids 
 
The in vitro and ex vivo dissolution studies were conducted in a previously described manner 
(Dünnhaupt et al., 2012). Each drug loaded hydrogel sample (hydrogel sample that 
contained theophylline, ciprofloxacin, indomethacin, metronidazole, sulfamethazole, 4-
aminosalcylic acid, zidovudine, sulpiride or naproxen) was placed within a 20mL glass 
polytop containing 10mL biorelevant dissolution fluid, USP dissolution fluid or isolated 
porcine gastrointestinal fluid for a time period of 24 hours. A limited volume of dissolution 
fluid utilized within this study because was due to a limited amount of isolated porcine 
gastrointestinal fluid that was available and the volume must stay constant for comparative 
purposes. The polytops were placed within an Orbit Shaker Incubator (LM-530-2, MRC 
Laboratory Instruments Ltd, Hahistadrut, Holon, Israel) at 37±0.5°C at 50rpm. Sink 
conditions were maintained throughout the study. At predetermined time points, a 1mL 
sample was withdrawn and replaced with a temperature equilibrated aliquot of the respective 
fluid. The samples were filtered through a 0.22μm Millipore Millex injection filter (Billerica, 
MA, USA) and subject to UPLC analysis. The cumulative percentage of drug dissolution and 
the concentration of drug dissolution were plotted against time. Each drug dissolution study 
was repeated in triplicate. 
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4.4.16. Drug release mechanism 
 
The drug release mechanism from the AAm-MAA hydrogel formulation 6 for each drug within 
each dissolution fluid was determined utilizing DDSolver add-in for Microsoft Excel 2007 
(Zhang et al., 2010). The release of drug from the AAm-MAA hydrogel formulation 6 was 
highly dependent on drug characteristics (log P values, pKa, molecular weight), 
environmental conditions (pH, ionic strength and temperature) and innate physicochemical 
characteristics of the hydrogel (effective crosslinker density, polymeric chain relaxation, and 
charged interactions between the drug molecule and the hydrogel macrostructure). The 
mean dissolution time at time point 90 minutes (MDT90) and 1440 minutes (MDT1440) were 
determined utilizing Equation 4.8: 
 
       
 
   
  
  
                                                                                                        (Eqn. 4.8) 
 
Where M is the fraction of drug dose release in time  i = (ti=ti-1)/2 and M  corresponds to 
the loading dose. The area under curve for each drug dissolution profile was determined 
according to the trapezoidal rule. The calculations (MDT90, MDT1440 and AUC) allow for 
efficient comparison between dissolution fluid types. The dissolution profile for each drug 
within each respective fluid was recorded within scatter plots and a regression fitting of each 
known drug dissolution model was applied to each profile. The five regression fittings which 
achieved a R2 adjusted value greater than 98% were considered viable dissolution models. The 
dissolution modeling allows for comparison between the mechanisms in which drug 
dissolution is achieved within a specific dissolution fluid type. All drug dissolution studies 
were conducted in triplicate.  
 
4.4.17. Morphological analysis images of crosslinked AAm-MAA formulation hydrogel 
6  
 
Scanning Electron Microscopy (SEM) imaging of F6 was conducted on a FEI ESEM Quanta 
400F (F  ™, Hillsboro, OR,  SA) electron microscope. Samples of F6 were placed within 
USP pH 1.2 dissolution fluid, USP pH 6.8 dissolution fluid and Millipore® water. At 
predetermined time points (0, 60, 90, 120, 150 and 180 minutes), a hydrogel sample for 
each dissolution fluid was withdrawn and flash frozen with liquid nitrogen (Yan et al., 2011). 
The samples were then maintained at -80°C for 48 hours and subsequently lypholized with a 
two hour condensation phase at -60°C, followed by a 24 hour sublimation phase at 25mm 
Torr utilizing a Freezone 12 freeze drier (Lanconco, Kansas City, USA). Images of each 
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hydrogel sample were captured with an accelerated voltage of 30.00kV at 100 times 
magnification for comparative purposes.  
 
4.4.18. Magnetic Resonance Imaging of crosslinked AAm-MAA formulation hydrogel 6  
 
A dry F6 was placed within the flow through cell of a benchtop Magnetic Resonance Imaging 
(MRI) machine (Maran-i, Oxford Instruments, Oxordshire, UK) which was equipped with a 
0.5 tesla permanent magnet system and had been stabilized at 37°C (Kulinowski et al., 
2008; Tajiri et al., 2010). The hydrogel sample was held in place with a rubber retaining band 
in a plastic holder. Images were collected over the course of 24 hours at predetermined time 
intervals to visualise the real time swelling of hydrogel sample within a continuous flow 
system. The real time swelling of the F6 was assessed within USP pH 1.2 dissolution fluids, 
USP pH 6.8 dissolution fluids and Millipore® water. Additionally, a hydrogel sample was 
allowed to swell in USP pH 6.8 dissolution fluid for a period of 24 hours, within the MRI 
machine, and subsequently the USP pH 6.8 dissolution fluid was exchanged with USP pH 
1.2 fluid. The ability of the crosslinked AAm-MAA hydrogel formulation to deswell in 
response to a decrease in pH was captured in real time. T1-weighted images were captured 
using a spin echo method and the single intensity of the MRI images was defined according 
to Equation 4.9 (Tajiri et al., 2010):  
 
        
   
  
       
   
  
                                                                               (Eqn. 4.9) 
 
Where   is magnetization,    and    are the relaxation times.    and    are repetition time 
and echo time, respectively. 
 
4.5. Results and Discussion 
 
4.5.1. Synthesis of hydrogel 
 
The crosslinked AAm-MAA hydrogel formulations were synthesized according to the 
concentrations within Table 4.1. The polymerizing solutions of F2-F11 could easily be 
poured into the cylindrical moulds but the ploymerizing solution of F1 would polymerize too 
quickly to be poured into the cylindrical moulds. The hydrogels generally were clear to white 
in colour of defined cylindrical shape. The dried hydrogels were very hard and brittle once 
placed under a significant mechanical force. Intial studies such as Attenuated Total 
Reflectance-Fourier Tansform Infareds analysis, thermal characeterization, viscosity 
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analysis of polymerizing hydrogel solutions, gel fraction determination, powdered x-ray 
diffraction and swelling studies were preformed for all hydrogel formulations. These studies 
were used to determine which hydrogel was sufficiently pH responsive and structurally 
suitable to be utilized within the OGDD device as the push mechanism for the mini-pellets 
within the device. Studies using biorelevant dissolution fluids for distance-time studies and 
swelling studies were utilized for the desirable formulation (F6), a formulation that had low 
sensitivity towards pH (F2) and a formulation with high sensitivity to pH but maintained 
reasonable structure under compression (F8). These studies were performed for 
comparative purposes. Lastely, porosity studies, MRI studies, drug (of different 
biopharmaceutical classification classes) dissolution studies that was performed in USP and 
biorelevant dissolution fluids and morphological studies were conducted on the most 
desireable formulation (F6) for the intended purpose for additional understanding of the how 
phyisomechanical properties of the hydrogel respond in different environments. 
 
4.5.2. Viscosity analysis of the polymerizing crosslinked AAm-MAA formulation 
hydrogels 
 
The viscosity of the crosslinking hydrogel formulations (Figure 4.1 and Figure 4.2) were 
assessed to determine the time point at which significant crosslinking occured and the 
relative time period allowed for the transfer of the polymerizing solution into a mould. This 
was observed by a deviation from Newtonian flow behaviour by an increase in viscosity. A 
cylindrical mould was utilized throughout the study to ensure that the available surface area 
and size of the hydrogel samples remained constant. Ideally, the blowing agent should be 
completely reacted before placing the polymerizing solution within a mould so that are 
maintained within the solution and bulk carbon dioxide gas has escaped the solution, 
preventing the formation of large heterogeneous voids within the gelled sample. Additionally, 
the polymerization reaction should occur at a rate that is economically viable for upscale 
applications. 
 
The result of this analysis indicated that an increase in viscosity was higher in F8 than F6. 
Additionally, the point where crosslinking took place in F8 occurred at ~2000 seconds 
whereas the initiation of crosslinking took place around ~1800 seconds for formulation 6 
when temperature conditions remained at 25°C. 
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Figure 4.1: The viscosity analysis of AAm-MAA hydrogel formulation (F2-F6) under thermal 
conditions of 10°C (red profile), 25°C (blue profile) and 40°C (green profile). The profiles represented 
are for hydrogel formulations: F2 (A), F3 (B), F4 (C), F5 (D) and F6 (E). 
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Figure 4.2: The viscosity analysis of AAm-MAA hydrogel formulation (F7-F11) under thermal 
conditions of 10°C (red profile), 25°C (blue profile) and 40°C (green profile). The profiles represented 
are for hydrogel formulations: F7 (A), F8 (B), F9 (C), F10 (D) and F11 (E). 
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There was no measurable increase in viscosity due to crosslinking under temperature 
conditions of 40°C. At 40°C, the evaporation of water from the polymerizing system occurs 
at a rapid rate, even with the utilization of a solvent trap. The removal of water from the 
polymerizing system inhibits the accurate determination of viscosity at this temperature. The 
viscosity measurement at 10°C results in a system that polymerizes too slowly for a notable 
change in viscosity to be determined. F2 underwent polymerization so rapidly that it was 
extremely difficult to obtain any accurate viscosity data before the solution had entered the 
gel state. It was noted that with increase concentrations of methacylic acid, the 
polymerization reaction occurred at a slower rate.  
 
As indicated in the viscosity results, a low temperature impacts the polymerization to the 
point where no polymerization may occur. Whereas a high temperature accelerates the 
evaporation of water from the system so rapidly that obtaining a flowable monomer solution 
that can be placed within a mould would be a challenge.  
 
Fortunately, the utilization of room temperature (25°C) allowed for the monomer solution to 
be flowable, polymerize within a timely manner and presents the most economically 
beneficial conditions. A trend was noted in the gel percent determination; the inclusion of 
higher concentrations of methacylic acid in the polymerizing solution reduced the ability of 
the APS/TEMED free radical polymerization system to be highly efficient. This was noted as 
well during the viscosity analysis of each polymerizing solution when the solutions generally 
required a longer time period to deviate from Newtonian flow. Some formulations with 
increase methacrylic acid did polymerize slightly faster than those with lower methacrylic 
acid but this may be due to a slightly more thermodynamically favoured reaction. For 
instance the polymerization was determined to occur in less than ~300 seconds for F2 (it 
was very difficult to obtain a precise time at which significant crosslinking initiation occurred) 
whereas F8 had an precise significant crosslinking time of 2000-2200 seconds. The initiation 
of significant crosslinking time between formulations is also important for upscale purposes. 
For instance, F1 formulation studies were suspended after the viscosity analysis because 
this formulation crosslinked too rapidly for a mould to be produced (even at low 
temperatures).  
 
4.5.3. Determination of the gel fraction percent of the crosslinked AAm-MAA hydrogel 
formulations 
 
The free monomers that were not incorporated within the hydrogel macrostructure during the 
free radical polymerization were removed from the hydrogel macrostructure during the gel 
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fraction percent analysis. The free monomers are removed by hydrating the solution within 
Millipore® water. An effective balance between the polymerization of polymeric monomers 
and incorporation of pH sensitivity has to be achieved. 
 
The gel fraction percent was determined to be above 85% for all of the synthesized hydrogel 
formulations. The gel fraction percentage was higher within formulations that contained a 
higher concentration of acrylamide than methacrylic acid. Hydrogel F1 which contains only 
acrylamide had a gel fraction percent of 98% which is almost completely crosslinked.  The 
gel fraction decreased to 85% for hydrogel F11 which contains only methylacrylic acid, 
indicating that methacrylic acid was not as effectively crosslinked by the free radical system 
(APS/TEMED). The bar graph representing the specific degrees of gel fraction percent for 
each formulation can be reviewed within the Figure 4.3. If the gel fraction percent becomes 
too low, the desirability of the formulation is significantly lowered. An example of this is in 
F11 which only contained monomers of methacrylic acid but had very low mechanical 
strength and maintenance of water within the macrostructure of the hydrogel was low. F1 
was the behaved in an opposing manner whereby the mechanical strength of the hydrogel 
was high, the loss of percentage of unreacted monomers was minimal but the hydrogel 
formulation had an extremely low degree of pH sensitivity. These properties are emphasized 
in characterization studies performed within this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Bar graph representing the gel fraction percent for each of the AAm-MAA hydrogel 
formulations. 
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4.5.4. Attenuated Total-Reflectance-Fourier Transform Infrared analysis of crosslinked 
AAm-MAA formulation hydrogels 
 
The ATR-FTIR analysis determined that the free radical polymerization of acrylamide and 
methacrylic acid was successful by incorporation of MBA within the hydrogel structure. 
Additionally, the absorbance intensity of characteristic functional groups within the hydrogel 
formulations may be reduced because these functional groups are participating in the 
crosslinking network structure. The ATR-FTIR spectrum of each AAm-MAA hydrogel 
formulation is shown in Figure 4.4. A peak occurred at 1648cm-1. The freshly synthesised 
AAm-MAA hydrogel had peaks at 1655cm-1  and 1453cm-1 which was similar to the dried 
AAm-MAA hydrogel that had peaks at 1648cm-1 and 1444cm-1 (data not shown). The peak 
located at 1648cm-1 was determined to occur due to an amide-I band of the amide group of 
acrylamide (Nakason et al., 2010). Wavenumber peaks present in MBA (2769cm-1 and 
1072cm-1) were present in the AAm-MAA hydrogel formulation 6 at 2763cm-1 and 1071cm-1.  
The characteristic wavenumber peak of methylacrylic acid at 1425cm-1 was lost within the 
polymerized hydrogel and a new peak occurred at 1425cm-1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: The ATR-FTIR spectra in (A) represent crosslinked AAm-MAA hydrogel formulation 1 
(pink profile), 2 (dark green profile), 3 (dark orange profile), 4 (purple profile) and 5 (dark blue profile). 
The ATR-FTIR spectra in (B) represent crosslinked AAm-MAA hydrogel formulation 6 (light orange 
profile), 7 (light blue profile), 8 (pink profile), 9 (light green profile), 10 (dark orange profile) and 11 
(purple profile) were determined from dry samples (after gel fraction percent determination) at 130psi 
between 650-4000cm
-1
 against absorbance. 
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Wavenumber peaks that were common between the polymerized hydrogel and acrylamide 
were located at 1049cm-1. This peak indicates that the AAm-MAA hydrogel may have C-O-C 
stretching vibrations (Dadsetan et al., 2010). The intensity of the wavenumber peaks was 
highest within formulation 1 and 11 that contained the highest concentration of acrylamide 
and methacrylic acid respectively. The reducing mass concentration ratio, with respect to 
each monomer, generally reduced the intensity of the characteristic wavenumber peaks. 
 
4.5.5. The powder X-ray diffraction of the hydrogel formulations and the precentage of 
crystallinity 
 
The PXRD indicates that the hydrogel formulations are highly crystalline in nature and have 
a similar crystal structure. A large variation in crystal structure was not expected because the 
formulations are composed of identical monomer and crosslinker components. The PXRD 
diffraction of the hydrogel formulations is shown in Figure 4.5 and the degree of crystallinity 
is also shown in Figure 4.5. The major reflections for these hydrogel formulations occurred 
at 2θ-values of 36.2°, 42.8°, 63.1°, 77.3° and 80.9°.  The degree of crystallinity was 
determined to be the highest for formulation 4 and 9 whereas the degree of crystallinity was 
determined to be lowest for formulation 11. The PXRD of the remaining hydrogel 
formulations can be reviewed in Appendix 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: The PXRD profile of formulation 6 (A) and a bar graph of the percentage of crystallinity for 
each hydrogel formulation (B). 
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4.5.6. Thermal analysis of crosslinked AAm-MAA hydrogel formulation 
 
The DSC thermograph traces for each stimuli responsive hydrogel can be reviewed within 
the Figure 4.6. The DSC of each hydrogel formulation has characteristic melting and 
crystalline events which are common throughout all the synthesized formulations. The DSC 
analysis of each hydrogel formulation at each heating rate generated unique degrees of 
melting and crystallization. For instance, F7 had a melting peak that occurred at 239.72°C 
(heating rate: 10°C/min; heat of fusion: -121.26J/g), 230.32°C (heating rate: 5°C/min; heat of 
fusion: -144.84J/g) and 218.38°C (heating rate: 2°C/min; heat of fusion: -167.04J/g). The 
main melting event of F10 occurred at 231.9°C (heating rate:10°C/min; heat of fusion: -
38.85J/g), 224.17°C (heating rate:5°C/min; heat of fusion: -268.21J/g) and 228.2°C (heating 
rate: 2°C/min; heat of fusion: -394.4J/g). The thermal events within DSC thermogram traces 
of the hydrogel formulations generally occurred at lower temperatures with slower heating 
rates. The DSC analysis of each hydrogel formulation was conducted in triplicate at each 
heating rate. 
 
4.5.7. Gravimetric swelling analysis of the crosslinked AAm-MAA hydrogel 
formulation 2, 6 and 8  
 
The ability of the hydrogel to swell within a solution has been attributed to the effective 
crosslinking that exists between the polymerized monomers within a hydrogel matrix (Hwang 
et al., 2010). The concentration of pH sensitive monomers in the presence of constant 
crosslinking agent (i.e. BIS) concentration will also have an important influence on the ability 
of a hydrogel to swell within a solvent. This was evident in the gel fraction percent 
determination whereby, even though a high concentration of methylacrylic acid was present, 
the ability of the crosslinker to induce polymerization was limited in comparison to 
acrylamide. Millipore® water was utilized to assess the swelling potential of a particular 
hydrogel formulation and compare this ability to that within a dissolution fluid. Millipore® 
water allows the hydrogel formulations to swell unimpeded by a significant reduction in metal 
ion concentration and relatively neutral pH characteristics.  
 
Gravimetric swelling analysis of F2, F6 and F8 were conducted in USP simulated dissolution 
fluids, biorelevant dissolution fluids and Millipore® water as shown in Figure 4.7. The 
swelling ability of the hydrogel formulation 2 could easily achieve over 2000% within neutral 
environments but also swelled up to 700% within acidic environments within a 24 hour 
period.  
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This had low sensitivity to pH when compared to formulation 6 which swells over 1200% 
within neutral environments but only swelled up to 130% within acidic environments. 
Formulation 6 is 3.6 times more sensitive to pH conditions than formulation 2. Formulation 8 
achieved an impressive swelling ability of more than 1400% within neutral environments and 
a swelling ability of less than 95% within acidic environments which is ~5 times more 
sensitive to pH than formulation 2. This would indicate that formulation 8 would be a 
desirable hydrogel for drug delivery applications due to its increased sensitivity towards pH. 
The swelling ability of the hydrogel to swell within different biorelevant dissolution fluids was 
also investigated. The swelling percent against time profile  
 
was determined using a regression fitting for the exponential to rise maximum (3 parameter 
model) as shown in Figure 4.7 (A).The swelling percent-time scatter plot point for each 
hydrogel, within each dissolution fluid, existed within the 95% confidence interval (blue line) 
and 95% predicted confidence interval (red line). The scatter plot and the fitted regression 
model for F2, F6 and F8 in gravimetric swelling within dissolution fluids can be reviewed 
within the provided Appendix 4. 
 
The area under the curve was determined using DDSolver add-in for Microsoft Excel 2007 
for each swelling percent-time profile. The area under curve allows for direct comparison 
between the swelling profiles of the hydrogel formulation 2, 6 and 8. UPS pH 6.8 generated 
some of the greatest swelling ability between 42% to 97% with respect to Millipore® water. 
Whereas swelling ability within USP pH 1.2 was comparable to biorelevant media within F6 
and F8. The swelling potential of F2 within USP pH 1.2 was 100% greater than comparative 
gastric simulating fluids. The swelling ability of hydrogel formulation 2 was much greater than 
hydrogel formulation 6 and 8. The degree or ability of the hydrogel formulation 6 and 8 to 
swell was similar but hydrogel formulation 8 did have a higher degree of pH sensitivity. The 
canine biorelevant media generally achieved a higher degree of swelling potential in 
comparison to human biorelevant media. The biggest difference was noted in F2 and F8 with 
FaSSGFc pH 6.5. This is likely due to the relatively low concentration of metal ions and bile 
salts, in addition to the high pH. These factors allow for the hydrogel formulations to retain a 
higher volume of water within a shorter time frame.  
 
The gravimetric swelling ability of F2 was the greatest because this formulation contained 
the lowest concentration of methacrylic acid. As the methacrylic acid concentration within the 
hydrogel formulations was increased, the ability of the hydrogel formulation to be pH 
responsive was increased but the swelling potential was diminished. This is particularly 
important for targeted drug delivery applications whereby the drug is entrapped within the 
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hydrogel or the hydrogel is utilized within a device to facilitate targeted release. For the 
application purpose within a drug delivery device or targeted drug delivery, controlling the 
concentration of the pH responsive component will enable the device to respond to the 
gastrointestinal pH profile in a tuneable manner. This is evident in the pH sensitivity between 
F6 and F8 which increased ~100%. Additionally, the swelling ability of these hydrogel 
formulations was highly predictable. A pH responsive hydrogel that is highly predictable and 
easily tuneable is highly attractive for drug delivery applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: The gravimetric swelling profile of AAm-MAA hydrogel formulation 6 (A) and the area 
under curve for the gravimetric swelling profiles for AAm-MAA hydrogel formulation 6 (B), AAm-MAA 
hydrogel formulation 2 (C) and AAm-MAA hydrogel formulation 8 (D) within biorelevant fluid and USP 
simulated fluid. 
 
4.5.8. Distance-time studies of the crosslinked AAm-MAA formulation hydrogels 
 
The compression under constant force at which a hydrogel formulation can swell against is 
an indication of the physicomechanical strength of the hydrogel macrostructure under 
constant strain. This assessment was conducted on F2, F6 and F8 to determine the 
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dissolution fluids but also within isolated porcine gastrointestinal fluids. The distance-time 
profile of F2, F6 and F8 is shown in Figure 4.8. The distance-time profile for each hydrogel 
formulation was plotted within a scatter plot and a regression curve was fitted to each scatter 
plot (data not shown). F6 deformed in FaSSGFc pH 1.5 and USP pH 1.2, whereas F8 
deformed in FaSSGFc pH 1.5, USP pH 1.2 and FaSSGF pH 1.6. F2 did not deform in any of 
the dissolution fluids and achieved the highest distance per mm rates. As a hydrogel 
absorbes solvent from the environment, the hydrogel expands, even against a compressive 
force and this is measured as the distance (mm) per second increased from the the intial 
measured distance from the zeroed point. When the hydrogel undergoes deformation, the 
distance per second measurement is negative with respect to the intial zeroed point. The 
solvent environment has hydrated the hydrogel which allows the dried hydrogel to move 
from the solid state to the semi solid state, but the solvent environment has not provided the 
hydrogel macrostructure in the semi solid state with the chemical bond integrity to withstand 
a compressive force, thus allowing the compressive force to progressively displace the 
hydrogel away from the direction of the applied force. The fastest distance-time rates were 
achieved within Millipore® water by F2. The distance-time profiles each hydrogel formulation 
within USP pH 1.2, USP pH 6.8 and Millipore® water can be reviewed in Appendix 5. 
 
The hydrogel formulations did not undergo deformation in any of the isolated porcine 
gastrointestinal fluids and the highest distance-time rates were achieved by F2. F2 
performed in the isolated intestinal porcine fluids to the same degree as that in FaSSGF pH 
1.6 and preformed slightly worst in the isolated gastric fluids than the in FaSSGFc pH 1.5. F6 
and F8 exerted a positive distance per time displacement but F6 was slightly greater than 
F8. Interestingly, F2 demonstrated a burst swelling profile within both the dissolution fluids 
and within the isolated gastrointestinal fluids of the porcine model.  
 
The performance of these hydrogel formulations within the dissolution fluids achieved similar 
initial compression resistance potential whereby F2 achieved the greatest compression 
resistance, followed by F6 and F8, respectively. But the compression resistance that was 
achieved within the isolated porcine gastrointestinal fluids did not correlate well with the 
velocities achieved within the dissolution fluids. The dissolution fluids are ideally utilized for 
preselection of the desirable hydrogel performance with respect to other hydrogel 
formulations, but the in vivo performance may be significantly reduced. This is particularly 
important for physicomechanical drug delivery applications and direct drug loading 
applications. 
 
 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: The distance-time profile of AAm-MAA hydrogel F2, F6 and F8 within biorelevant media 
and USP simulated fluids (A, B, C) and within isolated porcine fluids (D) with respect to sequential 
time points. 
 
The understanding of swelling ability for each hydrogel formulation demonstrates that even 
though F8 achieved greater retention of dissolution fluids during the gravitational swelling 
analysis, the resistance to compression with respect to time property of F8 with respect to F6 
was reduced. A drug delivery application which relies upon the ability of they hydrogel to 
swell in response to pH and resist a compressive force with respect to time would favour F6 
over F8. Comparatively, a drug delivery application with a preference to pH responsiveness 
over physicomechanical robustness, would favour F8 over F6. Interestingly, F2 
demonstrated a burst distance-time profile whereby the compression resistance of was 
initially very high and then reduced with time. This may have important implications for drug 
delivery applications whereby a burst compression resistance indicates that the 
macrostructure of the hydrogel was reinforced by the rapid accumulation of water. This 
occurs until the accumulation is slowed by the equalization of swelling capacity of the 
hydrogel formulation within the solvent environment and the applied downward force. F6 and 
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F8 accumulated higher velocities with respect to time that would be ideal for drug delivery 
applications whereby a steady increase dissolution of drug is preferred.  
 
4.5.9. The porositometric characteristics of crosslinked AAm-MAA formulation 
hydrogel 6  
 
The porositometric characterisation of F6 was conducted to determine the Brunauer–
Emmett–Teller (BET) adsorption and desorption profiles (Yushin et al., 2006). The porosity 
analysis is shown in Figure 4.9 (surface area), Figure 4.10 (volume of pores and pore 
diameter). The porositometric analysis of F6 was conducted in USP dissolution fluids to 
assess the increase in the surface area, pore diameter and pore size with respect to time. 
Additionally, the porositometric analysis was conducted in Millipore® water for comparative 
purposes. The isotherms obtained from each sample were noted as a type IV isotherm 
whereby a small hysteresis is present (Sutar et al., 2008; He et al., 2010). 
 
The surface area measurements demonstrated, as expected, that the F6 samples exposed 
to Millipore® water had the largest surface area. Additionally, the surface area determination 
of the hydrogel within USP pH 1.2 was significantly reduced in comparison to the other 
solvent environments utilized within this study. The surface area increases as the hydrogel is 
exposed to solvent because of the formation of progressively deeper channels that 
penetrates into the core of the hydrogel structure through the development of an intra-
connected network that extend from the opening of the pore. With time, these channels 
become larger with respect to diameter and length that results in an increased surface area 
measurement. The surface area at each time point, irrespective of the solvent type, 
increased with respect to time. F6 hydrogel samples surface area increased 12.4 times in 
single point surface area measurement in the USP pH 1.2 dissolution fluid environment 
whereas a 1.62 time increase in single point surface area measurement was achieved in the 
USP pH 6.8 dissolution fluid. A similar trend was noted in the BET surface area, BJH 
absorption and BJH desorption measurements whereby the surface area increased many 
time greater within USP pH 1.2 dissolution fluid than USP pH 6.8 dissolution fluid. The 
utilization of liquid nitrogen to flash freeze samples of hydrogel at the respective times (to 
preserve architecture) and then lypholization of the hydrogels allowed these measurements 
to be obtained. The lypholized samples were handled with great care throughout the study 
so that a dry sample that contained the correct structure was measureable.  
 
F6 had a mesoporous structure that can be deduced by the presence of H1-hysteresis loops 
within generally similar type IV isotherms (Chang et al., 2009; Sarawade et al., 2013). The 
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Figure 4.9: The porositometric surface area analysis with respect to time of AAm-MAA hydrogel F6 
within USP simulated gastric fluid (USP pH 1.2), USP simulated intestinal fluid (USP pH 6.8) and 
Millipore
®
 water.  
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Figure 4.10: The porositometric pore volume and pore diameter analysis with respect to time of AAm-
MAA hydrogel F6 within USP simulated gastric fluid (USP pH 1.2), USP simulated intestinal fluid 
(USP pH 6.8) and Millipore
®
 water.  
 
porositometric analysis indicated that within Millipore® water, these parameters increased 
several fold with respect to USP pH 1.2, illustrating that the increases observed during the 
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gravimetric swelling analysis and distance-time analysis is due to the expansion of pore 
dimensions that facilitated the capture of water within the macrostructure of the hydrogel (Shi 
et al., 2011; Guo et al., 2013). The lyophilisation process of the hydrogel samples removed 
aqueous solvent within the hydrogel macrostructure but maintained the architecture of the 
macrostructure that was achieved within each environment.   
 
The pore morphology was observed utilizing SEM imaging of F6 samples that had been 
exposed to USP dissolution fluids or Millipore® water at predetermined time points. The 
presence of methacrylic acid is responsible for the observable differences of pore 
morphology within the dissolution fluid whereby in an acidic environment, the methacrylic 
acid is in the non-ionized state (CH3C(CH3)COOH) (Wang et al., 2010; Adnadjevic et al., 
2011). The non-ionized state maintains a tight network structure due to extensive hydrogen 
bonding. This results in limited pores developing within the macrostructure of the hydrogel. 
The methacrylic acid undergoes ionization (CH3C(CH3)COO
-) within intestinal pH 
environments and results in repulsive electrostatic interactions which forces polymerized 
chains apart and facilitates the bulk movement of water into the hydrogel structure (Torres-
Lugo et al., 2002; Kumar et al., 2006; Wang et al., 2010). As water moves into the 
macrostructure of hydrogel, water cages are formed around the negatively charged oxygen 
in the carboxyl group (Meng et al., 2013).  
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Figure 4.11: Scanning Electron Microscopy images of the crosslinked AAm-MAA hydrogel F6 within 
Millipore
®
 water, USP simulated intestinal fluid (USP pH 6.8) and USP simulated gastric fluid (USP pH 
1.2) at predetermined time points over a period of 1440 minutes. 
 
These water cages stabilized the charged sites and allow the monomers within the hydrogel 
structure to relax during the expansion of pores. The utilization of a porogen, such as sodium 
hydrogen carbonate, was utilized to force the monomers to polymerize around the entrapped 
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carbon dioxide gas microbubbles (Kabiri et al., 2003). This physically reduced the density of 
crosslinker sites and allows for the accelerated dispersal of aqueous fluids through the 
hydrogel macrostructure by rapidly filling the voids created during the polymerization 
reaction.  These pores are observable within the SEM images when the solvent has been 
sublimated out of the liquid nitrogen frozen hydrogel (Yan et al., 2011). The presence of 
metal ions within the USP dissolution fluids disrupts the formation of water cages around the 
negatively charge oxygen in the carboxyl group, and reduces the relaxation of the 
methacrylic acid monomers within the hydrogel. The effect of this disruption can be observed 
within the SEM images of F6 hydrogel samples within USP pH 6.8 dissolution fluid in 
comparison to Millipore® water. The inclusion of sodium bicarbonate as the porogen within 
hydrogel formulations was previously being recognized to create large pores that facilitate 
high rates of swelling (Kabiri et al., 2003). 
 
4.5.10. UPLC detection of drug compounds 
 
Theophylline (a BCS class I drug) was the first drug isolated and separated within the study 
to generate a standard curve (against internal reference caffeine). The retention time (RT) of 
theophylline and caffeine was determined to be 3.6 minutes and 4.7 minutes, respectively. 
The UPLC method was then utilized to generate a standard curve for ciprofloxacin (RT: 
5.5min), indomethacin (RT: 11.7min), metronidazole (RT: 5.1min), sulfamethoxazole (RT: 
7.3min) and sulpiride (RT: 11.3min), zidovudine (RT: 5.5min), 4-aminosalcylic acid (RT: 
7.6min) and naprozen (RT: 8.7 min). The UPLC chromograph for these drugs can be 
reviewed in the Figure 4.11.  
 
The ability of the UPLC method to successfully separate the utilized drug compounds was 
determined in three different diluent solutions which clearly did not have overlapping 
retention times were assessed. The first dilutent contained theophylline, caffeine, 
ciprofloxacin and indomethacin. The second dilutent contained metronidazole, 
sulfamethoxazole and sulpiride whereas the third dilutent contained zidovudine, 4-
aminosalcylic acid and naproxen. 
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Figure 6: UPLC chromograph of a dilutent which contained theophylline (RT: 3.6 min), 
caffeine (RT: 4.7 min), ciprofloxacin (RT: 5.5 min) and indomethacin (RT: 11.7). 
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4.5.11. Determination of drug entrapment efficiency within pH responsive hydrogel F6 
 
The drug entrapment efficiency for hydrogel F6 for theophylline (0.003M), ciprofloxacin 
(0.17M), indomethacin (0.18M), metronidazole (0.007M), sulfamethazole (0.003M), 4-
aminosalcylic acid (0.0014M) and zidovudine (0.001M) was determined to be 98.2%, 66.3%, 
98.5%, 98.6%, 47.8%, 96.1% and 98.7%, respectively. The entrapment efficiency (0.03M) of 
sulpiride (0.003M) and naproxen was determined to be 31.4% and 24.8%, respectively. 
Sulpiride and naproxen had extremely low entrapment efficiency due to their very low water 
solubility, thus demonstrating that entrapment of a drug compound within the pH responsive 
hydrogel in this manner requires that the innate solubility of the API within water is high. 
 
4.5.12. Dissolution analysis of crosslinked AAm-MAA hydrogel F6 
 
The drug dissolution studies conducted in USP dissolution fluids, biorelevant dissolution 
fluids and isolated porcine GIT fluids indicate that the drug dissolution was, as expected, 
highly dependent on the physicochemical properties of the drug compound. Drug dissolution 
studies were conducted only on F6 because this formulation was the most desirable 
formulations from the tested formulations and there was a highly restrictive volume amount 
of isolated porcine GIT fluids available. The in vitro drug dissolution studies are shown in 
Figures 4.12 4.13. The in vitro dissolution of ciprofloxacin, indomethacin, metronidazole, 
sulfamethazole, 4-aminosalcylic acid and zidovudine is presented in Appendix 6 and five 
fitted dissolution modelling with an R2 adjusted above 0.98 is shown in Appendix 7. The ex vivo 
dissolution (conducted in isolated gastrointestinal fluids of the porcine model during the 
fasted state) of theophylline and ciprofloxacin is shown within Figure 4.14. The fractional 
dissolution of theophylline and ciprofloxacin against time was assessed with DDSolver add-
in for Microsoft Excel 2007 and the five dissolution models that achieved an Radjusted value 
greater of 0.998 was utilized. F6 was able to control the dissolution of some drugs. The 
presence of bile acids accelerated the dissolution of theophylline within biorelevant 
dissolution fluids and had a greater impact on the dissolution of theophylline than the pH of 
the dissolution fluid.  
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Figure 4.13: The in vitro dissolution of theophylline within USP simulated gastric fluid (USP pH 1.2), 
USP simulated intestinal fluid (USP pH 6.8), Fasted State Simulated Gastric Fluid pH 1.6 (FaSSGF 
pH 1.6) and Fasted State Simulated Intestinal Fluid Version 2 pH 6.5 (FaSSIF-V2 pH 6.5). The Area 
Under Curve (AUC), Mean Dissolution Time at 90 minutes (MDT90) and Mean Dissolution Time at 
1440 minutes (MDT1440) was determined for each dissolution profile. Five fitted dissolution modelling 
(red line, blue line, pink line, black line and green line) was shown for each dissolution profile. 
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Figure 4.14: Fed State Simulated Intestinal Fluid pH 5.0 (FeSSIF pH 5.0) and Fasted State Simulated 
Gastric Fluid canine pH 1.5 (FaSSGFc pH 1.5), Fasted State Simulated Gastric Fluid canine pH 6.5 
(FaSSGFc pH 6.5) and Fasted Stated Simulated Intestinal Fluid canine pH 7.5 (FaSSIFc pH 7.5). The 
Area Under Curve (AUC), Mean Dissolution Time at 90 minutes (MDT90) and Mean Dissolution Time 
at 1440 minutes (MDT1440) was determined for each dissolution profile. Five fitted dissolution 
modelling (red line, blue line, pink line, black line and green line) was shown for each dissolution 
profile. 
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Figure 4.15: The ex vivo dissolution of theophylline and ciprofloxacin within isolated fasted gastric 
fluids and isolated fasted intestinal fluids of the porcine model. Dissolution modelling profile (R
adjusted 
value greater than 0.998) was determined utilizing DDSolver add-in for Microsoft Excel 2007 and is 
represented over the drug concentration-time scatter plot profiles. Mean dissolution time at 90 
minutes (MDT90), mean dissolution time at 1440 (MDT1440) and area under curve (AUC) was 
determined for each profile. 
 
The ex vivo analysis of drug dissolution was assessed with theophylline because of the high 
solubility capacity of the compound. Ciprofloxacin which is highly soluble within a gastric 
environment and has limited solubility within the intestinal environment was selected for 
dissolution studies within isolated porcine fluids. The n-octanol/pH 7.0 buffered solution 
partition coefficient (log P) of ciprofloxacin and the lipophilicity of ciprofloxacin has been 
calculated utilizing fragmentation methods of atomic contributions to be -1.15 for C log P and 
1.32 for log P (Vázquez et al., 2001; Kasim et al,. 2004). 
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The mean dissolution time at 90 minutes (MDT90) established that the drug dissolution of 
ciprofloxacin was the least restrictive within isolated gastric fluids but the most restrictive 
within isolated intestinal fluids. The restrictiveness of ciprofloxacin from the hydrogel matrix 
cannot be explained by the pH responsiveness of the hydrogel and is attributed to the innate 
physicochemical properties of ciprofloxacin. The MDT90 for theophylline increased only by 10 
units between isolated porcine gastric fluid and isolated intestinal fluid.  
 
The mean dissolution time at 1440 minutes (MDT1440) increased for ciprofloxacin by 289% 
from isolated porcine gastric fluids to isolated porcine intestinal fluids. The MDT1440 of 
theophylline decreased 45% in isolated porcine intestinal fluid with respect to isolated 
porcine gastric fluid. The AUC is an indication of the extent at which the drug is successfully 
released, from the hydrogel sample within a solution, over the entire dissolution time period. 
The dissolution extent of theophylline increased 22% but the dissolution extent of 
ciprofloxacin decreased by 43%, within isolated porcine intestinal fluid with respect to 
isolated porcine gastric fluid.  
 
Ciprofloxacin has been characterized as a zwitterionic molecule that has pKa1 and pKa2 
values at 6.2 and 8.59, respectively, at 37°C (Escribano et al., 1997). The low solubility of 
ciprofloxacin within isolated porcine intestinal fluids (pH 8.4±0.3), USP pH 6.8 and near 
neutral biorelevant dissolution fluids is due to the convergence of the isoelectric point of the 
compound and the pH of the dissolution environment. The criprofloxacin dissolution within 
FaSSGF achieved the most similar extent of drug dissolution in comparison to isolated 
porcine gastric fluids, even though the extent was slightly underrepresented within FaSSGF. 
 
The BCS classification of ciprofloxacin is a point of contention whereby some researchers 
have indicated that the drug belongs in BCS IV compounds (Wu et al., 2005; Brenda et al., 
2009; Olivera et al., 2011) and other researchers (Custodia et al., 2008; Varma et al., 2012) 
has placed ciprofloxacin within BSC III. The BSC III classification of ciprofloxacin was 
incorrect, according to Olivera and co-workers (2001), due to the original determination 
within non-buffered aqueous solution at 25°C. Additionally, ciprofloxacin has been assigned 
a BDDCS IV (Benet et al., 2011). Whereas theophylline has been classified as a BCS I 
compound (Custodia et al., 2008; Varma et al., 2012) and a BDDCS I compound (Benet et 
al., 2011). Theophylline has been indicated to have a log P of 0.05 and a pKa of 8.6, 
respectively (Hrabálek et al., 2006). The extent of theophylline dissolution within the isolated 
porcine gastric fluids was slightly lower than that in USP pH 6.8. FaSSGF and FaSSGFc pH 
1.5. Whereas the extent of theophylline dissolution was very similar to that achieved within 
USP pH 6.8, FaSSIF-V2 and FeSSIF-V2. The purpose of this study was to demonstrate that 
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a dissolution profile within an in vivo gastrointestinal luminal environment can be highly 
dependent on the innate physicochemical properties of the drug compound in tandem with 
the physicomechanical properties of the drug delivery platform.  
  
The F2 hydrogel has demonstrated altered physicomechanical properties within the 
biorelevant media and isolated porcine gastrointestinal fluids. The altered 
physicomechanical properties within these dissolution fluids had a significant impact in the 
drug dissolution profiling. The dissolution of metronidazole, sulfamethoxazole, 4-
aminosalicylic acid, indomethacin, zidovudine and theophylline in near neutral pH 
biorelevant dissolution fluids was far more extensive than within an acidic pH biorelevant 
dissolution fluid. Comparatively, the dissolution of ciprofloxacin was far more extensive 
within acidic dissolution fluid than within near neutral dissolution fluid.  
 
The physicomechanical properties of a hydrogel drug delivery platform can be 
underestimated or overestimated within dissolution fluids, which can have a knock on effect 
on the accurate prediction of drug release. Understanding of the innate physicochemical 
properties of the drug compound and the physicomechanical properties of a hydrogel within 
a specific dissolution environment should not be underestimated. For instance, the hydrogel 
formulations achieved a far greater ability to gravimetrically swell within USP dissolution 
fluids but the compression resistance of the hydrogel swelling under a constant force 
favoured near neutral biorelevant dissolution fluids. The dissolution of a drug compound may 
occur in an extremely extensive manner within FaSSGFc pH 6.5 in comparison to FaSSIFc 
pH 7.5 or vice versa. The pH difference between the two solutions is relatively small, but the 
concentration of bile salt and lipid compounds is vastly higher in FaSSIFc pH 7.5. The bile 
salt and lipid component within biorelevant dissolution fluids may reduce swelling, which 
limits the physical dissolution of the drug compound or the bile salt and lipid component may 
accelerate drug solubility which increases the extent of drug release. The collective 
understanding of a drug dissolution profile from the perspective of the innate 
physicochemical and physicomechanical properties of the drug compound and the hydrogel 
drug delivery platform will facilitate more successful applications of these technologies in the 
oral gastrointestinal tract. 
 
4.5.14. Magnetic Resonance Imaging of crosslinked AAm-MAA formulation hydrogel 6  
 
The real time Magnetic Resonance Imaging (MRI) analysis of F6 was determined in USP 
dissolution fluids and Millipore® water. Additionally, the dynamic swelling capability of F6 was 
assessed in response to the substitution of USP pH 6.8 to USP pH 1.2. The MRI of AAm-
106 
 
MAA hydrogel F6 is shown in Figure 4.16.  
 
 
Figure 4.16: Magnetic Resonance Imaging of AAm-MAA hydrogel formulation 6 within deionised 
water, simulated gastric buffer (pH 1.2), simulated intestinal buffer (pH 6.8) and the dynamic 
equilibrating hydrogel that was first exposed to simulated intestinal buffer and then placed within 
simulated gastric buffer. 
 
The real time swelling of the hydrogel formulation within Millipore® water demonstrated that 
swelled extensively whereas the hydrogel formulation swelled in a very limited capacity 
within USP pH 1.2 dissolution fluid. The real time measurement of the ability of the hydrogel 
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to respond to pH affirms the covalent crosslinking bonds between the monomers that make 
up this hydrogel and the truly pH responsive nature of the crosslinked AAm-MAA hydrogel 
formulation. 
 
The ability of the F6 to shrink in response to a lower pH illustrates the true ability of the 
hydrogel to respond to pH and to maintain its structure during this process. This is extremely 
important for drug delivery applications. If the hydrogel had fractured upon reversal of pH 
(occurs with hydrogel systems composed of alginates), the surface area from which the 
loaded drug could be liberated from would be increased (Hamidi et al., 2008; Dadsetan et 
al., 2010; Matricaridi et al., 2013). The increased drug dissolution could cause the plasma 
concentration of a drug to reach toxic concentrations. Additionally, if the hydrogel formulation 
was utilized within a drug delivery device from a physicomechanical perspective, the ability 
of the hydrogel to retain structure and respond to the gastrointestinal environment in a 
predictable manner would be highly preferable. The human gastrointestinal tract is a 
dynamic environment that is in constant flux due to population genetics, diet, and disease 
state (Guerra et al., 2012; Roeselers et al., 2012). A drug delivery application should attempt 
to account for this variability so that if the gastrointestinal pH profile of the individual patient 
is not representative of the population, the targeted dissolution of a drug can still be 
achieved. Even, if the dissolution of the drug compound is predictably faster or slower than 
what has been characterized under “ideal” circumstances. These studies indicated that F6 
was very sensitive to the ex vivo gastrointestinal luminal environment and the MRI analysis 
indicates F6 would be able to predicatively respond to the dynamic gastrointestinal in vivo 
environment.   
 
4.6. Concluding remarks 
 
The physicomechanical and physicochemical properties of oral drug delivery hydrogel 
formulations should be assessed within biorelevant dissolution fluids. As demonstrated in 
this study, the gravimetric swelling and distance-time studies of a hydrogel formulation can 
be significantly altered by the presence of physiologically relevant entities such as bile acids 
and lipid components, even at similar pH. This can be an indication that in vivo drug 
dissolution may be altered by the cumulative effect of the physicochemical properties of the 
drug and the in vivo environment. The utilization of pH-sensitive hydrogel drug delivery 
formulations within an animal model should be reduced with the utilization of biorelevant 
dissolution fluids, as these dissolution fluids generally provide a more accurate determination 
of physicomechanical characteristics than simple USP dissolution buffers.  
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CHAPTER 5 
Optimized Eudragit® Coated Insulin Loaded Trimethyl Chitosan mPEG-EDTA Mini-
Pellet Using a Box-Behnken Design 
 
5.1. Introduction 
 
The oral administration of peptide therapeutics is one of the most challenging aspects of 
current pharmaceutical research due to the innate susceptibility of these compounds to the 
GIT. Intensive research efforts into the oral administration of peptide therapeutics have been 
driven by promoting patient compliance, advances in mass peptide synthesis and 
exponential increases in peptide therapeutics availability (Jintapattanakit et al., 2009; 
Karsdal et al., 2011). There have been many approaches to achieve enhanced oral 
therapeutic peptide absorption within the GIT such as direct modification of the peptide 
molecule or modification of the localized environment (Fetih et  al., 2009; Cui et al., 2009; 
Cheng and Lim, 2008, 2010; Huang et al., 2011). The in vitro development of a drug 
formulation which can alter the localized environment for the administration of a peptide 
therapeutic is a long and complicated process.  
 
The principle focus of this chapter is the physicochemical perspective whereby the trimethyl 
chitosan (TMC) will be characterized and a Box-Behnken design will be utilized to generate 
an optimized oral dosage form. Insulin was utilized in this optimization study because this 
peptide is relatively inexpensive, widely available (in pure form) and has been utilized with 
trimethyl chitosan for oral delivery applications (du Plessis et al., 2010). In Chapter 6, insulin 
is substituted with salmon calcitonin because of ethical constraints in inducing diabetes 
within large mammal animals (e.g. the Large White Pig species) and salmon calcitonin has 
also been administered with TMC (Huang et al., 2011). TMC is a chitosan derivative which 
contains three methyl groups covalently attached to amino functional groups located within 
the chitosan backbone (Bravo-Osuna et al., 2007; Amidi et al., 2010). Interest in TMC:Cl as 
a safe polysaccharide polymer that can be co-administered with peptide or protein 
therapeutics has increased significantly over the years (Bravo-Osuna et al., 2007; du Plessis 
et al., 2010). The five main properties of TMC:Cl which has been the motivating force behind 
the interest in this particular chitosan derivative are: permeation enhancing abilities within 
the small intestine; bacteriostatic properties; non-toxic properties; mucoadhesive properties; 
and the in vivo degradation properties. The ability of this polymer to perform all these roles 
has been demonstrated in recent research and has even been used as a standard for 
comparing systemic absorption of a peptide therapeutic against newly developed permeation 
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enhancers (du Plessis et al., 2010). The main negative offset of TMC:Cl is the limited 
compressibility of the excipient.  
 
In addition, auxiliary excipients ethylenediaminetetraacetic acid (EDTA), 
methoxypolyethylene glycol (mPEG), Ac-Di-Sol® and bile salt sodium, dicholate will be 
utilized within the mini-pellet formulations. Ac-Di-Sol® is a superdisintegrate excipient that 
enhances physical properties of a formulation when the formulation is not suspended in a 
solution and enhances rapid disintegration of the formulation when suspended in a solution. 
Bile salts such as sodium dicholate were utilized in the statistical formulation design to lower 
the surface tension and act as an additional permeation enhancer element (Fathi-
Azarbayjani et al., 2009; Guan et al., 2011; Chun et al., 2012). The reduction of surface 
tension within a localized intestinal environment allows for increased solubilization rates, 
thereby liberating the peptide therapeutic within the desired location rapidly. 
 
5.2. Materials and Methods 
 
5.3. Materials  
 
Chitosan (medium molecular weight) with a degree of deacetylation of 77.0% was purchased 
from Aldrich (Schnelldorf, Germany). Trimethyl chitosan chloride (TMC:Cl) was prepared by 
reductive methylation. Methoxypolyethylene glycol 2000 (mPEG), 
ethylenediaminetetraacetic acid (EDTA, 99.995% pure), sodium iodide (≥99.5  pure), 
methyl iodide (99.5% pure), sodium hydroxide (≥98  pure), sodium chloride (≥99  pure), 
hydrochloric acid (37%v/v), sodium deoxycholate (≥98  pure), sodium sulphate (≥99  pure), 
maleic acid (99% pure), lysophosphatidylcholine (≥99% pure), sodium taurocholate (≥90  
purity), sodium taurodeoxycholate (≥97  purity), dichloromethane (≥99.9  pure), sodium 
dihydrogen phosphate monohydrate (≥99  purity) and orthophosphoric acid (85%w/v, 
99.99% pure) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA) at reagent 
grade and were utilised without further purification. Acetonitrile (≥99.9  pure) and sodium 
oleate (≥99  pure) was purchased from Sigma (St. Louis, Missouri, USA) at UPLC grade. 
Diethyl ether (≥98  purity), ethanol (≥99.8  pure), N-methyl-2-pyrrolidone (≥99.5  pure) 
was purchased from Merck (Halfway House, Gauteng, South Africa) at reagent grade and 
were utilised without further purification.  Actrapid® HM (insulin) was purchased from a local 
pharmacy (Novo Nordisk Ltd., West Sussex, UK). Ac-Di-Sol® was purchased from FMC 
BioPolymer (Posterminalen, Haugesund, Norway). Egg phosphoatidylchloline (97.5% pure) 
purchased from Lipoid GmbH (Ludwigshafen, Germany).  
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5.4. Methods 
 
5.4.1. Synthesis of mini-pellet components 
 
5.4.1.1. Preparation and characterization of trimethyl chitosan chloride 
 
TMC:Cl was synthesized with slight modification as previously described (Polnok et al., 
2004). Briefly, TMC:Cl was synthesized by a two reaction step and an ion-exchange step 
process. Two grams of chitosan (medium molecular weight, 77% deacetylated), 10mL of 
20%w/v sodium hydroxide solution and 4.8 grams of sodium iodide was dissolved in 80mL of 
pre-warmed N-methyl pyrrolidonone (60±0.2°C). The reaction was carried out over a 30 
minute period in a heated water bath (60±0.2°C). The homogenous solution was then 
removed from the heated water bath and 12mL of methyl iodide was immediately 
incorporated within the solution. The reaction was allowed to complete under reflux, by 
utilization of a Liebig condenser, under constant magnetic stirring (300rpm) for 90 minutes 
(60±0.2°C). The homogenous polymer solution is then removed and the trimethyl chitosan 
iodine precipitated out of solution with 250mL diethyl ether and 250mL ethanol. Trimethyl 
chitosan iodine was collected and dried in vacuo (60±0.5°C for 48 hours). The dry trimethyl 
chitosan iodine was ground into a fine powder and utilized within the second reaction step. 
The second reaction step utilized the same procedure as that preformed in the first step but 
chitosan was substituted with trimethyl chitosan iodine. Once the polymer product from the 
second reaction had been dried and ground into a fine powder, the ion-exchange step was 
conducted. The second reaction step trimethyl chitosan iodine powder was dissolved in 
80mL of 5%w/v sodium chloride solution for 30 minutes under constant magnetic stirring 
(300rpm). Diethyl ether (250mL) and ethanol (250mL) was utilized to precipitate trimethyl 
chitosan chloride. The precipitated TMC:Cl was isolated by filtration and dried in vacuo 
(60±0.5°C for 24 hours). The reaction process can be reviewed in Figure 5.1. 
 
5.4.1.2. Preparation of EDTA-mPEG in situ hot melt dispersion powder (a component 
of the trimethyl chitosan mini-pellet formulation) 
 
An in situ hot melt dispersion of 50%w/w EDTA-mPEG was prepared. Briefly, the solid phase 
mPEG was heated to a liquid phase by melting at a temperature of 60°C.  EDTA was added 
to the molten mPEG and homogenously mixed until a uniform distribution was achieved. The 
EDTA-mPEG in situ hot melt dispersion was allowed to cool under constant stirring until a 
solid phase was achieved. The solid mass was placed through a metal sieve with an 
aperture of 850μm to form a fine powder. 
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5.4.2. Characterisation of trimethyl chitosan and chitosan 
 
5.4.2.1. Attenuated Total Reflectance-Fourier Transform Infrared analysis 
 
Attenuated Total Reflectance-Fourier Transform (ATR-FTIR) spectroscopy was carried out 
on chitosan and TMC:Cl as a means of validating the successful inclusion of trimethyl 
groups at amino group sites along the chitosan backbone. A Perkin Elmer Spectrum 2000 
FTIR spectrometer with a single reflectance MIRTGS detector, (PerkinElmer Spectrum 100, 
Llantrisant, Wales, UK) was utilized. Samples of chitosan and TMC:Cl were prepared and 
placed on a diamond crystal which was then processed by a universal ATR polarization 
accessory for the ATR-FTIR spectrum series, at a resolution of 4cm-1. Each sample was 
analyzed after 100 scans (SNR:10) at 130psi between 650-4000cm-1 range against 100 
0background scans. 
 
 
Figure 5.1: Schematic representation ofr the synthesis of trimethyl chitosan chloride. 
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5.4.2.2. Thermal Gravimetric Analysis of trimethyl chitosan and chitosan for the 
temperature at which maximal degradation occurs 
 
Thermal gravimetric analysis (TGA) of chitosan and TMC:Cl was carried out with the 
utilization of a Thermogravitational Analysis-4000 (Perkin Elmer, Waltham, MA, USA) under 
constant inert nitrogen atmosphere. Accurately weighed samples (10±0.5mg) were placed 
within the textile crucible. The weight percentage of water, the maximum temperature of 
degradation (first derivative), the rate of degradation, onset of degradation and the endset of 
degradation was determined. The TGA protocol was preformed with a ramping temperature 
of 10°C/min between the temperature range of 30°C to 700°C. 
 
5.4.2.3. Differential Scanning Calorimetry analysis to determine the unique heat 
capacities of trimethyl chitosan and chitosan 
 
Dry samples of chitosan and TMC:Cl were subjected to Differential Scanning Calorimetry 
(DSC) analysis utilizing a Differential Scanning Calorimeter (Mettler Toledo, Columbus, OH, 
USA). Accurately weighted samples (10±0.4mg) were placed in 40µL aluminium crucible 
pans. An open crucible system was induced by a 0.2mm hole in the lid of the aluminium 
crucible pan, which was then hermetically sealed. An inert nitrogen atmosphere (50 mL/min) 
was maintained throughout the DSC protocols. The thermogram traces were compared to 
determine changes in the onset of melting, melting peak temperature and heat of fusion for 
each sample. DSC protocols where run with a ramping temperature of 2°C/min , 5°C/min 
and 10°C/min between the temperature range of 25-110°C (first run) and, was repeated for 
the same sample between the temperature range of 25-500°C (second run). 
 
5.4.2.4. Powdered X-ray Diffraction for the determination of crystaility in trimethyl 
chitosan and amorphism in chitosan 
 
The powder XRD patterns were determined for chitosan and trimethyl chitosan chloride 
samples utilizing a 600 Watt Miniflex diffractometer (Rigaku, Toyko, Japan) with CuK∞ 
(1.5406Å) radiation. The powdered samples were analysed over a 0-90° 2-Theta range.  
The crystallinity degree was determined to correlate the observed chitosan and trimethyl 
chitosan morphology.    
 
5.4.2.5. Morphological analysis of trimethyl chitosan and chitosan 
 
Scanning Electron Microscopy (SEM) imaging was conducted in order to determine the 
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surface structure and morphology of chitosan and TMC:Cl. Each sample was mounted on a 
stub with silicon tape and sputtered coated with gold for 210 seconds. Each sample was 
then placed in a F   Phenom™ Desktop Scanning  lectron Microscopy ( indhoven, The 
Netherlands) so that SEM images could be acquired.  
 
5.4.3. Isolation of porcine small intestinal tissue and gastrointestinal fluids 
 
The Large White pigs utilized in this study were obtained according to the Guide for the Care 
and Use of Laboratory Animals that was approved by the Animal Ethics Screening 
Committee of the University of Witwatersrand (Ethics number:2011/33/03). The gastric and 
small intestinal fluids were collected after euthanization. The gastrointestinal fluids isolated 
from the pigs were collected during the fasted state. The fasted state was induced within the 
pigs by restricting food for 12 hours but the pigs were provided water ad libitum. This is a 
standard procedure for dosing pigs with an oral drug delivery system. The pigs were 
euthanized to achieve two objectives, retrieval of the small intestinal tissue and ensuring that 
the isolated gastrointestinal fluids was withdrawn from the appropriate organ by dissection. 
The stomach and small intestine was isolated and a small incision was made to perforate the 
respective organ wall. Blood was removed from the incision points with highly absorbent 
tissue paper and injection plungers were inserted into the incision points for the removal of 
the luminal fluid from the respective organ.  
 
The pH and buffer capacity of the isolated gastric and small intestinal fluids (individual and 
pooled samples) were measured immediately. The pooled sample was maintained with an 
equal addition from each individual sample. To preserve the composition of the 
gastrointestinal fluid, the samples were immediately frozen in liquid nitrogen and maintained 
at -80°C. In order for drug dissolution and disintegration studies to be effectively preformed, 
removal of solid matter (food particles and ingested hay) from the samples was achieved by 
centrifugation at 5000rpm for 10 minutes at 10°C, followed by filtration of the supernatant 
through a 0.44μm injection filter. 
 
5.4.4. USP 35 and biorelevant dissolution fluid utilized for rheological, dissolution and 
disintegration experimentation 
 
The USP 35 dissolution media for the simulated gastric (pH 1.2) and simulated small 
intestinal (pH 6.8) conditions were prepared according to the USP 35. The fasted and fed 
state biorelevant media (FaSSGF, FaSSIF V2, FeSSIF V2) for the human model was 
prepared as previously described (Jantratid and Dressman, 2009; Fotaki and Vertzoni, 2010; 
114 
 
Klein, 2010). The fasted and fed state biorelevant media (FaSSIFc, FaSSGFc pH 1.5, 
FaSSGFc pH 6.5) for the canine model was also prepared according to a previously 
described methodology (Arndt et al., 2013). 
 
5.4.5. Viscosity analysis of the trimethyl chitosan chloride within dissolution media 
and isolated gastrointestinal fluids of the porcine model 
 
The viscosity properties of dissolution fluids (USP and Biorelevant), isolated porcine 
gastrointestinal fluids (fasted state) and 0.1%w/v TMC weight concentrations within each 
solvent were determined. The viscosity (η) was determined using a Modular Advanced 
Rheometer (ThermoHaake MARS Modular Advanced Rheometer, Thermo Electron, 
Karlsruche, Germany) equipped with a C35/1° Ti sensor. Measurements were performed 
employing the rheological parameters shown in Table 5.1. All rheological procedures were 
run at 37°C. 
 
Table 5.1. Rheological parameters utilized for the analysis of trimethyl chitosan chloride 
within dissolution media and isolated gastrointestinal fluids of the porcine model 
 
Parameter Value 
Cone and plate gap 0.0051m 
Driver version 0.29 
Inertia 89051.00PA 
A-factor 1.721x10-6Kg.m2 
M-factor 57.01rad/s 
Temperature 37°C 
Damping 30.00 
 
The solutions were prepared and immediately placed between the cone and base plate of 
the rheometer. The samples (1mL) for 180s at a yield stress of 5s-1 and 200s-1. The results 
were recorded (n=3) and subjected to a box and whisker statistical analysis.  
 
5.4.6. Box-Behnken Design of insulin loaded trimethyl chitosan chloride mini-pellet 
formulations 
 
A 3-factor Box-Behnken statistical experimental design was generated using Minitab® V15 
software (Minitab Inc., PA, USA) in order to obtain 15 statistically relevant formulations. The 
Box-Behnken statistical design is utilized to establish a relationship between independent 
formulations variables with physicochemical and physicomechanical responses obtained 
from the insulin loaded trimethyl chitosan mini-pellet (insulin-TMC:Cl MiPe) formulations. Ac-
Di-Sol® (10-30mg), sodium deoxycholate (0-5mg) and EDTA-mPEG in situ hot melt 
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dispersion (10-20mg) were selected as independent formulation variables. Insulin-TMC:Cl 
(90mg) was included within each formulation and TMC:Cl was added to each formulation so 
that the total weight of each formulation was 145mg.  The responses deemed most 
important for these formulations were the matrix hardness, the mean dissolution time after 
2.5 hours and the fractional dissolution after 8 hours. The polynominal equation for this 
design is shown as Equation 5.1. The independent factors and the dependent variables 
used in the design are listed in Table 5.2. 
 
  
                                   
         
        
  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                    
Where y is the measured response associated with each factor combination of 50%w/w 
mPEG-EDTA in situ hot melt dispersion, Ac-Di-Sol® (ADS) and sodium deoxycholate (BS). 
The regression co-efficients are represented by b0 to b9. The design required a total of 105 
experimental runs (each formulation was measured in triplicate) and was analyzed using 
Minitab® V15 software. 
 
Table 5.2. The 3-factor, 3-level Box-Behnken Design variables utilizing MINITAB V15 software 
 
Independent Variables Levels 
Low Medium High 
mPEG-EDTA (%w/w)
a 10 15 20 
Ac-Di-Sol® (%w/w)
b 10 20 30 
BS (%w/w)
c 0 2.5 5 
Dependent Variables Low High Objective 
Matrix Hardness 60 110 Maximum 
MDT within 2.5 hoursd 0.9 1.55 Maximum 
Maximal fractional dissolution after 8 hours 0.4 1.0 Maximum 
a
mPEG-EDTA indicate 50%
w
/w methoxypolyethylene  
glycol 2000-ethylenediaminetetraacetic acid 
b
Ac-Di-Sol
®
 indicates croscarmellose sodium 
c
BS indicates sodium deoxycholate 
d
MDT indicates mean dissolution time 
 
5.4.7. Preparation of insulin loaded trimethyl chitosan chloride mini-pellet 
formulations 
 
5.4.7.1. High Performance Liquid Chromatography of insulin  
 
The concentration of insulin within dissolution solvents was determined utilizing a High 
Performance Liquid Chromatography (HPLC) machine with a Waters 1525 Binary Pump, 
(Eqn. 5.1) 
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2489 UV/visible detector and an auto-sampler attachment (Waters, Milford, MA, USA). A C18 
silica based reverse phase Symmetry 300 column (Waters, Milford, MA, USA) with a particle 
size of 5μm was utilized for isolation and accurate determination of insulin concentration. 
The absorbance was monitored at 214nm and the column temperature was maintained at 
40°C. Solvent A (100% acetonitrile) and Solvent B (28.4g of sodium sulphate dissolved in 
1000mL Millipore water, and 2.7mL orthophosphoric acid to adjust pH to 2.3 [the pH of the 
solution was adjusted with ethanolamine]) was utilized in an isocratic gradient of Solvent A 
and Solvent B at a ratio of 26:74 (Yomota et al., 1996). 
 
 
5.4.7.2. Insulin incorporation and entrapment studies of insulin within trimethyl 
chitosan chloride powder 
 
The homogenous incorporation of insulin within TMC:Cl powder was achieved by accurately 
weighing 2500mg TMC:Cl powder which was dissolved in Millipore® water to a final 
concentration of 5%w/v. The TMC:Cl solution was stirred at 30rpm for 30 minutes, at which 
point a viscous yellow solution was obtained. The insulin solution (Actrapid® HM 100) was 
added and homogenously incorporated within the TMC:Cl solution at room temperature for 
30 minutes, in order to obtain a final concentration of 1IU insulin per 3.2mg of TMC:Cl 
powder. The dispersion was frozen at -80°C for 48 hours. The frozen insulin-TMC:Cl solution 
was lyophilized with a 2 hour condensation phase at -60°C and a 24 hour sublimation phase 
at 25 mmTorr utilizing Freezone 12 freeze drier (Lanconco, Kansas City, USA). After freeze-
drying, the sample was placed within sealed glass polytops and maintained at -20°C 
(Pringels et al., 2004; Silva et al., 2006). The water content of the lyophilized insulin samples 
was determined with a Karl Fischer volumetric titrator (Mettler Toledo, Columbus, USA) with 
a DN143-SC sensor attachment. The Karl Fischer volumetric titrator was maintained at 25°C 
with a start potential of 596.5mV and a titrant concentration of 5.33724mg/mL. The 
homogenous entrapment efficiency of insulin within TMC:Cl powder was determined by 
weighing a defined amount of lyophilized TMC:Cl powder (n=3). The TMC:Cl powder/insulin 
lyophilized product was dissolved within 20mL of USP 35 simulated intestinal buffer (pH 6.8, 
37°C). A 1mL sample was withdrawn from each solution after 3 hours and placed within an 
ANSI HPLC vial. The concentration of the samples was measured using HPLC. The 
homogenous entrapment efficiency was calculated according to Equation 5.2. 
 
    
              
           
                                                                                               (Eqn. 5.2) 
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Where HEE is homogenous entrapment efficiency, Ct3 (measured) is the concentration of insulin 
measured at 3 hours; Cloaded dose is the amount of insulin originally loaded into the trimethyl-
chitosan suspension. 
 
5.4.7.3. Direct compression of mini-pellets  
 
Insulin-TMC:Cl powder, mPEG-EDTA in situ hot melt dispersion powder, Ac-Di-Sol® 
microcrystalline cellulose and dry TMC:Cl powder was accurately weighed according to the 
Box-Behnken design and utilized to produce mini-pellet formulations through dry granulation. 
The homogenous excipient mixtures were compressed at 3.4MPa within a modified punch 
and die set to produce 4mm diameter mini-pellets. The mini-pellets were immediately stored 
at -20°C.   
 
5.4.8. Textural profile analysis of insulin loaded trimethyl chitosan chloride mini-pellet 
formulations 
 
5.4.8.1. Physicomechanical analysis 
 
The physicochemical properties of the mini-pellet formulations were evaluated with respect 
to matrix hardness (MH), and deformation energy (DE). A calibrated Textural Analyzer 
(TA.XTplus, Stable Microsystems, Surrey, UK) fitted with a flat tip steel probe (2mm 
diameter; for MH and DE) was utilized. The parameters utilized for the analysis is outlined in 
Table 5.3. All studies (n=3) were conducted at standard operating procedures (25°C, 1atm. 
pressure). MH (N/mm2) and DE(J) were both determined based on force-distance profiles, in 
particular, MH was elucidated from the gradient between the initial force and the maximum 
force attained, and the DE from the Area Under Curve (AUC). 
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Table 5.3. Textural profiling parameters settings employed for physicochemical, mucoadhesive and 
disintegration characterisation of the mini-pellet formulations 
 
Parameters MHa(N/mm2) DEb(J) Mucoadhesive 
test 
Disintegration 
test 
Option Return to start Hold until reset 
Pre-test speed 
(mm/s) 
1 1 0.5 2.0 
Test speed (mm/s) 0.5 0.5 0.5 3.0 
Post-test speed 
(mm/s) 
10 10 10 10.0 
Applied force (N) 0.1 0.1 5 0.01 
Trigger type Auto Auto Auto Auto 
Trigger force (N) 0.05  0.05  0.05  0.05 
Load cell (Kg) 5  5  5  5 
Target mode Distance Distance Distance Distance 
Tare mode Auto Auto Auto Auto 
aMatrix Hardness 
bDeformation energy 
  
5.4.8.2. Ex vivo mucoadhesive analysis  
 
The ex vivo mucoadhesive analysis was performed (n=3) for each mini-pellet formulation 
generated within the Box-Behnken design and a blank chitosan mini-pellet formulation. 
Fresh porcine small intestine epithelium tissue was dissected longitudinally and then 
dissected horizontally into 5cm x 5cm square pieces (Hagesaether et al., 2009). The small 
intestinal epithelium tissue pieces were then washed with sterile saline solution (0.9%w/v 
NaCl) to remove the mucus layer which was tainted with imbedded partly digested matter. A 
solution which contained mucin (3%w/v) and phosphate buffer (pH 6.8) was prepared to 
simulate the mucous layer (Hagesaether et al., 2009). The small intestine epithelium tissue 
samples were attached to a 2cm cylindrical probe with nylon string and then attached to the 
TA.TX plus Texture Analyzer (Stable Micro Systems, Surrey, UK). The mini-pellet was 
attached to the stage of the Texture Analyzer using double sided adhesive tape 
(Hagesaether et al., 2009). Mucin solution (60μL) was applied to the mini-pellet formulation 
and the Textural analyzer probe was immediately lowered to come in contact with the mini-
pellet. This process facilitated mucoadhesion between the insulin-TMC:Cl MiPe formulation 
and the porcine small intestinal tissue sample. The probe was then raised slowly to measure 
the Work of Adhesion (WA) which is determined from the AUC in the force distance profile. 
The maximum detachment force (MDF) was determined from the maximum inflection point 
of the force distance profile. The procedure was repeated with fresh small intestine 
epithelium tissue samples for each insulin-TMC:Cl MiPe formulation without the application 
of mucin solution for comparative purposes. The parameters utilized within this analysis are 
presented in Table 5.3. 
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5.4.9. Dissolution studies and dissolution fitting analysis of mini-pellet formulations  
 
In vitro dissolution of insulin from the Eudragit® coated insulin-TMC:Cl MiPe formulations 
was determined by a method described previously (Dünnhaupt et al., 2012). Insulin-TMC:Cl 
mini-pellets were spray coated with Eudragit® (4%w/w solution of Eudragit
® L100 and 4%w/w 
solution of Eudragit® S100 within an organic solvent composed of 33%v/v ethanol and 67%
v/v 
acetone. Triethyl citrate was added to the solution at a concentration of 35%w/w of the 
Eudragit® component of the spray coating solution). The Eudragit® coated insulin-TMC:Cl 
MiPe formulations were dried at room temperature for 3 hours (coating layer was 
0.5mm/surface as determined by comparative measurements between pre-coated and 
coated mini-pellet formulations). Eudragit® coated insulin-TMC:Cl MiPe formulations were 
placed in 20mL glass polytops containing 10mL USP 35 simulated gastric fluid (pH 1.2) for 2 
hours and in 10mL USP 35 simulated intestinal fluid (pH 6.8) for 8 hours.  Polytops were 
placed within an Orbit Shaker Incubator (LM-530-2, MRC Laboratory Instruments Ltd, 
Hahistadrut, Holon, Israel) at 37±0.5°C and 50rpm, sink conditions were maintained 
throughout the study.  
 
For each mini-pellet formulation, nine replicates were tested, all from the same production 
batch. Samples were withdrawn at 0, 15, 45, 90, 150, 270, 390 and 450 minutes and 
replaced with an equal volume of USP 35 simulated gastric or intestinal fluid which had been 
equilibrated at 37±0.5°C to maintain sink conditions. The samples were filtered through a 
0.22μm Millipore Millex filter (Billerica, MA,  SA) and placed within ANSI 48 HPLC vials. The 
samples were maintained at 4°C and analyzed using HPLC within 12 hours of acquisition. 
Concentrations were calculated by interpolation from a standard curve. Cumulative 
corrections were made for previously removed samples in determining the total amount 
released. The concentration of insulin (IU/mL) against time (hour) profile for each Eudragit® 
coated insulin-TMC:Cl MiPe formulation was generated utilizing DDSolver add-in for 
Microsoft Excel 2007. The mean dissolution time (MDT) over the first 2.5 hours was 
determined according to the Equation 5.3. The fractional dissolution of insulin after 8 hours 
for each formulation was determined according to Equation 5.4.  
 
       
 
   
  
  
                                                                                                        (Eqn. 5.3) 
 
Where M is the fraction of dose released in time  i = (ti=ti-1)/2 and M  corresponds to the 
loading dose.  
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                                                                                                                  (Eqn. 5.4) 
 
Where FRt8 is fractional dissolution after 8 hours, Ct8 is the concentration of insulin at 8 
hours, CTD is the total dose of insulin within the formulation. 
 
5.4.10. In vitro and ex vivo characterization of the optimized Eudragit® insulin loaded 
mini-pellet formulation within biorelevant dissolution fluid and isolated porcine 
gastrointestinal fluids 
 
5.4.10.1 Physicomechanical characterization of the optimized insulin loaded trimethyl 
mini-pellet formulation  
 
The physicomechanical characterization and ex vivo mucoadhesive analysis of the 
optimized insulin-TMC:Cl MiPe formulation was conducted in the same manner as described 
during the Box-Behnken studies. 
 
5.4.10.2. Disintegration analysis 
 
The disintegration studies of the optimized Eudragit® insulin-TMC:Cl MiPe formulation was 
evaluated on a Textural analyzer (TA.XT plus, Stable Microsystems, UK). A specialty probe 
was attached to the Textural analyzer that facilitates the capture of a disintegration profile. 
Water soluble glue was used to attach the optimized Eudragit® insulin-TMC:Cl MiPe to a 
probe head which magnetically attaches to the probe shaft. A reservoir of USP 35 simulated 
fluids, biorelevant dissolution fluids for the canine and human model was utilized as reservoir 
fluids. In addition, isolated porcine gastric and small intestinal fluids (fasted state) were also 
utilized as reservoir fluids. The optimized Eudragit® coated insulin-TMC:Cl MiPe formulation 
was lowered into the reservoir, the mini-pellet comes in contact with a magnetic gridded 
base plate and the distance from the magnetic gridded base plate to the surface of the probe 
head is captured. As the insulin-TMC:Cl MiPe formulation disintegrates within the respective 
dissolution solvent or isolated gastrointestinal fluid, the probe is lowered and the distance 
moved over time is captured as a disintegration profile. The disintegration profile for each 
fluid was compiled and the disintegration rate at each respective time period was determined 
(n=3). The obtained data points (including standard deviations) were placed within a scatter 
plot and a regression curve was fitted to these scatter points. The parameters utilized for 
Textural disintegration analysis is outlined in Table 5.3. 
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5.4.10.3. Dissolution of optimized Eudragit® coated insulin loaded trimethyl chitosan 
mini-pellet formulation 
 
The optimized Eudragit® coated insulin-TMC:Cl MiPe formulation was prepared in the same 
manner as that of the Eudragit® coated Insulin-TMC:Cl MiPe formulations from the Box-
Behnken design. The major addition to these dissolution studies is the inclusion of 
biorelevant media. Additionally, isolated gastrointestinal porcine fluids (fasted state) were 
utilized for ex vivo dissolution studies.  
 
The concentration of insulin (IU/mL) against time (hour) profile for each dissolution fluid or 
isolated gastrointestinal fluid was generated utilizing DDSolver add-in for Microsoft Excel 
2007. The mean dissolution time (MDT) over the first 2.5 hours was determined according to 
the Equation 5.3. The fractional dissolution of insulin after 8 hours for each formulation was 
determined according to Equation 5.4.  
 
5.4.11. Statistical regression analysis of obtained data measurements  
 
The statistical deviation of each obtained data measurement (n=3) was determined using 
Microsoft® Office Excel® 2007 (Build 12.0.4518.1014, Microsoft Corporation, USA). The 
obtained data measurements and the standard deviations were plotted within scatter plots 
using SigmaPlot V11.0 (Build 11.0.0.77, Systat Software Inc., Germany). Regression curves 
were fitted to the scatter plots and R2 values for each regression curve were determined 
using SigmaPlot V11.0. A Shapiro-Wilk test was utilized during the calculation of each 
regression curve to determine if obtained data measurements were normally distributed 
populations at an alpha level of 0.05 using SigmPlot V11.0. In addition, a constant variance 
test (P=0.05) for each regression curve was determined to indicate if the dependent variable 
remains constant despite a dynamically changing value of the independent variable using 
SigmaPlot V11.0. The 95% confidence interval and 95% predicted confidence interval was 
determined for the each regression curves.  
 
5.5. Results and Discussion 
 
This Chapter attempts to fully illustrate the in vitro development process of an oral peptide 
drug delivery dosage form from characterization of polymer excipients to development of an 
optimal formulation through a statistical design. The TMC bulk excipient characterization is 
very important because the grade of the parent material chitosan and method of 
synthesizing TMC:Cl can vary significantly and thus alter the properties of the final derived 
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polymer product. Finally, the porcine model fluid was utilized in this study as this model 
animal has been indicated to have very similar anatomical and physiological gastrointestinal 
tract features to that of the human species. In addition, the physical mass of the porcine 
model can easily achieve equivalent mass to that of an average adult human which allows 
for a drug molecule to distribute within a similar volume of biological fluid volume.  
 
5.5.1. Characterization of trimethyl chitosan chloride and chitosan 
 
5.5.1.1. Attenuated Total Reflectance-Fourier Transform infrared analysis 
 
TMC:Cl is a synthesized derivative of chitosan that is a pale yellow, free flowing powder 
excipient that readily dissolves within neutral solvents to form a light yellow solution. 
Chitosan was not utilized in this study because chitosan does not dissolve within neutral 
conditions and this is a formulation issue when the biological perspective is considered. 
Therefore, TMC:Cl was synthesized in order to retain the positive innate properties of 
chitosan and allow for these highly desirable properties to be extended into the neutral 
environment by increasing the solubility of the parent compound. During the synthesis of 
TMC:Cl the number of positive charges on the polymer chain is increased causing the 
polymeric molecule to expand in solution due to repelling electrostatic forces between the 
functional groups (Martins et al., 2011). TMC:Cl is able to increase transport of large 
compounds, such as peptide therapeutics, because the charge density and structural 
features along the backbone structure of this chitosan derivative enables augmented 
absorption across mucosal epithelia by opening tight junctions (Martins et al., 2011). 
 
The ATR-FTIR analysis of TMC:Cl and chitosan are utilized for comparative purposes. The 
ATR-FTIR spectra of TMC:Cl (A), insulin-TMC:Cl powder (B) and chitosan (C) are shown in 
Figure 5.2. The chemical structures of TMC:Cl and chitosan can also be reviewed at the 
respective ATR-FTIR profile. The maximum peaks obtained from the ATR-FTIR analysis of 
TMC:Cl, insulin loaded chitosan and chitosan is shown in Table 5.4. The ATR-FTIR indicate 
that TMC:Cl was successfully synthesized as indicated by the presence peak 1475cm-1 and 
1559cm-1, whereas peak 1577cm-1 is specific to chitosan (Mourya and Inamdar, 2009). The 
peak located at 1475cm-1 is attributed to the asymmetrical angular deformation of the C-H 
bonds of methyl groups. The peak at 1577cm-1 for chitosan and 1555cm-1 for TMC:Cl is due 
to angular deformation of N-H bond of amino groups but the intensity of peak 1555cm-1 is 
reduced in comparison to peak 1577cm-1 due to N-methylation (Martins et al., 2011). The 
peak at 1555cm-1 within the TMC:Cl spectra indicates the presence of N-H bending but the 
N-methylation reaction was partial, as the presence of mono and disubstituted amino groups 
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are possible. The peak range 1415-1430cm-1 is assigned to the characteristic absorption of 
N-CH3. The alterations of peak 1150cm
-1 within chitosan indicate that the introduction of alkyl 
groups occurred at C-3 and C-6 within TMC:Cl (Mourya and Inamadar, 2009).  
 
 
Figure 5.2: ATR-FTIR spectra of trimethyl chitosan chloride (A), insulin-loaded trimethyl chitosan 
chloride powder (B), and medium molecular weight chitosan (C) between the spectra range of 
1800cm
-1
 and 650cm
-1
 at 130psi. The chemical structures of trimethyl chitosan chloride and chitosan 
is represented above the respective ATR-FTIR profiles. 
 
Table 5.4. ATR-FTIR of trimethyl chitosan chloride, insulin-loaded trimethyl chitosan chloride powder 
and medium molecular weight chitosan 
 
ATR-FTIR Peaks (cm-1) 
Chita TMC:Clb Insulin 
-TMC:Clc 
1579 1557 1555 
1312 1474 1475 
1150 1415 1415 
1023 1306 1375 
892 1241 1307 
 1198 1240 
 1055 1198 
 948 1039 
  951 
a:Chitosan 
b: Trimethyl chitosan chloride 
c: Insulin-loaded trimethyl chitosan chloride powder 
 
 
 
N
+
CH3
CH3
CH3
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The characteristic ATR-FTIR wavenumber peaks for the methyl group was observed within 
the synthesized TMC:Cl but absent within the parent compound chitosan. This indicates that 
TMC:Cl was successfully synthesized. The presence of insulin within the insulin-TMC:Cl 
powder was not detectable with ATR-FTIR analysis because the physical mass of the 
peptide therapeutic was so low. 
 
5.5.1.2. Thermal gravimetric analysis of trimethyl chitosan chloride and chitosan 
 
The thermal gravimetric analysis (TGA) of TMC:Cl and chitosan determined that there were 
two stages during which weight of polymer was lost. The two stages were observed within 
the first derivative of the TGA profile for each respective polymer. TGA of TMC:Cl and 
chitosan is shown in Figure 5.3. The TGA profile for TMC:Cl is represented by the solid blue 
line (A) and chitosan by the solid red line (B). The first derivative profile of TMC:Cl is 
represented by the broken blue line (C) and the first derivative profile of chitosan is 
represented by the broken red line (D). The maximum degradation temperature, water loss 
at maximum temperature, percentage of water loss, weight percentage loss of polymer at 
maximum degradation temperature and the weight percentage of the polymer remaining at 
500°C values are presented in Table 5.5 for TMC:Cl and chitosan. 
 
 
Figure 5.3: Thermogravitational Analysis (TGA) profiles of trimethyl chitosan chloride (A), TGA profile 
of chitosan (B), first derivative TGA profile of trimethyl chitosan chloride (C) and first derivative TGA 
profile of chitosan (D). 
 
The first stage of polymer weight loss occurred with the liberation of microscopic water from 
the respective polymers and was represented as a broad peak in the first derivative profile. 
This broad peak indicates the thermal range at which water was lost (onset and endset) and 
the highest point of this peak indicates the maximal percentage of water loss. Additionally, 
A 
B 
C 
D 
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the highest point of the first stage peak (in the first derivative profile) also indicates the 
temperature at which the maximal amount of water is liberated from the sample and is 
referred to as one of the maximal degradation temperatures.  
 
The percentage of weight of macroscopic water present was minimally different between 
TMC:Cl and chitosan (~1.7%). Chitosan had a slightly lower amount of water content 
compared to TMC:Cl but the temperature at which maximal weight percentage of water is 
removed is 4.15°C higher in TMC:Cl. In addition, the percentage of weight loss, at 500°C, 
was ~11.6% less for TMC:Cl in comparison to chitosan. It should be noted that the extent of 
degradation within TMC:Cl was significantly less than that of chitosan, as seen in Figure 5.4.  
 
Table 5.5. Thermogravitational analysis of trimethyl chitosan chloride and chitosan 
 
Parameter Chitosan Trimethyl Chitosan 
Chloride 
Maximum degradation temperature (°C) 314.8 238.91 
Water loss at maximum temperature (°C) 77.63 81.78 
Percentage of water loss at maximal 
degradation temperature (%) 
5.789 7.486 
Percentage of weight loss at maximal 
degradation temperature (%) 
60.471 45.25 
Weight remaining at 500°C (%) 37.705 49.298 
 
It was noted that chitosan had a higher amount of microscopic water content but liberated 
the water content at a lower temperature. The presence of a greater density of hydroxyl and 
amino groups within chitosan, in comparison to TMC:Cl, may provide a greater number of 
dipole-dipole interactions with water molecules and enhance the volumeric entrapment of 
water within the polymeric network (Domard et al., 1986; Martins et al., 2011). 
 
The primary degradation of TMC:Cl and chitosan occurs within the second stage that can be 
observed as the second large peak within the first derivative profile for each respective 
polymer. The temperature at which maximum degradation occurs within chitosan is higher 
than within TMC:Cl, suggesting that chitosan is more thermally stable than TMC:Cl (Britto 
and Campana-Filho, 2004). The percentage of degradation within the second stage of 
degradation was lower in TMC:Cl than the parent compound chitosan. Therefore, even 
though TMC:Cl started to degrade at a lower temperature, the physical amount of 
degradation was lower with respect to chitosan. And this becomes more apparent when the 
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TGA profiles of TMC:Cl and chitosan intersect at ~325°C, after which the percent of 
degradation for TMC:Cl is less than chitosan. This suggests that chitosan acts as a more 
efficient thermal sink initially, whereby heat energy is absorbed and prevents degradation of 
the chitosan network until a critical temperature is achieved. Whereas TMC:Cl had less of 
this heat sink capacity initially, possibly due to the quaternization process, and therefore 
degradation began more rapidly but never achieves the level of degradation that occurred 
within chitosan. This information is important with respect to formulation and indicates the 
degree water affinity of TMC with chitosan and the stability of these excipients.  
 
5.5.1.3. Dynamic Scanning Calorimetry analysis  
 
The DSC first run (data not shown) was utilized to remove macroscopic water from the 
sample without destroying the sample (Kittur et al., 2002). The second run DSC profiles for 
TMC:Cl and chitosan at each respective heating rate is shown in Figure 5.4. A melting-
crystallization-melting-crystallization pattern is always observed for DSC thermogram profiles 
of TMC whereas a single crystallization peak (excluding initial melting peak) is always 
observed within DSC thermograms of chitosan. The DSC thermogram indicates that 
TMC:Cl, at heating rate of 10°C/min, presents a melting and crystalline peak located at 
217°C and 270°C, respectively. Whereas during the second DSC run (at heating rate 
10°C/min) of chitosan presented one major crystalline peak at 306°C. The calculated heat of 
fusion and peak temperatures for TMC:Cl and chitosan at each heating rate is shown in 
Table 5.6. 
 
The DSC profiles of TMC:Cl and chitosan, at each heating rate, appeared visually similar in 
Figure 5.4, but analysis of the peak temperatures and heat of fusions differ significantly 
between the samples. The exothermic events in the thermogram are crystallization peaks 
whereby an increased amount of heat energy, with respect to the reference sample, is 
required to increase the temperature of the sample. Whereas, endothermic events are 
melting peaks (the amount of heat energy, with respect to the reference sample, required to 
increase the temperature of the sample is reduced). The major exothermic peak for chitosan 
has been suggested to be indicative of the amine decomposition within 2-amino-2-deoxy-β-
D-glucopyranose monomers (Guinesi and Cavalheiro, 2006). The exothermic events 
occurred within TMC:Cl at lower temperatures than that of chitosan, indicating that the heat 
capacity of TMC:Cl was altered during the quaternization process.  
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Figure 5.4: Dynamic Scanning Calorimetry (DSC) of trimethyl chitosan chloride and chitosan at 
increasing heating rates of 10°C/min, 5°C/min and 2°C/min between the temperature range of 30°C 
to 500°C. Each DSC thermogram represents chitosan (black line), TMC:Cl (blue line) and insulin 
loaded trimethyl chitosan chloride powder (red line). 
 
The broad exothermic peak indicates that TMC:Cl underwent a slowed thermal event 
because the heat capacity over this temperature range increased. The heat capacity of 
chitosan over the same thermal range remained constant with respect to the reference 
sample. The thermal profile comparison between chitosan and TMC:Cl indicates that the 
parent compound has been modified due to the quaternization process.  
128 
 
Table 5.6. Dynamic Scanning Calorimetry (DSC) analysis of trimethyl chitosan chloride and chitosan 
at heating rate 10°C/min, 5°C/min and 2°C/min 
 
 Trimethyl Chitosan 
 Heating rate 10°C/min 
 Peak 1 Peak 2 Peak 3 Peak 4 
Heat of Fusion 
(∆H) 
-4.55 (±0.39) 4.06 (±0.31) 68.68 (±1.14) -137.28 
(±2.42) 
Peak (°C) 198.08 (±0.17) 210.27 
(±0.61) 
217.51 (±0.03) 
 
239.19 (±0.75) 
 Heating rate 5°C/min 
Heat of Fusion 
(∆H) 
-13.75 (±2.1) 5.13 (±0.35) -5.1 (±0.72) 65.37 (±3.45) 
Peak (°C) 208.31 (±1.53) 201.91 
(±0.19) 
190.95 (±0.63) 
 
222.06 (±0.76) 
 Heating rate 2°C/min 
Heat of Fusion 
(∆H) 
-148.38 (±1.68) 4.96 (±1.67) 39.25(±1.53) -236.39 
(±3.67) 
Peak (°C) 196.86 (±1.42) 198.26(±1.14) 202.47(±0.72) 202.53(±1.27) 
 Insulin loaded Trimethyl Chitosan 
 Heating rate 10°C/min 
Heat of Fusion 
(∆H) 
-7.55 (±0.11) 2.89 (±0.43) 74.39 (±0.71) -111.62 
(±0.48) 
Peak (°C) 199.42 (±0.85) 206.27 
(±0.28) 
211.39 (±0.73) 
 
243.31 (±0.14) 
 Heating rate 5°C/min 
Heat of Fusion 
(∆H) 
-9.61 (±4.8) 7.63 (±2.15) -9.76 (±0.28) 54.16 (±1.55) 
Peak (°C) 211.83 (±0.64) 197.26 
(±3.23) 
189.51 (±3.71) 
 
215.88 (±2.84) 
 Heating rate 2°C/min 
Heat of Fusion 
(∆H) 
-146.82 (±3.93) 4.27 (±4.7) 32.47(±5.92) -228.38 
(±5.33) 
Peak (°C) 193.47 (±0.29) 197.69(±2.85) 202.53(±1.27) 216.57(±0.92) 
 Chitosan 
 Heating rate 10°C/min 
Heat of Fusion 
(∆H) 
-90.6 (±2.5) 164.86 
(±3.99) 
NA NA 
Peak (°C) 119.63 (±0.95) 306.38 
(±0.08) 
NA NA 
 Heating rate 5°C/min 
Heat of Fusion 
(∆H) 
-53.86 (±0.98) 146.51 
(±1.59) 
NA 
 
NA 
Peak (°C) 109.21 (±0.48) 293.54 
(±0.45) 
NA NA 
 Heating rate 2°C/min 
Heat of Fusion 
(∆H) 
-46.32(±4.67) 152.41 
(±1.83) 
NA 
 
NA 
Peak (°C) 99.08(±2.35) 277.13 
(±0.23) 
NA NA 
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5.5.1.4. Scanning Electron Microscopy images of trimethyl chitosan and chitosan 
 
The Scanning Electron Microscopy images obtained of trimethyl chitosan chloride and 
chitosan can be reviewed in Figure 5.5. The trimethyl chitosan chloride sample (A) has 
uniformly flat surfaces and reduced charging. Chitosan sample (B) demonstrated a higher 
degree of charging and contained more amorphous surfaces. A significant difference in the 
morphology between chitosan and TMC:Cl can be observed within the acquired SEM 
images. TMC:Cl has flat angular surfaces whereas chitosan has an amorphous surface 
structure. Additionally, regions of charging within chitosan is more apparent than trimethyl 
chitosan which indicates that the electrons are not as effectively distributed across the 
surface of chitosan due to the amorphous structure of chitosan. This prompted the utilization 
powdered XRD to determine the precise change in the physical crystalline properties that 
occurred within chitosan after the quaternization process. 
 
 
Figure 5.5: Scanning Electron Microscopy (SEM) images of trimethyl chitosan chloride (A) and 
chitosan (B). 
 
5.5.1.5. Powdered X-ray Diffraction analysis of trimethyl chitosan chloride and 
chitosan 
 
The powder XRD profiles of TMC:Cl (blue profile) and chitosan (red profile) is shown in 
Figure 5.6 for comparative analysis. The major XRD reflections for medium molecular 
weight chitosan occurred at 2θ-values of 20.0° (58590), 36.7° (79700 cps), 42.9° (46670 
cps), 63.3° (17888 cps), 76.4° (37853 cps) and 80.6° (31535 cps). Whereas the major XRD 
reflections for TMC:Cl occurred at 2θ-values of 20.0 (11495 cps), 31.5° (31771 cps), 45.2° 
(17010 cps), 56.3° (7723 cps), 66° (5033 cps), 75.1° (5548 cps) and 83.8° (4918 cps). The 
degree of crystallinity was determined to be 31.8% for chitosan and 86% for TMC:Cl.  
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Figure 5.6: Powdered X-ray Diffraction profiles of trimethyl chitosan chloride (blue profile) and 77% 
deacetylated medium molecular weight chitosan (red profile). 
 
The major XRD reflection that occurred at 20.0° within chitosan became was essentially lost 
within the trimethyl chitosan. Interestingly the major reflection peaks did not overlap between 
the parent compound and the derivative product.  The major change in the powdered XRD 
pattern between chitosan and TMC:Cl indicates that the physical crystal structure of the 
derivative changed significantly during the quaternization process. The increase of the 
crystallinity can also be attributed to the quaterinization process. Additionally, the intensity of 
the XRD reflections within TMC:Cl was reduced in comparison to chitosan. The higher 
degree of crystallinity within the TMC:Cl is one of the major factors that impacts the 
compaction of this excipient into a solid dosage form. Auxiliary excipients, EDTA-mPEG hot 
melt dispersion powder and Ac-Di-Sol®, were utilized to reduce the impact of the crystalline 
nature of TMC:Cl.    
 
The low compressibility of this highly soluble crystalline derivative presents a formulation 
challenge during the tableting process. This challenge was overcome by incorporating 
mPEG-EDTA in situ hot melt dispersion powder into the formulations so that during the 
tableting process, the heat energy output from the mechanical compaction of the excipients 
can be mitigated by the EDTA-mPEG in situ hot melt dispersion powder during the thermal-
physical deformation process and induce the process of “void filling”.  oid filling allows for 
the TMC to be compacted more efficiently and generate a more desirable macrostructure. 
TMC:Cl was synthesized according to a previously described methodology, with slight 
modification, that generated the most favourable outcomes. These outcomes include the 
optimal degree of quaternization that facilitates paracellular transport of peptide therapeutics 
and limits the loss of mucoadhesivity (Kotzé et al., 1999; van der Merwe et al., 2004; Atyabi 
et al., 2007; Sayin et al., 2008; Markov et al., 2010).  
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5.5.2. Viscosity analysis of fluids and mini-pellet components 
 
The viscosity analysis of the biorelevant media, isolated gastrointestinal fluids and the 
respective fluids which contained 0.1%w/v trimethyl chitosan was determined at a two 
different shear rates and was characterised as having Newtonian flow. A box and whisker 
plot was utilized to determine the average and mean viscosity of each fluid under a different 
shear rate. The results for the shear rate 5s-1 and 200s-1 is shown in Figure 5.7.  The 
average viscosity of the biorelevant fluids was ~10 000mPas less than that of the isolated 
gastrointestinal fluids (even though the gastrointestinal fluids had been filtered). Additionally 
the mean viscosity of Millipore® water was slightly less than that of biorelevant media. The 
most unexpected result was that the presence of low concentrations of TMC:Cl resulted in a 
general decrease in viscosity. 
 
The Newtonian flow characteristic observed in the isolated gastrointestinal fluids of the 
porcine model is mainly due to the removal of the mucus through the utilization of filtration. 
Even with the removal of the vast majority of the mucus content within the gastrointestinal 
fluids, the viscosity of the isolated fluids was still higher than that biorelevant media. The 
reduction of the viscosity due to the presence of low concentrations of TMC:Cl could be due 
to the development of a slippage zone around the polymer chains through the presence of 
bile acids and micronized mucus particles. The molecular weight of TMC:Cl has been 
suggested to decrease with increased exposure to hydroxide ions by facilitating the cleavage 
of glycosidic bonds (Hamman and Kotzé, 2001; Snyman et al., 2002; Verheul et al., 2008; 
Martins et al., 2013). The reduced viscosity of the TMC:Cl solution is directly affected by the 
number of quaternization steps employed to synthesis the TMC:Cl (Hamman an Kotzé, 
2001). 
 
The viscosity of a fluid is extremely important for the application of drug delivery. The 
reduction of viscosity due to low concentrations of trimethyl chitosan, which would occur in 
vivo due to progressive disintegration and the hydrodynamic nature of the gastrointestinal 
tract, could result in the accelerated dispersion of the peptide therapeutic within the localized 
environment.  Additionally, this could have an impact the glycocalix portion of the mucosal 
layer within the small intestine significantly. With a reduced viscosity, the top layer of the 
mucosal structure breaks down more rapidly and provides accelerated access to the 
glycocalix. Additionally, the mucoadhesivenes of TMC:Cl can facilitate a closer proximity 
between the peptide therapeutic and the tight junctions located within the intestinal 
epithelium.   
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Figure 5.7: The viscosity analysis of biorelevant media and isolated gastrointestinal fluids of the 
porcine model (fasted state). Trimethyl chitosan (0.1%
w
/v) was dissolved in the respective solvents. 
 
5.5.3. Box-Behnken Design of insulin loaded trimethyl chitosan chloride mini-pellet 
formulations 
 
The inclusion of the excipient types within these formulations was designed to optimize the 
properties of a physical oral dosage form but also to enhance the bioavailability/release of a 
peptide therapeutic. The use of EDTA-mPEG in situ hot melt dispersion was thought to 
enhance the disintegration potential of the mini-pellet formulations. In addition, EDTA-mPEG 
in situ hot melt dispersion also efficiently filled void spaces that occurred due to the presence 
of crystalline TMC:Cl. It was found that with the inclusion of this melt dispersion, that the 
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matrix hardness was reduced. The reduced matrix hardness was then offset with the 
inclusion of Ac-Di-Sol®, because Ac-Di-Sol® is a known disintergrant and increased the 
matrix hardness (Mehat et al., 2012; Aduja et al., 2013). This combination complemented 
each other to produce a synergist effect, where the highly soluble EDTA-mPEG hot melt 
dispersion would rapidly increase the surface area upon exposure with a solvent and Ac-Si-
Sol® would swell upon exposure with a solvent.  This sets up a dynamic whereby as voids 
are created in the macrostructure of the mini-pellet (due to EDTA-mPEG in situ hot melt 
dispersion), the macrostructure of the mini-pellet decomposed into granules (due to Ac-Di-
Sol®), thus promoting a highly efficient disintegration mechanism. The combination of these 
excipients was utilized to generate formulations by a Box-Behnken design, as shown in 
Table 5.7. Each formulation was prepared in triplicate and subjected to drug dissolution 
studies, physicomechanical analysis to determine matrix hardness and mucoadhesion. 
 
The ability of the excipients to reduce or accelerate free drug dissolution was measured as 
the mean dissolution time (MDT). A rapid peptide therapeutic dissolution was assessed by 
determining the MDT after 2.5 hours. The mPEG-EDTA in situ hot melt dispersion had 
minimal effect on MDT whereas Ac-Di-Sol® significantly affected MDT on the mini-pellet 
formulations. Low concentrations of Ac-Di-Sol® resulted in an increase of MDT, as expected, 
since Ac-Di-Sol® is utilized as a superdisintergrant for solid dosage forms (Güres and 
Kleinbudde, 2011; Iwao et al., 2013). The mini-pellet formulations which could achieve a 
high degree of MH and effectively limit the instantaneous dissolution of the peptide 
therapeutic is extremely important when considering the bulk excipient TMC:Cl. TMC:Cl is a 
exceptional chitosan derivative which allows for enhanced paracellular transport of peptide 
therapeutics and contains a significant mucoadhesive element (van der Merwe et al., 2004; 
Sandri et al., 2005; Jintapattanakit et al., 2008). The mucoadhesive property of trimethyl 
chitosan would be circumvented, with respect to drug delivery, if the peptide therapeutic is 
released too rapidly. The peptide therapeutic would dissociate from the dosage form into the 
intraluminal environment and not in close proximity to the intestinal wall where the 
mucoadhesive properties and the paracellular promoting transport of TMC:Cl would be 
effective for absorption. If the MH of the formulation is poor, the solid dosage form would be 
very difficult to transport and manufacture (Tang et al., 2008; Moore et al., 2010). The mini-
pellet formulation must also achieve a high degree of fractional dissolution as this is the 
ability of the entire dosage form to dissolute the entire loaded insulin peptide therapeutic.  
 
The fractional dissolution is a measure of the amount of drug that was liberated at a certain 
time point. The fractional dissolution was assessed after 8 hours because most, if not all, the 
effective loaded peptide therapeutic should be liberated from the dosage form.  The 
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formulations that achieved the highest fractional dissolution were highly desirable. The 
fractional dissolution analysis indicated that a high concentration of sodium deoxycholate is 
beneficial to the formulation. It should be noted that the positive effects of Ac-Di-Sol® can be 
mitigated by a low concentration ratio of mPEG-EDTA in situ hot melt dispersion powder or 
sodium deoxycholate. This may be due to the high water soluble property of mPEG-EDTA in 
situ hot melt dispersion powder or sodium deoxycholate which at lower quantities can limit 
the formation of erosion cracks and reduce the rate at which the surface area of the internal 
mini-pellet macrostructure is available for solvent attack.  
 
Table 5.7. The formulation of the mini-pellets according to a Box-Behnken design 
 
Formulation StdOrder RunOrder PtType Blocks mPEG-
EDTA* 
(mg) 
Ac-Di-
Sol® 
(mg) 
Bile 
Salt 
(mg) 
1 12 1 2 1 15 30 5 
2 3 2 2 1 10 30 2.5 
3 1 3 2 1 10 10 2.5 
4 8 4 2 1 20 20 5 
5 7 5 2 1 10 20 5 
6 11 6 2 1 15 10 5 
7 4 7 2 1 20 30 2.5 
8 14 8 0 1 15 20 2.5 
9 10 9 2 1 15 30 0 
10 5 10 2 1 10 20 0 
11 9 11 2 1 15 10 0 
12 6 12 2 1 20 20 0 
13 13 13 0 1 15 20 2.5 
14 15 14 0 1 15 20 2.5 
15 2 15 2 1 20 10 2.5 
*50%w/w mPEG-EDTA hot melt dispersion 
 
The residual plots for the generated formulations are shown in Figure 5.8. The normal 
probability plot of residuals for the responses indicates that the matrix hardness had the best 
representation within the generated formulations whereas the Mean Dissolution Time (MDT) 
at 2.5 hours had the weakest representation.  
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Figure 5.8: Residual Plots of Fractional Dissolution after 8 hours, Mean Dissolution Time (MDT) after 
2.5 hours and Matrix Hardness determined from the Box-Behnken design of insulin-TMC:Cl mini-
pellets. 
 
5.5.4. Physicomechanical and ex vivo mucoadhesive analysis of insulin loaded 
trimethyl chitosan chloride mini-pellet formulations 
 
The optimized insulin-TMC:Cl MiPe formulation was determined using the Box-Behnken 
design. The in silico predicted responses of the optimized formulation were very similar to 
the obtained experimental results. The MDT, fractional dissolution after 8 hours and the 
matrix hardness were considered important parameters because a rapid dissolution of 
insulin is desirable to maintain an in vivo concentration gradient (Maroni et al., 2012; Ling 
and Chen, 2013).  
 
The physicomechanical analysis of the fifteen mini-pellet formulations and a chitosan mini-
pellet formulation is shown in Figure 5.9. Additionally, the ex vivo mucoadhesion analysis of 
the fifteen mini-pellet formulations and a chitosan mini-pellet formulation is also shown in 
Figure 5.9. The formulations that are isolated within the blue area represent formulations 
which are desirable whereas formulations that are within the red areas are considered to 
have performed poorly within the current set of parameters and conditions. The formulations 
which are located within the green area are considered neutral as these formulations have 
not performed exceptionally well or exceptionally poorly. 
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Figure 5.9: Three dimensional scatter plots of the matrix hardness against dissolution analysis (A) 
and mucoadhesive analysis, respectively, for the Box-Behnken mini-pellet formulations (F1-F15) and 
chitosan mini-pellet formulation (Chit). Mucin-coated porcine intestinal epithelium samples (B) and 
non-mucin-coated porcine intestinal epithelium samples (C) were utilized to determine mucoadhesive 
properties of the mini-pellet formulations.  
 
The insulin loaded TMC:Cl MiPe formulation 9 and 10 achieved the worst MDT and 
fractional dissolution after 8 hours performance with respect to matrix hardness. Whereas 
formulation 1, 4, 5, and 11 achieved the best MDT and fractional dissolution after 8 hours 
performance with respect to matrix hardness. The mucoadhesive performance of the 
formulations was evaluated with respect to matrix hardness as well. Interestingly, poor 
formulation (F1 and F2) performance in the presence of mucin solution was not indicative of 
poor performance in the absence of mucin solution. Comparatively, formulation (F3, F7, F11 
and F15) performance in the presence of mucin solution was indicative of excellent 
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performance in comparison the the physicomechanical performance of these formulations in 
the absence of mucin solution. The work of adhesion of the fifteen formulations increases as 
the TMC:Cl weight concentration increases. The WA of the mini-pellet formulations remained 
relatively constant (±1N difference) when a 0.3%w/v mucin solution was not utilized during 
the mucoadhesive analysis.  
 
The maximum detachment force (MDF), measured as adhesion, was determined for the 
fifteen Box-Behnken design mini-pellet formulations and the chitosan mini-pellet formulation. 
MDF was determined to be greater for formulations which contained TMC:Cl, with respect to 
the chitosan containing formulation, when a mucin solution was applied. The MDF of the 
mini-pellets remained relatively constant, similar to the WA measurements, when no mucin 
solution was utilized. The maximum detachment force was reduced ~10 fold and the work of 
adhesion was reduced ~100 fold when the 0.3% mucin solution was not present.  
 
The mucoadhesive properties of TMC:Cl has been compared with many other 
mucoadhesive polymers, such as pectinate, and has often demonstrated significant 
mucoadhesive properties but sometimes failing to be equivalent with known mucoadhesive 
polymers (Hagesaether et al., 2009). This has been attributed to overhydration of the 
TMC:Cl which causes a significant reduction in the mucoadhesive properties of the polymer 
(Atyabi et al., 2007). The Eudragit® spray coating that was utilized in this study was 
incorporated to reduce the overhydration of TMC:Cl and to target the mini-pellet formulation 
for the jejunum-ileum environment of the small intestine. The jejunum-ileum environment of 
the small intestine is the best site for TMC:Cl mediated peptide therapeutic absorption due to 
the reduced integrity of tight junctions and the presence of a mucus layer (Kotzé et al., 1999; 
Markov et al., 2010). The chitosan mini-pellet formulation demonstrated the lowest degree of 
mucoadhesive ability in comparison the mini-pellet formulations which contained trimethyl 
chitosan. The increased positive charge that exists within trimethyl chitosan, with respect to 
chitosan, may assist in enhanced dipole-dipole interactions between these molecules. The 
mucoadhesive ability was effectively terminated in the absence of the 0.3%w/v mucin solution 
and was comparable with that of chitosan. This indicates that the ability of TMC:Cl to 
facilitate drug delivery applications, since if no mucin is present within the site of delivery, the 
ability of TMC:Cl to interact with tight junctions would be limited and maintaining a close 
proximal association with the intestinal wall would be negatively impacted. 
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5.5.5. Insulin entrapment studies, dissolution studies and dissolution fitting analysis 
of optimized Eudragit® coated insulin loaded trimethyl chitosan chloride mini-pellet 
formulation  
 
High Performance Liquid Chromatography (HPLC) was utilized to determine the 
concentration of insulin entrapped within the lyophilized insulin-TMC:Cl to be 95(±0.4)% of 
the original loaded dose. HPLC analysis was conducted on all dissolution samples to 
determine the concentration of insulin at each time point. Insulin was detected at retention 
time (RT) at 10 (±0.1) minutes and the HPLC chromogram can be reviewed in Figure 5.10. 
The concentrations of insulin at each dissolution time point were determined by utilizing a 
standard curve of insulin concentration against absorbance (data not shown). The Eudragit® 
coated insulin-TMC:Cl MiPe formulations generally had a high correlation with Makoid-
Banakar that had a time lag parameter, which can also be reviewed in Figure 5.10.  
 
 
Figure 5.10: Dissolution profile of insulin for Formulation 1 of insulin-loaded trimethyl chitosan 
chloride mini-pellet which conforms to a Makoid-Banakar with Tlag regression fitted scatter plot (A). 
The High Performance Liquid Chromatography analysis of the market available Intramuscular (I.M.) 
insulin formulation (B) and insulin released from trimethyl chitosan formulation 1 (C). 
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5.5.6. The statistical analysis of the experimental results obtained from the Box-
Behnken design formulations  
 
The experimental results obtained from the Box-Behnken design formulations were analysed 
using Minitab. The responses (fractional dissolution after 8 hours; MDT and MH) were 
compared against the major excipient components as surface plots (which can be reviewed 
in Figure 5.11). These results were then utilized to generate a desired optimized formulation 
which had the highest possible degree of responses. The generated optimized formulation 
had a desirability of 94.16% and the calculated in silico responses and can be reviewed in 
Figure 5.12.  
 
 
Figure 5.11: Three dimensional surface plots of the insulin-loaded trimethyl chitosan chloride mini-
pellet components with respect to the responses (Fractional Dissolution after 8 hours, Mean 
Dissolution Time (MDT) after 2.5 hours and Matrix Hardness). 
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Figure 5.12: Optimized insulin-loaded trimethyl chitosan chloride mini-pellet formulation output from 
Box-Behnken Design. 
 
5.5.7. In vitro and ex vivo characterisation of the optimized Eudragit® insulin loaded 
mini-pellet formulation within biorelevant dissolution fluid and isolated porcine 
gastrointestinal fluids 
 
5.5.7.1. Physicomechanical characterisation of the optimized insulin loaded trimethyl 
chitosan chloride mini-pellet formulation  
 
The optimized formulation of insulin-TMC:Cl MiPe formulation from the Box-Behnken design 
and responses (MDT after 2.5 hours and the fractional dissolution after 8 hours) which can 
be reviewed in Figure 5.13. The optimized formulation was experimentally determined to 
have a MDT time of 1.3959 hours whereas the MDT value generated in silico was 1.3962 
hours. The experimentally determined fractional dissolution after 8 hours was determined to 
be 94.06% whereas the in silico predicted fractional dissolution was 92.59%.  
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Figure 5.13: A graphical representation of the three responses (mean dissolution time after 2.5 hours 
[1.3959 hours] and fractional dissolution after 8 hours [94.06%] for the optimized insulin-loaded 
trimethyl chitosan chloride mini-pellet formulation. A Makoid-Banakar with Tlag regression kinetic 
model was fitted to the concentration of insulin versus time scatter plot with an R
2
 value of 0.99. 
 
The ex vivo mucoadhesive Textural analysis force distance profile of 3%w/v mucin coated 
porcine small intestine epithelium tissue, non mucin coated porcine small intestine 
epithelium tissue and matrix hardness of the optimized insulin loaded Box-Behnken mini-
pellet formulation is shown in Figure 5.14.  The WA of the optimized insulin-TMC:Cl MiPe 
formulation was determined to be 0.457mJ and 0.003mJ for mucin coated and non mucin 
coated intestinal epithelium tissue, respectively. The maximum MDF determined as 
adhesion is 0.405N and 0.031N for mucin coated and none mucin coated intestinal 
epithelium tissue, respectively. The matrix hardness was determined experimentally to be 
94.22N/mm whereas the in silico predicted matrix hardness was 92.76N/mm. The in silico 
predicted matrix hardness under estimated the experimental matrix hardness by ~2N/mm 
which is minimal and accurate within experimental error conditions.   
 
Fractional release at 
8 hours: 94.06% 
Mean dissolution 
time: 1.3959 hr 
                                       
Makoid-Banakar with Tlag 
R
adjusted
: 0.99 
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Figure 5.14: The Textural analysis force distance profile of 3%
w
/v mucin coated porcine small 
intestine epithelium tissue (A), none mucin coated porcine small intestine epithelium tissue (B) and 
matrix hardness (C) of the optimized insulin loaded Box-Behnken mini-pellet formulation.   
 
5.5.7.2. Disintegration analysis of the optimized Eudragit® coated insulin loaded 
trimethyl chitosan mini-pellet formulation 
 
The disintegration behaviour within biorelevant media and isolated gastrointestinal fluids of 
the porcine model was assessed on the optimized Eudragit® coated insulin-TMC MiPe 
formulation. The disintegration rate of the optimized Eudragit® coated TMC:Cl MiPe 
formulation at predetermined time points within each biorelevant media is shown in Figure 
5.15. The canine media that was near neutral pH achieved the highest rates of disintegration 
initially. The initial disintegration rate of trimethyl chitosan within FaSSIF and FeSSIF was 
almost identical but the rates were significantly reduced in comparison to the canine neutral 
pH media. The disintegration within acidic media was significantly reduced by the presence 
of Eudragit® coating. This indicated that the macrostructure of the mini-pellet is significantly 
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affected by the dissolution media. The isolated intestinal fluids of the porcine model had the 
third highest initial rate of disintegration.  
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Figure 5.15: Three dimensional bar graph of the disintegration profile of the optimized Eudragit
®
 
coated insulin loaded trimethyl chitosan mini-pellet within biorelevant media and USP dissolution 
fluids (n=3; SD within 10% of the measured value).  
 
The ability of a solid dosage form to directly impact the drug plasma concentration has been 
demonstrated with the development of controlled release formulations. The utilization of 
biorelevant media to characterize the solubility profiling of new chemical entities (NCE) or 
dissolution profiling is considered a major advancement to obtaining closer in vitro-in vivo 
correlations. Currently, the direct profiling of disintegration behaviours of a solid dosage form 
in biorelevant media has not been investigated. As observed within Figure 5.15, the 
biorelevant media type has a significant impact on the disintegration behaviour of the 
formulation. Additionally, the disintegration behaviour within the intestinal fluids of the 
porcine model more closely resembles that of the biorelevant canine media than the 
biorelevant human media. The USP simulated intestinal media was a poor representation of 
the disintegration behaviour of the solid dosage form. FaSSIF V2 and FeSSIF V2 almost 
preformed identically, which suggested that the presence of bile salts did not play a 
significant role in the disintegration profile. Incidentally, the disintegration profile of the 
FaSSIF V2 and FeSSIF V2 was similar to that of FaSSIFc where there is an initial high rate 
of disintegration followed by a much slower rate of disintegration. This indicates that the 
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presence of bile salts or lipophilic components within the biorelevant media had a significant 
effect on the disintegration behaviour of the optimized mini-pellet formulation. As indicated 
during the acquisition of viscosity profiling of the biorelevant media, a “slippage layer” may 
be formed during solubilisation which could assist in disrupting the macrostructure of the 
mini-pellet and accelerating the rate of disintegration within these media.   
 
5.5.7.3. Dissolution of the optimized Eudragit® coated insulin loaded trimethyl 
chitosan chloride mini-pellet formulation  
 
The dissolution of the optimized Eudragit® coated insulin loaded TMC:Cl MiPe was 
determined in a step up procedure whereby the dosage form was first exposed to the gastric 
environment and then transferred to the small intestinal environment. The dissolution profile 
of the optimized Eudragit® coated insulin loaded TMC:Cl MiPe formulation within biorelevant 
media and isolated gastrointestinal fluids of the porcine model is shown in Figure 5.16. In 
addition, the respective MDT at 2.5 hours and 10.5 hours is represented within each profile. 
This dissolution profiles have been fitted to the Makoid-Banakar (with Tlag) dissolution 
model to a R2 adjusted value between 0.96 to 0.99. The dissolution of the model peptide 
therapeutic insulin during these experiments was significantly reduced by the presence of 
the Eudragit® coating. Interestingly, the dissolution profile obtained from isolated 
gastrointestinal tract fluids of the porcine model is most closely represented to that obtained 
from canine biorelevant media (with respect to MDT and AUC).  The optimized Eudragit® 
coated insulin loaded MiPe formulation retained its structure after being placed within the 
acidic environment for 1.5 hours and then rapidly released insulin within intestinal 
environment.  
 
The resulting dissolution profile indicates that the fundamental elements (pH, buffer capacity, 
surface tension and osmolality) are more similar to the canine model than that of the human 
model. The results from the disintegration analysis indicated that rate of disintegration for the 
mini-pellet formulation initially occurred faster within the canine biorelevant media than that 
of the human biorelevant media. The faster disintegration within the canine biorelevant 
media facilitated the faster liberation of insulin. The trimethyl chitosan chloride component of 
the mini-pellet formulations within FaSSIFc could have undergone faster solubilisation 
because of a higher pH (e.g. with respect FeSSIF-V2) or bile salt concentration (e.g. with 
respect FaSSIF-V2). Insulin could have then been permitted into the solubilised state due to 
the accelerated breakdown of the macrostructure within the canine media and isolated 
porcine small intestinal fluids. The Makoid-Banakar with Tlag dissolution model was fitted to 
the dissolution profile within each respective fluid because there was a lag period where no 
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drug was being released. This is due to the Eudragit® coating and the delayed onset of 
disintegration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: The dissolution profiles of Eudragit
®
 coated insulin loaded trimethyl chitosan mini-pellets 
within biorelevant media (human and canine) and isolated gastrointestinal fluids of the porcine model 
(fasted state). The blue areas within the dissolution profiles is the time period in which the dosage 
form was placed within the corresponding gastric environment and the green areas within the 
dissolution profiles is the time period which the same dosage form was placed within the 
corresponding intestinal environment.  
 
5.6. Concluding remarks 
 
Peptide drugs are highly potent but are highly sensitive to the hostile environment within the 
gastrointestinal tract (Frokjaer and Otzen, 2005). The full characterization of TMC:Cl was 
utilized to overcome the negative attributes of this polymer, such as the high crystallinity of 
this polymer. The weight percentage of peptide therapeutic which is included within an oral 
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formulation is so small that the physical presence of the peptide therapeutic will have little 
effect on the overall dissolution or physicomechanical properties of the solid dosage form. 
An optimized mini-pellet formulation which contained 10mg of EDTA-mPEG hot melt 
dispersion (50:50), 12.57mg of Ac-Di-Sol®, 3.58mg sodium deoxycholate, and the mass of 
trimethyl chitosan was adjustable to achieve a final pellet weight of 145mg. This formulation 
achieved the predicted in silico responses generated by the Box-Behnken design precisely. 
The dissolution of insulin from the optimized formulation was altered within the biorelevant 
dissolution fluid with respect to the USP dissolution fluid. This was attributed to the unique 
physicochemical properties of this formulation being affected by the innate physicochemical 
properties of the biorelevant fluid such as the presence of bile acids and lipophilic entities 
within the dissolution fluid.Additionally, the disintergration profiling of this formulation within 
biorelevant dissolution fluid was also affected significantly by the innate physicochemical 
properties of these fluid with respect to the USP dissolution fluid. An optimized formulation 
should be evaluated within biorelevant dissolution fluid, even though this process is time 
consuming and relatively expensive, because these dissolution fluids have a superior 
representation of the in vivo luminal fluid that the USP dissolution fluid.   
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CHAPTER 6 
In Vitro-In Vivo Correlation of the Optimised Oral Ghost Drug Delivery Device in the 
Porcine Model 
 
6.1. Introduction 
 
The protocol for the in vivo analysis of the Oral Ghost Drug Delivery device was reviewed by 
the Animal Ethics Screening Committee (AESC) of the University of Witwatersrand and was 
assigned the clearance certificate number 2011/33/03 (Appendix 1). The development of 
the non-degradable non-responsive shell component and the assembly of the Oral Delivery 
Device was considered the final challenge. Insulin is a hormone utilized for the treatment of 
type I diabetes and in extreme instances can be administered as second line treatment for 
type II diabetes (Katzung, 2007). Insulin was utilized in this study as a model peptide for the 
optimization of the peptide loaded trimethyl chitosan mini-pellet formulations. Insulin was not 
utilized within in vivo studies because of the ethical and moral implications of inducing a 
diabetic condition within large animals such as porcine. Salmon calcitonin was utilized within 
in vivo studies as this hormone is a xenobotic peptide within the porcine model, has a low 
toxicity profile, can be accurately measured with ELISA techniques and salmon calcitonin 
could be placed within an adult sized dosage form. Insulin and salmon calcitonin have been 
successfully administered with trimethyl chitosan for oral applications (Yin et al., 2009; du 
Plessis et al., 2010; Chaudhury and Das., 2011; Huang et al., 2011; Marais et al., 2013). 
Calcitonin is a hormone used to prevent bone reabsorption in osteoporosis patients, 
treatment of Paget’s disease and hypercalcaemia. Calcitonin is administered as an 
intravenous (I.V) infusion, subcutaneous injection or intramuscular injection between three 
times weekly to a daily basis (Katzung, 2007). Parenteral administered salmon calcitonin is 
often administered as a dose between 50 to 100IU (Hartman, 2007).  
 
The Oral Ghost Drug Delivery device was evaluated within the porcine model due to the 
ability of the porcine model to achieve a body mass (≥50Kg) similar to an adult human, 
tolerance to frequent blood sampling and similar physiological with respect to humans 
(Thörn et al., 2011). Additionally, the porcine model has been implemented for a multitude of 
multisampling studies that investigated drug transport and metabolism due to the close 
similarities of these processes with respect to humans (Petri et al., 2006; Persson et al., 
2008; Sjodin et al., 2008; Bergman et al., 2009; Thörn et al., 2009). The gastrointestinal tract 
of the pig model is very similar to that of the human with respect to a remarkable 
gastrointestinal pH profile, dietary similarities and transition times within the gastrointestinal 
tract (Lennernäs, 2007). A further similarity can be found in the coronary artery distribution of 
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the porcine model which very similar to that of the human model (Brunet et al., 2006).  Small 
animal models such as rats and mice cannot survive frequent withdrawals of blood sampling 
and cannot ingest large dosage forms that are intended for adult humans (Cryan et al., 
2007). The frequency in which blood samples can be withdrawn from the animal allows for 
accurate determination of the pharmacokinetic data and allows for effective implementation 
of in vitro-in vivo correlations.   
 
The in vivo studies were conducted to achieve two unique objectives. The first objective was 
the determination of the pharmacokinetic characteristics of salmon calcitonin that had been 
administered with the Oral Ghost Drug Delivery device. The pharmacokinetic parameters 
were determined with noncompartemental modelling and compartmental modelling. The 
noncompartemental model (based on algebraic functions) does not take into account 
recirculation and exchange of a drug from the accessible to the non-accessible sampling 
locations (e.g. from muscle tissue to plasma) or vice versa. Whereas, compartmental models 
(based on linear or nonlinear differential equations) take into account of recirculation and 
exchange of a drug from accessible to non-accessible sampling locations. The second 
objective was developing an in vitro-in vivo correlation between the dissolution profiling and 
the measured plasma concentrations of salmon calcitonin. The in vitro dissolution profiling 
was conducted within USP dissolution fluid and biorelevant dissolution fluid. Additionally, 
dissolution of salmon calcitonin from the Oral Ghost Drug Delivery device was evaluated 
within isolated gastrointestinal fluid of the porcine model. This allowed for the determination 
of which dissolution fluid achieved the most accurate profile with respect to the in vivo 
pharmacokinetic parameters. The in vitro-in vivo correlation between the in vitro dissolution 
profiling and the in vivo plasma drug concentrations has seven processes: measuring the in 
vitro dissolution; fitting the in vitro dissolution to a known dissolution model; measuring the 
plasma drug concentration with respect to time; generating a Unit Impulse Response (UIR); 
deconvolution of the UIR, correlation building and correlation validation. The correlation 
validation was utilized to determine which pharmacokinetic parameter was most accurately 
represented by an in vitro dissolution fluid.  
 
6.2. Materials and Methods 
 
6.3. Materials 
 
A total of 5 healthy female white pigs were used in this study with an average weight of 35kg 
were purchased from a local farmer. Fresh blank plasma was routinely drawn and supplied 
from the catheterised pigs. Chitosan (medium molecular weight) with a degree of 
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deacetylation of 77.0% was purchased from Aldrich (Schnelldorf, Germany). GMP grade 
salmon calcitonin was purchased from Bachem (Bachem AG, Bubendorf, Switzerland). A 
salmon calcitonin immunoassay kit (S-1166) was purchased from Bachem (Bachem AG, 
Bubendorf, Switzerland). Trimethyl chitosan was prepared through reductive methylation. 
Acrylamide (≥98  pure, MW 71.08g/mol) was purchased from Fluka (Sigma-Aldrich, Buchs, 
Switzerland). Methacrylic acid (99% pure, 86.09g/mol) was purchased from Aldrich 
(Schnelldorf, Germany). Methoxypolyethylene glycol 2000 (≥99  pure), sodium iodide 
(99.999% pure), methyl iodide (≥99.0 ), sodium hydroxide (≥98  pure), sodium chloride 
(≥98  pure), sodium dihydrogen phosphate monohydrate (≥99  pure), sodium bicarbonate 
(≥99.5  pure), hydrochloric acid (37%v/v), sodium deoxycholate (≥98  pure), sodium 
taurocholate (≥90  pure), sodium taurodeoxycholate (≥97  pure), orthophosphoric acid 
(85%w/v ,99.99% pure), tetramethylethylenediamine (99% pure, 116.20g/mol), ammonium 
persulfate (≥98  pure, 228.20g/mol), Pluronic F-127, N,N’-methylenebis(acrylamide) (99% 
pure, 154.17g/mol), maleic acid (99% pure), ethylenediaminetetraacetic acid (≥99.995  
pure) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA) at reagent grade and 
where utilised without further purification. Dichloromethane (≥99.9  pure), diethyl ether 
(≥99.0  pure), acetic acid (99.99% pure), ethanol (≥99.8  pure) and N-methyl-2-
pyrrolidone (≥99.5  pure) were purchased from Merck at reagent grade and were utilised 
without further purification.  Ac-Di-Sol® and Avicel® RC/CL type RC-591 (co-dried blend of 
microcrystalline cellulose and sodium carboxymethylcellulose) was purchased from FMC 
BioPolymer (Philadelphia, PA, USA). Egg phosphoatidylchloline (97.5% pure) purchased 
from Lipoid GmbH (Ludwigshafen, Germany). Acetonitrile (≥99.9  pure) and sodium oleate 
(≥99  pure) was purchased from Sigma (St. Louis, Missouri, USA) at UPLC grade.  
 
6.4. Methods 
 
6.4.1. Preparation of the optimised Oral Ghost Delivery Device 
 
6.4.2. Manufacture of non-responsive non-degradable shell component 
 
The non-responsive non-degradable shell component was manufactured utilising a USA 
Food and Drug Administration approved plastic for food grade materials. The plastic 
composes of Ultra High Molecular Weight Polyethylene (UHMW-PE) under the trade name 
Polystone® M. Rods of UHMW-PE were purchased and lathed to an accurate diameter of 6 
mm. The lathed rods of UHMW-PE were cut into lengths of 10mm segments. A 750 CNC 
Bed milling machine (Ajax Machine Tools,  Hampshire, UK) was utilised to hollow out the rod 
segments to a depth of 9mm and a diameter of 5.5mm. A rod segment was then placed in a 
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table top vice grip and eight 1mm diameter orifices were drilled along the base (part of the 
rod segment which was not hollowed out) and an additional four 1mm orifices were drilled 
into the base of the UHMW-PE segment. This formed the non-responsive non-degradable 
shell component. The schematic representation of the non-responsive non-degradable shell 
component is illustrated in Figure 6.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Schematic representation of the non-responsive non-degradable shell component of the 
Oral Ghost Drug Delivery device manufacture process. 
 
6.4.3. Synthesis of the stimuli responsive hydrogel as the trigger mechanism of the 
Oral Ghost Delivery Device 
 
The stimuli responsive hydrogel was synthesised in the same manner as Section 4.4.1. 
Briefly, the stimuli responsive hydrogel was synthesized using acrylamide (AAm) monomers 
and methyacrylic acid (MAA). N-N’-Methylenebisacrylamide (BIS) is a crosslinking agent that 
was utilised to crosslink AAm to MAA. Pluronic F-127 was used to enhance the solubilisation 
of AAm, MAA and MBA in deionised water. Ammonium persulfate, a radical initiator, and 
tetramethylethylenediamine (TEMED), a catalyst, were used in the crosslinking reaction 
between AAm and MAA. The concentrations and sequential addition of chemical 
components that make up the AAm-MAA stimuli responsive hydrogel can be reviewed in 
Table 6.1. 
 
Once all the respective solutions where prepared and added to a glass beaker under 
constant magnetic stirring, 100mg of sodium bicarbonate was immediately added. The 
sodium bicarbonate generated carbon dioxide gas within the polymerising solution, thus 
 
 
 
Ultra Molecular Weight Polyethylene rods were lathed to obtain 
a diameter of 6mm. The lathed rods were cut into 10mm 
segments. 
A milling press was utilized to hollow out the 
centre of the rod segments to contain a cavity 
with an internal diameter of 5.5mm and an 
internal length of 9mm. 
Orifices were drilled into the 
base and around the base of 
the non-responsive non-
degradable shell component 
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inducing the formation of a porous gel. Moulds where produced that would allow the in situ 
curing process to take place within a cylindrical shape (inner diameter of cylindrical moulds 
was 4.77mm). The moulds where placed in a glass beaker and incubated in a water bath at 
37±0.5°C for 12 hours. Once the curing process was completed, the in situ cured rods were 
then removed from the cylindrical moulds and cut, transversely, into 0.5mm pieces and then 
longitudinally into 0.3mm pieces.  
 
Table 6.1. The concentrations of sequentially added chemical components whilst constantly stirring, 
in order to form the AAm-MAA stimuli responsive hydrogel 
 
Solution component Concentration  
(%w/v) 
Volume added to final  
in situ gelling solution (mL) 
Acrylamide 50 3 
Methacrylic acid 50 2 
N,N’-Methylenebis(acrylamide) 2.5 0.7 
Deionised water - 3 
Pluronic F-127 10 0.3 
Ammonium persulfate 20 0.25 
Tetramethylethylenediamine 20 0.25 
 
6.4.4. Manufacture of the erodible methyl cellulose disc 
 
Erodible methyl cellulose disc were manufactured in a similar manner to that of the Avicel®-
EDTA-mPEG in situ hot melt dispersion mini-pellets. Methyl cellulose was accurately 
weighted out (20mg) and placed within the punch and die set to produce mini-pellets with a 
diameter of 4mm and a length of 1mm. A methyl cellulose disc was placed between the 
stimuli responsive hydrogel and the drug carriers to restrict contact with water within the drug 
delivery system. In addition, the methyl cellulose disc, which eroded very slowly within a 
hydrophilic environment, acted as a surface that the stimuli responsive hydrogel could 
physically act against. The ability of the stimuli responsive hydrogel to act as the Trigger 
Mechanism within the drug delivery system was enhanced by the presence of the methyl 
cellulose disc. 
 
6.4.5. Manufacture of the Avicel®-EDTA-mPEG in situ hot melt dispersion mini-pellet 
 
The Avicel®-EDTA-mPEG in situ hot melt dispersion mini-pellet was manufactured in the 
same manner as that in Section 3.4.1. Melt dispersions of EDTA-mPEG where synthesised 
at the respective ratio of 33.5%w/w mPEG, 33.5%
w/w EDTA and 33%
w/w Avicel
® RC/CL type 
R-591. The mPEG was first melted to 60°C on a watch glass heated by a calibrated hot 
plate magnetic stirrer. Once the solid mass of mPEG was melted to a liquid phase, EDTA 
was added to the molten mPEG. The EDTA was homogenously distributed within the molten 
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mPEG with a wooden spatula. Once a uniform distribution was obtained, the EDTA-mPEG 
hot melt dispersion was removed from the hot plate magnetic stirrer and allowed to cool 
under constant stirring. Once the EDTA-mPEG hot melt dispersion had become a cool solid, 
the solid mass was place through a metal sieve with an aperture of 850µm to form a fine 
powder. Avicel® RC/CL type R-591 was accurately weighted out and mixed (at 250rpm) with 
the fine EDTA-mPEG powder until a homogenous mixture was obtained. The homogenous 
mixture was then accurately weighted out into 30mg aliquots and placed within the punch 
and die set. Mini-pellets were produced under a pressure of 3.5MPa with a diameter of 4mm 
and a length of 3.27mm. 
 
6.4.6. Synthesis of trimethyl chitosan 
 
TMC:Cl was synthesized in the same manner as in Section 5.4.1. Briefly, TMC:Cl was 
synthesized by a two reaction step and an ion-exchange step process. Two grams of 
chitosan (medium molecular weight, 77% deacetylated), 10mL of 20%w/v sodium hydroxide 
solution and 4.8g of sodium iodide was dissolved in 80mL of pre-warmed N-methyl 
pyrrolidonone (60±0.2°C). The reaction was carried out over a 30 minute period in a heated 
water bath (60±0.2°C). The homogenous solution was then removed from the heated water 
bath and 12mL of methyl iodide was immediately incorporated within the solution. The 
reaction was allowed to complete under reflux, by utilization of a Liebig condenser, under 
constant magnetic stirring (300rpm) for 90 minutes (60±0.2°C). The homogenous polymer 
solution is then removed and the trimethyl chitosan iodine precipitated out of solution with 
250mL diethyl ether and 250mL ethanol. Trimethyl chitosan iodine was collected and dried in 
vacuo (60±0.5°C for 48 hours). The dry trimethyl chitosan iodine was ground into a fine 
powder and utilized within the second reaction step.  
 
The second reaction step utilized the same procedure as that preformed in the first step but 
chitosan was substituted with trimethyl chitosan iodine. Once the polymer product from the 
second reaction had been dried and ground into a fine powder, the ion-exchange step was 
conducted.    
 
The second reaction step trimethyl chitosan iodine powder was dissolved in 80mL of 5%w/v 
sodium chloride solution for 30 minutes under constant magnetic stirring (300rpm). Diethyl 
ether (250mL) and ethanol (250mL) was utilized to precipitate trimethyl chitosan chloride. 
The precipitated TMC:Cl was isolated by filtration and dried in vacuo (60±0.5°C for 24 
hours). 
 
153 
 
6.4.7. Manufacture of salmon calcitonin loaded trimethyl chitosan mini-pellet 
 
The dried trimethyl chitosan (TMC) was dried and ground into a fine powder which was 
placed though a 400μm aperture sieve to ensure uniform powder. An accurate weight of 
2500mg trimethyl chitosan powder was dissolved in 40mL of Millipore water (pH 7.0) by 
magnetic stirring at 300rpm for 30 minutes, at which point a viscous yellow solution was 
obtained. The salmon calcitonin was added in order to obtain a final concentration of 600IU 
salmon calcitonin per 3.2mg of powder. The dispersion was frozen at 193K for 48 hours. The 
powder sample was lyophilised with a 2 hour condensation phase at -60°C and a 24 hour 
sublimation phase at 25mm Torr in a Freezone 12 freeze drier (Lanconco, Kansas City, 
USA). After freeze-drying, the sample was placed in sealed glass polytops and frozen at -
20°C (Silva et al., 2006; Pringels et al., 2008). 
 
Dry granulation was utilised, which involved: salmon calcitonin loaded-lyophilised trimethyl 
chitosan, mPEG, Ac-Di-Sol® microcrystalline cellulose and dry trimethyl chitosan powder 
which were accurately weighted according to the optimised insulin-loaded trimethyl chitosan 
mini-pellet optimised Box Behnken design formulation. Once the powdered components 
were accurately weighted, the samples were mixed until a homogenous mixture was 
obtained. The homogenous mixture was compressed within a modified punch and die set to 
produce 4mm pellets under a compression of 3.4MPa. The pellets were immediately placed 
in glass polytops and frozen at -20°C.   
 
6.4.8. Assembly of the Oral Ghost Drug Delivery device and spray coating Eudragit®  
 
The Oral Ghost Drug Delivery device was assembled by placing the swellable trigger system 
(accurately weighted 10mg) within the internal bottom of the non-responsive non-degradable 
shell component. A methyl cellulose disc was placed onto the swellable trigger system, 
followed by a salmon calcitonin-loaded trimethyl chitosan mini-pellet and finally an Avicel®-
EDTA-mPEG in situ hot melt dispersion mini-pellet. The top system was then spray coated 
in an enteric coating solution. The enteric coating solution contained a 4%w/w solution of 
Eudragit® L100 and a 4%w/w solution of Eudragit
® S100 within an organic solvent composed 
of 33%v/v ethanol and 67%
v/v acetone. Triethyl citrate was added to the solution at a 
concentration of 35%w/w of the Eudragit
® component of the coating solution. The top coated 
Oral Ghost Drug Delivery device was placed within glass polytops and stored at -20°C until 
use. A schematic representation of the Oral Ghost Delivery Device assembly is illustrated in 
Figure 6.2. 
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Figure 6.2: A schematic representation of the Oral Ghost Drug Delivery device assembly. 
 
 
Placement of the swellable trigger mechanism 
within the non-responsive non-degradable shell 
component of the Oral Ghost Delivery Device 
 
 
 
 
Placement of the salmon calcitonin-loaded 
trimethyl chitosan within the non-responsive non-
degradable shell component of the Oral Ghost 
Delivery Device 
Placement of the EDTA-mPEG-Avicel melt 
dispersion mini-pellet within the non-responsive 
non-degradable shell component of the Oral Ghost 
Delivery Device 
Addition of enteric cap to the top of the non-
responsive non-degradable shell component of the 
Oral Ghost Delivery Device 
Non-responsive 
non-degradable 
shell component 
Salmon calcitonin-
loaded trimethyl 
chitosan mini-
pellet 
Swellable 
trigger 
mechanism 
EDTA-mPEG-
Avicel melt 
dispersion mini-
pellet 
Eudragit cap 
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6.4.9. Isolation of porcine gastrointestinal fluids 
 
The Large White pigs utilized in this study were obtained according to the Guide for the Care 
and Use of Laboratory Animals that was approved by the Animal Ethics Screening 
Committee of the University of Witwatersrand (Ethics number:2011/33/03). The isolation of 
gastrointestinal fluid was conducted in the same manner as indicated in Section 4.4.7.  
Briefly, the gastrointestinal fluids isolated from the pigs were collected during the fasted state 
which was induced by restricting food for 12 hours (water was provided ad libitum). This is 
the standard operating procedure for dosing pigs with an oral drug delivery system. The 
gastric and small intestinal fluids were collected after euthanization. The stomach and small 
intestine were isolated and a small incision was made to perforate the respective organ wall.  
 
The pH and buffer capacity of the isolated gastric and small intestinal fluids (individual and 
pooled samples) were measured immediately. The pooled sample was maintained with an 
equal addition from each individual sample. To preserve the composition of the 
gastrointestinal fluid, the samples were immediately frozen in liquid nitrogen and maintained 
at -80°C. In order the drug dissolution studies to be effectively preformed, removal of solid 
matter (food particles and ingested hay) from the samples was achieved by centrifugation at 
5000rpm for 10min at 10°C, followed by filtration of the supernatant through a 0.44μm 
Millipore Millex injection filter (Billerica, MA, USA). 
 
6.4.10. Dissolution of salmon calcitonin form the Oral Ghost Drug Delivery device 
 
The dissolution of salmon calcitonin from the Oral Ghost Drug Delivery device was 
conducted in a similar manner as described in Section 5.4.9. Briefly, the Oral Ghost Drug 
Delivery device was placed within a dissolution fluid set (USP pH 1.2-USP pH 6.8; FaSSGF-
FaSSIF V2; FaSSGF-FeSSIF V2, FaSSGFc pH 1.5-FaSSIFc pH 7.5, isolated porcine gastric 
fluid-isolated porcine small intestinal fluid) that had been previously described (Dünnhaupt et 
al., 2012). A 10mL volume of dissolution fluid was placed into a polytop and was equilibrated 
at 37±0.5°C and 50rpm within an Orbit Shaker Incubator (LM-530-2, MRC Laboratory 
Instruments Ltd, Hahistadrut, Holon, Israel).   A 0.01mL sample was withdrawn at each 
predetermined time point, and diluted in 4.99mL Millipore water to achieve a dilution factor of 
500.  A volume of 50μL was placed within the salmon calcitonin  L SA kit and was further 
diluted to achieve a dilution factor of 1000. The extremely high dilution factor was utilized to 
reduce the impact of the bile acid components on the UV spectroscopic absorption readings 
and to for the ex vivo dissolution procedures to be conducted in triplicate (a limited volume of 
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isolated gastrointestinal fluid was available after filtration procedures).The ELISA kit 
procedure will be discussed in Section 6.4.13.   
 
6.4.11. Standard market product for absolute bioavailability comparison 
 
Miacalcin® (Novartis Pharma AG, Basel, Switzerland) was purchased and administered 
intramuscularly at the standard dosage (100IU) to the pig model as recommended for the 
treatment of post menopausal osteoporosis. In reality an IM injection is not the absolute 
reference for pharmacokinetic parameters, but in this current administration application is 
appropriate as there is no IV injectable forms utilized for the treatment of osteoporosis.  
 
6.4.12. In vivo studies in the pig model utilising the optimised Oral Ghost Drug 
Delivery device 
 
6.4.12.1. Animal studies design for the in vivo assessment of the salmon calcitonin 
bioavailability from the Oral Ghost Delivery Device in comparison to the marketed 
product Miacalcin® 
 
The animal study included three groups: Group 1 (Test) which included administration of the 
Oral Ghost Delivery Device (salmon calcitonin-loaded) to 5 pigs; Group 2 (Control) which 
included administration of the Oral Ghost Delivery Device (no salmon calcitonin) to 5 pigs; 
Group 3 (Comparison) which included administration of an intramuscular injection of 
Miacalcin® (contains salmon calcitonin) to 5 pigs. Blood samples from each group will be 
collected from the respective groups at predetermined time points. The concentration and 
amount of salmon calcitonin from each blood sample will be determined so that the 
pharmacokinetic data can be compared for each group within the study. A flow chart of the 
animal study design may be reviewed within Figure 6.3. The 5 pigs utilized for this study 
was utilized for each arm of this study with a 2 day washout period (>9 half lives of salmon 
calcitonin).  
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Figure 6.3: Animal study design which contains three groups: Group 1 (Test) consists of animal 
administered salmon calcitonin containing Oral Ghost Delivery Device; Group 2 (Control) consist of 
the Oral Ghost Delivery Device within loaded salmon calcitonin and Group 3 (Comparison) consist of 
the marketed intramuscular drug delivery system containing salmon calcitonin. 
 
6.4.12.2. Development of a blood sampling protocol through the insertion of a resident 
catheter for the accurate analysis of plasma samples 
 
The implantation of a permanent catheter within the pig model was preformed to reduce 
suffering to the animal due to the frequency of blood sampling and to increase the accuracy 
of blood sampling from the animals. Six Large White pigs which weighed between 35-37Kg 
was anaesthetised with ketamine (11mg/Kg intramuscularly) and midazolam (0.3mg/Kg 
intramuscularly). To reduce analgesia and inflammation Buprenorphine (0.5mg/Kg 
intramuscularly) and Carpofen (4mg/Kg intramuscularly) were administered. The pigs were 
intubated and anaesthesia was maintained with a gas mixture of 2%v/v isoflurane and 
100%v/v oxygen.   
 
Salmon calcitonin EIA kit: Plasma concentrations of drug were analyzed 
Group 3 (comparison): 
conventional drug delivery 
system on market (5 pigs) 
Intramuscular injection 
 
Anaesthesia for intrajugular catheter (30-60 minutes) followed by 10 day rest period 
Sedation (less than 30 minutes) and drug administration after 10 day rest period via 
intragastric tube administration of Oral Ghost Delivery Device or subcutaneous administration 
of the marketed product while under anaesthesia 
Blood sampling: 5mL blood samples was taken from a catheterized jugular vein at 0, 15, 30, 
45, 60, 75, 90, 105, 120, 135, 150, 180, 240, 300 and 360 minutes for after administration. 
Samples will be stored in EDTA tubes at -80°C until further analysis. 
Total: 5 pigs 
Group 1 (test): drug 
delivery system loaded with 
drug (5 pigs) for the Oral 
Ghost Delivery Device 
 
 
 
Group 2 (control): placebo 
of drug delivery system (5 
pigs) for the Oral Ghost 
Delivery Device 
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The pigs were then transferred to the operation theatre where aseptic conditions could be 
maintained. A 7 French gauge double lumen 35cm (CS-28702) (Arrow Deutschland GmdH, 
Erding, Germany) was surgically implanted into the left jugular vein of the pig. The left 
jugular vein was first exposed by blunt dissection along the dorsal side of the jugular groove 
located on the left lateral aspect of the neck. The catheter was inserted into the lumen of the 
jugular vein to a length of 10cm. The lumen of the catheter was sutured into place within the 
vein utilising a purse suture technique. A trocar was utilised to tunnel subcutaneously to an 
exit point cranial to the dorsal aspect of the scapula so that the remaining length of the 
catheter (25cm) could exit the animals neck. The external injection ports of the catheter were 
sutured to the skin to limit bending and the incidence of the catheter being pulled out of 
place by the pig after surgery. The catheter was immediately flushed with heparinised saline 
(5000IU/L of 0.9%w/v NaCl saline). The pigs were allowed to heal after surgery for a period of 
10 days and undergo further habituation through the removal of small volumes of blood from 
the ports of the implanted jugular catheter. The catheter was maintained by regular (twice 
daily) flushing with 5000IU/L 0.9%w/v NaCl heparinised saline.   
 
6.4.12.3. Dosing procedure for the Oral Ghost Drug Delivery device and intramuscular 
administration of salmon calcitonin 
 
The pigs were anaesthetised with ketamine (11mg/Kg) and midazolam (0.3mg/Kg) directly 
into the jugular vein catheter. Once anaesthetised, the pig was maintained in the 
anaesthetised state with the utilisation of a 2%v/v isoflurane and 100%
v/v oxygen gas mixture. 
An intragastric tube (1.8cm outer diameter and 1.3cm inner diameter) was inserted into the 
stomach of the pig and the OGDD device was placed within the intragastric tube. Water was 
used to flush the OGDD device into the stomach of the pig. The anaesthetised state allowed 
for maintenance of the catheter (e.g. signs of infection and removal of dirt located at the site 
at which the catheter exited the pig’s neck) and removal of stitches along the dorsal jugular 
grove of the neck. The pigs were returned to their respective pens to recover under 
observation. 
 
6.4.12.4. Blood withdrawal protocol 
 
Blood (5mL) was withdrawn from the conscious pig at 0, 15, 30, 45, 60, 75, 90, 105, 120, 
135, 150, 180, 240, 300 and 360min.  Blood samples were stored in EDTA blood tubes and 
then centrifuged at 5000rpm for 15 minutes at 4°C. The separated plasma was removed and 
stored in a -80°C freezer until further analysis. The catheter was disinfected during each 
withdrawal point to prevent local and systemic infection. The catheter was first flushed with 
159 
 
heparinised saline to remove any clots that may have formed within the catheter or at the 
end of the catheter which was inserted into the jugular vein.  
 
6.4.13. Procedure of utilizing the enzyme linked immunoassay kit for the 
determination of salmon calcitonin concentration  
 
The concentration of salmon calcitonin within blood samples was determined utilising an EIA 
according to the kits standard operating procedure. A standard curve was generated by 
preparing standards at 25ng/mL, 5ng/mL, 1ng/mL, 0.2ng/mL, 0.04ng/mL, 0.008ng/mL and 
0ng/mL. These standards were added to the plate in duplicate and generated an OD value 
between 0 and 3.4 at final wavelength measurement at 450nm. Two buffer solutions, Buffer 
A and Buffer B, where included with the purchase of the kit. An equal volume ratio of Buffer 
A and blood plasma was placed within an eppendorf. The sample was centrifuged at 
5000rpm for 20 minutes at 4°C. The supernatant was removed from the sample and placed 
within an eppendorf tube. A SEP-COLUMN was washed with 1mL Buffer B. The SEP-
COLUMN was washed three times with Buffer to generate an equilibrated SEP-COLUMN. 
The supernatant of the sample was then placed onto the SEP-COLUMN and a volume of 
6mL Buffer A was utilised to wash the column. A 3mL volume of Buffer B was then utilised 
and the salmon calcitonin containing wash was collected within an eppendorf tube. The 
eppendorf was placed within a dry ice bath and UPLC grade methanol was utilised to 
evaporate the water phase from the sample. Finally, the residue remaining within the 
eppendorf tube was dissolved within EIA buffer (provided with purchase), a 50μL volume of 
sample containing EIA buffer was removed and pippetted into a well of the 96 well plate. A 
volume of 25μL antiserum within   A buffer was added to each well that contained a sample 
(a standard curve utilised known concentrations of salmon calcitonin instead of samples 
derived from pig plasma). The EIA 96 well plate was incubated at room temperature for 1 
hour.  ach well which contained blank, sample and standard had 25μL Bt-tracer (provided 
with purchase) added to it and was incubated for an additional 2 hours. The plate was 
washed with   A buffer and 100μL of streptabidin-HRP was added to each well and 
incubated for another hour. Each well was washed once again and 100μL TMB solution 
(provided with purchase) was added to each well. The EIA 96 well plate was incubated for 
another hour and the reaction was terminated with the addition of 100μL 2 N HCl per well. 
The entire well plate was read simultaneously at 450nm within 5 minutes of HCl addition. 
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6.4.14. Pharmacokinetic analysis of in vivo drug concentration profiles 
 
The concentrations of salmon calcitonin were determined from the blood plasma utilizing the 
ELISA kit and these plasma drug concentrations were plotted against time in a scatter plot. 
The Area Under Curve from time 0 to infinity (AUC0-∞) was determined from the plasma drug 
concentration-time profile at each time point and plotted against time. Additionally, the Area 
Under Moment Curve from time 0 to infinity (AUMC0-∞) was also determined from the plasma 
drug concentration-time profile and also plotted against time. The AUMC0-∞ was determined by 
dividing the last concentration of drug observed in plasma by respective Kel (Qurrat-ul-Ain et 
al., 2003; Gavini et al., 2006). The AUMC from the last value to infinity was calculated as 
Equation 6.1: 
 
                        
     
   
 
     
   
                                                                         (Eqn. 6.1) 
 
The plasma drug concentration-time profiles were utilized to determine the pharmacokinetic 
parameters in both compartmental and noncompartmental analysis for the orally administered 
Oral Ghost Drug Delivery device and the intramuscular administered marketed standard 
Miacalcin®. All pharmacokinetic analysis was conducted with Winnonlin (Pharsight, Version 
5.1).  
 
6.4.15. In vitro-in vivo correlation 
 
The in vitro-in vivo correlation was conducted with the utilization of dissolution profiling of 
salmon calcitonin within biorelevant media, the orally administered OGDD device which had 
been loaded with salmon calcitonin and intramuscularly administered salmon calcitonin. The 
in vitro-in vivo correlation was generated utilizing Winnonlin  (Pharsight, version 5.1). The in 
vitro-in vivo correlation was built up over a seven processes (in vitro dissolution, in vitro 
dissolution model fitting, in vivo plasma drug concentration-time profiling, generation of a 
Unit Impulse Response, deconvolution, correlation building and correlation validation). 
These processes are discussed in Emami and more recently in Lu et al. (Emami, 2006; Lu et 
al., 2011). 
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6.4.15.1. The in vitro dissolution of salmon calcitonin within USP and biorelevant 
dissolution fluids 
 
The in vitro dissolution of the OGDD device was conducted in a two step process whereby 
the dosage form was initially placed within gastric representative dissolution fluid for 60 
minutes and then placed within intestinal representative dissolution fluid for 8.5 hours. A total 
of four dissolution sets (USP pH 1.2 to USP pH 6.8; FaSSGF to FaSSIF-V2; FaSSGF-
FeSSIF-V2; FaSSGFc pH 1.6 to FaSSIFc pH 7.5) were utilized to generate fractional 
release-time profiles. Additionally, a fractional release-time profile was determined within an 
ex vivo set (isolated porcine gastric fluid to isolated porcine intestinal fluid). The utilization of 
these dissolution sets allows for the determination of which dissolution fluid facilitates the 
closest in vivo plasma drug concentration-time profile. 
 
6.4.15.2. In vivo administration of salmon calcitonin  
 
The in vivo administration of salmon calcitonin was carried out in via the oral route with the 
utilization of the OGDD device and intramuscularly. The intramuscular administration of 
salmon calcitonin was required to achieve a 100% absorption profile so that an effective 
bioavailability of salmon calcitonin via the oral route can be calculated. 
 
6.4.15.3. Deconvolution of the Unit Impulse Response  
 
The Unit Impulse Response (UIR) is derived to describe the in vivo pharmacokinetic profile 
following an instantaneous dose (e.g. I.M. administration of salmon calcitonin) to obtain the 
rate at which one unit of drug enters the central compartment. The process of deconvolution 
utilizes the UIR generated from the in vivo pharmacokinetics to determine the drug 
absorption rate required to achieve an observed plasma drug concentration-time profile from 
an orally administered formulation. In this study the deconvolution process was determined 
to calculate the absorption rate of salmon calcitonin from the small intestine into the systemic 
circulation and was applied to generate the in vitro-in vivo correlation. The underpinning 
principles that facilitate the exploitation of deconvolution will be discussed briefly. The first 
underpinning principle is that of linear assumptions defined by the linear superposition 
principle. The linear superposition principle, in a pharmacokinetic perspective, establishes 
that under linear conditions the total concentration of drug in the body is the sum of the 
remaining concentrations from each administered dose at that point in time when a 
measurement was observed. This is achieved by considering drug transportation kinetics as 
non-parametric (having no characteristic structure or defining structure) and that drug 
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transport is stochastic (a system that is determined probabilistically). It can then be asserted 
that drug transport (point A) and subsequent absorption-distribution can be measured (point 
B).  
 
A drug molecule at time point 0 can be measured in a volume (V) within a system by 
entering the system at location A (the transportation point). With respect to time, the drug 
molecule will move within a defined volume through the process of absorption-distribution at 
point B. The probability that a drug molecule will be at point B with respect to point A at time 
0 can be represented as function g(t). A dosage form usually consists of an astronomical 
number of drug molecules (N) and is administered simultaneously. It is also assumed, 
usually, that no interaction between drug molecules exists at the transportation point A and 
therefore no transportation kinetic alteration occurs due to presence of high amounts of drug 
molecules at transport point A. The probability of a drug molecule of being at point B at time t 
is random and independent for each drug molecule of the administered dosage and the g(t)  
for each drug molecule is identical. The identical function g(t) for each drug molecule 
facilitates the implementation of  the liner superposition principle and that the concentration 
of drug molecules at point B at time t is proportional to dose (A large dose N has a large 
number of drug molecules will probably be greater at measurement point B than a smaller 
dose with less drug molecules) but g(t) is also independent because transport of each drug 
molecule is independent other drug molecules. 
 
A system usually has a constant transport process (i.e. diffusion) that has a constant 
transport rate for each drug molecule from point A to point B, with respect to time. The 
probability of a drug molecule being present at point B at time t is dependent on the time 
since being transported at point A and is independent of the eclipsed time span at point A. It 
can then be asserted that the probability of a molecule being at point B is g(t-tA) where tA is 
the time since being transported from point A to point B. This is referred to as time-
invariance. If N drug molecules leave point A simultaneously, the probability of a drug 
molecule being located at point B at time t is equal. The exact time for a drug molecule to 
start leaving point A is always unknown within a system and tA can be replaced with a 
probability density function  h(t), as shown in Equation 6.2: 
 
                
 
 
                                                                                              (Eqn. 6.2) 
 
Where h(u) is the probability function of an unknown time. The probability of the drug 
molecule at point B at time t is the average of g(t-tA) because if the same drug molecule 
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entered the same point A and was transported to point B at time t, a multitude to times, an 
average can be achieved. The possible values of tA can be calculated according to Equation 
6.3: 
 
                      
 
 
                                                                                    (Eqn. 6.3) 
 
If N drug molecules enter point A, and each drug molecule leaves point A at random times 
as indicated by the probability density function h(t), then the number of drug molecules at 
point B at time t is the product of N and the probability of being at B at time t, as shown by 
Equation 6.4: 
 
                                          
 
        
 
 
 
 
                    (Eqn. 6.4) 
 
If the number of molecules present at point B at time t is converted to mass units, as shown 
by Equation 6.5: 
 
                       
 
 
                                                                                 (Eqn. 6.5) 
 
Where MB(t) is the mass of drug molecules at point B at time t and f(t) is the rate of 
absorption (mass per unit time) into point A at time t. Additionally, the volume of the system 
(Vs) of point B can be included to determine the concentration of the drug molecule with 
respect to time (c(t)) at point B, and calculated by Equation 6.6: 
 
                               
 
 
                                                               (Eqn. 6.6) 
 
Where cδ is equal to g(t)/Vs and is known as the Unit Impulse Response (UIR). The drug 
input rate is represented at f(t) in the above equation. The process of determining the input 
function f(t) is known as deconvolution because in order to obtain this parameter, the 
convolution integral needs to be deconvolved. Additionally, the UIR function (cδ) is equal to 
the probability that a drug molecule that entered point A at time 0 will be present at point B at 
time t is divided by the volume of the system.  
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6.4.15.4. Correlation of fitted salmon calcitonin dissolution observations and fitted 
dissolution model profiles 
 
A correlation between the fitted dissolution of salmon calcitonin from the Oral Ghost Drug 
Delivery device within the dissolution environment (e.g. FaSSGF-FaSSIF V2 dissolution set) 
and the absorption of salmon calcitonin in the in vivo environment is generated through the 
process of determining the input rate function f(t), as described in Section 6.4.14.3.  
 
6.4.15.5. Correlation validation 
 
The in vitro-in vivo correlation is validated by determining the AUC and maximum 
concentration based on model predictions and compared to the AUC and maximum 
concentrations obtained within the in vivo environment. In order to achieve this validation, 
the fitted fractions absorbed and UIRs are convolved and a noncompartmental analysis is 
run to predict the pharmacokinetic data observed within the in vivo plasma drug 
concentration-time profile. The greater the number of noncompartmental parameters that 
achieve similar or identical observations that are similar to fitted pharmacokinetic 
parameters, the better the correlation. The ideal ratio of observed to fitted pharmacokinetic 
parameters should be a 1:1 ratio. The correlation was conducted for each salmon calcitonin 
dissolution profile within each dissolution fluid and isolated porcine gastrointestinal fluid to 
determine which dissolution fluid set achieved the greatest in vitro-in vivo correlation. 
 
6.5. Results and Discussion 
 
6.5.1. The insertion of a chronic catheter for chronic withdrawal of blood samples 
 
The 6 pigs were prepared for surgery by the administration of an anaesthetic agent ketamine 
(11mg/Kg intramuscularly) and midazolam (0.3mg/Kg intramuscularly) directly into the neck. 
In all 6 pigs an endotracheal tube was inserted to maintain free passage of air to the lungs 
and for the administration of isoflurane/oxygen during surgical procedures. The oxygen 
levels and blood pressure was monitored for each pig throughout the anesthetised 
procedures. In order for the insertion of the intrajugular catheter to occur without inducing 
infection at the site of the surgery, the neck was prepared by shaving the neck hair and 
cleaning the skin with veterinary disinfectant spray. The animal was then wheeled into the 
operating theatre to undergo insertion of the jugular catheter surgery. The preparation of the 
pig for surgery photographs may be reviewed in Figure 6.4. 
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The pig underwent surgery as described in Section 6.2.4.2. The insertion of the intrajugular 
catheter within each pig was successful and all the utilized pigs for this study recovered fully 
from the surgery. The heath of the pigs utilized for this study was monitored by measuring 
body weight weekly and observation of any adverse event such as infection at the site of the 
surgery. The insertion of the intrajugular catheter photographs may be reviewed in Figure 
6.5. 
 
 
6.5.2. Isolation of the porcine gastrointestinal fluids in the fasted state 
 
The isolation of the porcine gastrointestinal fluids in the fasted state was carried out for 
comparative dissolution. The pH of the fasted gastric intraluminal fluids and fasted small 
intestinal intraluminal fluids from the porcine model was determined to have a mean pH of 
1.54 (SD±0.4) and 8.4 (SD±0.27), respectively. The buffer capacity of the fasted gastric 
intraluminal fluids and fasted small intestinal intraluminal fluids from the porcine model was 
determine to have a mean of 26.4mmol/L/pH and 38.2mmol/L/pH, respectively. The isolation 
and subsequent filtered isolated porcine gastrointestinal tract is photographed in Figure 6.6. 
 
 
 
 
 
 
 
 
 
Figure 6.4: Photographic depiction of the surgical preparative measures utilised for the pigs in this 
study. The blood pressure was monitored (A), the endotracheal tube was inserted into the pig (B), a 
gas mixture of oxygen and isoflurane gas was utilized to maintain sedation (C) and the pig was then 
transferred into the sterile surgical room (D). 
 
 
A B 
C D 
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Figure 6.5: Photographic depiction of the insertion of the intrajugular catheter surgery utilised for the 
pigs in this study. The components and surgical tools utilized for the implantation of the intrajugular 
catheter is photographed in (A). The first stage of the intrajugular catheter implantation surgery is the 
blunt dissection along the neck and is photographed in (B). The isolation of the jugular vein in the 
neck is photographed in (C). The implantation of the intrajugular catheter within the jugular vein is 
photographed in (D).  The intermuscular positioning of the remaining catheter tubing (so that the pig 
may grow without pulling out the catheter which has been placed within the jugular vein) is 
photographed in (E). The sutured external ports of the intrajugular catheter to the dosal aspect of the 
neck are photographed in (F). The sutured incision along the ventral aspect of the neck is 
photographed in (G).  
A 
B C 
D E 
F G 
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Figure 6.6: Isolation of the gastrointestinal fluid from the porcine model (A) and the filtered porcine 
gastrointestinal fluid (B). 
 
6.5.3. Dissolution of the salmon calcitonin loaded Oral Ghost Drug Delivery device 
 
The dissolution of salmon calcitonin from the Oral Ghost Drug Delivery device, in FaSSGF-
FeSSIF V2 set and isolated porcine gastrointestinal fluid set, was fitted with Winnonlin 
(Pharsight, Version 5.1) and shown in Figure 6.7. The mean dissolution time (MDT) and the 
slope factor (β) for the Weibull dissolution fitting model at each time point of the dissolution 
profiling is shown in Figure 6.7. The dissolution fitting, MDT and β profiling for the  SP pH 
1.2-USP pH 6.8, FaSSGF-FaSSIF V2 and FaSSGFc pH 1.5-FaSSFGc pH 7.5 can be 
reviewed in Appendix 8. The Weibull model fitting achieved a high correlation for the 
FaSSGF-FeSSIF V2 set (0.9989) and isolated gastrointestinal fluid set (0.9964) was 
achieved. These fitted dissolution models are utilized in the in vitro-in vivo correlation for the 
principle aim of this study that is the determination of the dissolution fluid set that would 
generate the tightest in vitro-in vivo correlation. The utilization of biorelevant dissolution 
fluids typically does not occur during quality assurance because of the high costs associated 
with pure bile salt and egg phosphatidylcholine (Vertzoni et al., 2004).  
 
The components of biorelelvant dissolution fluid, as discuss previously, has been indicated 
to represent the intraluminal fluids that exist within the small intestine and the stomach 
(Dressman et al., 1998). The details that enables biorelevant dissolution fluid to be more 
representative than USP dissolution fluids will be discussed briefly. The inclusion of 
osmolality-adjusting agents such as potassium and sodium ions are often included within 
dissolution fluid to enable an effective electrolyte-water representation of the biological fluid 
under a specific condition. The electrolyte-water representation of USP simulated intestinal 
 
A 
Small intestine 
Large intestine 
 
B 
Filtered isolated 
porcine gastric 
fluid 
Filtered isolated 
porcine intestinal 
fluid 
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fluids incorporates potassium ions but the concentrations implemented within this dissolution 
fluid are too high when compared with the biological fluid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: The in vitro dissolution modeling of salmon calcitonin from the Oral Ghost Drug Delivery 
device within biorelevant dissolution fluid FaSSGF-FeSSIF V2 set (A) and isolated porcine gastric-
isolated intestinal set (B).  
 
The fasted human intestinal fluid has potassium ionic concentration of ~5mM whereas the 
USP simulated intestinal fluid (pH 6.8) utilizes an ionic concentration of 50mM potassium 
ions, which is a 10 fold overrepresentation with respect to the biological fluid (Banwell et al., 
1971; Lindahl et al., 1997; The USP, 2012; Vertzoni et al., 2004). Additionally, the sodium 
ionic concentration within the fasted human small intestine has been indicated within the 
range of 100-140mM whereas the sodium ionic concentration that is currently implemented 
within USP simulated intestinal fluids is 22mM, which is at least a 4.5 fold 
underrepresentation with respect to the biological fluid (Banwell et al., 1971; Davenport, 
1982; Lindahl et al., 1997; The USP, 2012;  Vertzoni et al., 2004).  
 
During the development of the biorelevant human fasted state simulated intestinal fluid, the 
osmolality-adjusting agent was substituted from potassium to sodium to achieve a higher 
degree of representation with respect to the biological fluid (Vertzoni et al., 2004). For 
interests sake, the osmolality and buffer capacity of USP simulated intestinal fluid (pH 6.8) is 
114mOsmol/Kg and 18.5mmol/L/pH, respectively (Verzoni et al., 2004). Bicarbonates are 
Time (hours)
0 2 4 6 8 10 12
F
ra
c
ti
o
n
a
l 
R
e
le
a
s
e
 (
%
)
0
20
40
60
80
100
120
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
S
a
lm
o
n
 C
a
lc
it
o
n
in
 (
m
o
l/
L
)
0.0
5.0e-6
1.0e-5
1.5e-5
2.0e-5
2.5e-5
3.0e-5
3.5e-5
Time (hours)
0 2 4 6 8 10 12
F
ra
c
ti
o
n
a
l 
R
e
le
a
s
e
 (
%
)
0
20
40
60
80
100
120
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
S
a
lm
o
n
 C
a
lc
it
o
n
in
 (
m
o
l/
L
)
0.0
5.0e-6
1.0e-5
1.5e-5
2.0e-5
2.5e-5
3.0e-5
3.5e-5
 
R
e
le
a
s
e
 P
e
rc
e
n
t 
(%
) 
R
e
le
a
s
e
 P
e
rc
e
n
t 
(%
) 
A B 
F
a
S
S
G
F
 
FeSSIF-V2 
Observed Fractional Release 
Fitted Fractional Release 
 
 
Is
o
la
te
d
 P
o
rc
in
e
 G
a
s
tr
ic
 F
lu
id
 
Isolated Porcine Intestinal Fluid 
Observed Fractional Release 
Fitted Fractional Release 
 
 
MDT=3.211146 (SE: 0.138478) 
β=2.711821 (SE:0.303508) 
Corrected Sum of Squared Observations: 1.87318 
Sum of Squared Residuals: 0.149517E-01 
S: 0.432314E-01 with 8 degrees of freedom 
Correlation (Observed, Predicted): 0.9964 
AIC criteria: -38.02933 
SBC: -37.42416 
AUC (0 to last time) by trapezoidal rule: 7.40861 
MDT: 2.613786 (SE: 0.050601) 
β: 4.714172 (S : 0.550093) 
Corrected Sum of Squared Observations: 1.91019 
Sum of Squared Residuals: 0.630804E-02 
S: 0.280803E-01 with 8 degrees of freedom 
Correlation(Observed, Predicted): 0.9989 
AIC criteria: -46.65930 
SBC criteria: -46.05413 
AUC (0 to last time) by trapezoidal rule: 7.66803 
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the buffering species utilized within the fasted small intestinal luminal fluids to maintain pH 
and buffer capacity (Dressman et al., 1998). But the incorporation of biocarbonates as a 
buffering species within buffers intended for dissolution purposes proved impractical due to a 
host of introduced variabilities (variable pH, buffer capacity, ionic strength, and osmolality) if 
carbon dioxide was not continually introduced into the buffer system (Vertzoni et al., 2004). 
This eventually lead to the utilization of maleic acid as the buffering system for biorelevant 
dissolution fluids, even though this buffer system is not physiologically relevant, it does 
accurately represent the physiological buffer system within the human fasted intestine and a 
step up from utilizing phosphate ions as the combined osmlality/buffer system mechanism 
(Vertzoni et al., 2004; Sandra Klein, 2010). Sodium taurocholate was utilized as the principle 
representative bile acid (sodium taurocholate is the salt derivative of taurocholic acid) 
species within the biorelevant dissolution fluids because human bile contains tri-hydroxy-
taurine, relatively insensitive to pH/ionic/temperature changes that causes aggregation of 
taurocholate micelles and was considered highly desirable for extended storage periods or 
dissolution applications that may occur over a 24 hour period (Hofmann, 1993; Weidmann 
and Kamel, 2002;  Verzoni et al., 2004).  
 
The last consideration for the development of biorelevant dissolution fluids was the 
phosphatidylcholine concentration and species type that was representative of the human 
biliary phospholipid excretion, of which 95% is phosphatidylcholine and 5% is 
phosphatidylethanolamine (Alvaro et al., 1986; Verzoni et al., 2004). Egg 
phosphatidylcholine was selected and included within the biorelevant dissolution fluid 
formulation because egg phoshatidylcholine contains the phospholipid species that are 
representative, and at mass concentrations that were very similar, of the human fasted state 
intestinal fluid (Angelico et al., 1992; Hayes et al., 1992; Hatsushika et al., 1993; Hay et al., 
1993; Verzoni et al., 2004). 
 
6.5.4. Pharmacokinetic analysis of in vivo drug concentration profiles 
 
The in vivo salmon calcitonin concentration-time profile is shown in Figure 6.8. The data 
from five pigs were utilized only because one pig was removed from the study before dosing 
could take place. The pig that was removed from the study fell ill and it was deemed ethical 
to remove this pig from the study. The in vivo profile of intramuscular (I.M.) administrated 
salmon calcitonin is the classical single dose profile of a parenteral administered formulation 
whereby the plasma salmon calcitonin concentration decreases exponentially with respect to 
time. The plasma salmon calcitonin concentration was undetectable within 60 minutes of 
administration. Whereas the plasma salmon calcitonin concentration-time profile achieved 
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from the oral administration of the salmon calcitonin within the Oral Ghost Drug Delivery 
device had an initial lag time. Thereafter a significant increase of plasma salmon calcitonin 
concentration increases rapidly but it should be noted that at time point 60 minutes, a 
significant standard deviation is noted. The large standard deviation at this time point could 
be due to the high intersubject variable or the slight deviation of the pH profile that exists 
within the gastrointestinal tract of the porcine model. The orally administered salmon 
calcitonin demonstrated the classical single dose profile of an orally administered formulation 
whereby initially there is absorption phase until a peak drug concentration is achieved 
followed by an exponential decrease in drug concentration. 
 
The AUC and AUMC from time 0 to time infinity was calculated and is the profiles of these 
parameters against time is shown in Figure 6.9. The AUC-time and AUMC-time profiling of 
salmon calcitonin for the I.M. administration of salmon calcitonin generated, as expected for 
a 100% bioavailable single dose, an exponential rise to a maximum value. Whereas the 
AUC and AUMC for the orally administered salmon calcitonin profiles demonstrated a 
sigmodial fit which is correlates with the lag time of absorption. The lag time of salmon 
calcitonin absorption from the Oral Ghost Drug Delivery device is due to the utilization of an 
enteric coating that is pH responsive to the jejunum-ileum environment and the presence of 
a pH responsive hydrogel utilized for the physicomechanical application of ejecting the mini-
pellet formulations from the device. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: The in vivo plasma salmon calcitonin concentration-time profile for the intramuscular 
administration of salmon calcitonin (A) and the orally administered salmon calcitonin-time profile for 
the Oral Ghost Drug Delivery device (B) [*High variability due to the gastrointestinal transition time 
from the stomach to the small intestine induces high intersubject variability]. 
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The AUC and AUMC were utilized within the noncompartmental analysis to determine the 
mean residence time. The AUC and AUMC are both calculated with the trapezoidal rule from 
time 0 time infinity. The terminal elimination rate constant is calculated using Equation 6.7: 
 
     
   
       
 
            or                        
     
              
 
   
       
  
            (Eqn. 6.7) 
 
Where      
   is the area under the curve from time 0 to time infinity,         is the plasma 
drug concentration that was last measured, λ is the terminal elimination rate constant, 
      
   is the area under the moment curve from time 0 to time infinity,                is the 
plasma drug concentration measured against the last time point. 
 
The AUC and AUMC are thereafter utilized to measure the MRT for an intravenously 
administered dose, accord to Equation 6.8: 
 
    
    
   
                                                                                                             (Eqn. 6.8) 
 
Where MRT is the mean residence time, AUMC is the area under the moment curve, AUC is 
the area under the curve. 
 
For the extravascularly administrated drug the mean transit time (MTT) is calculated, 
according to Equation 6.9: 
 
                                                                                                              (Eqn. 6.9) 
 
Where MTT is the mean transit time, MRT is the mean residence time and MAT is the mean 
absorption time. The MTT can be calculated according to Equation 6.10: 
 
    
    
   
                                                                                                             (Eqn. 6.10) 
 
Where MRT is the mean residence time, AUMC is the area under the moment curve, and 
AUC is the area under the moment curve. 
  
The MRT for an intravenous administration and the MTT for an extravascular administration 
is not equivalent because the difference between the MRT and MTT is the MAT for the 
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extravasular administration of a drug. The MTT and MRT for the intramuscular and oral 
administration for salmon calcitonin will be estimated in Section 6.5.4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9. The AUC (A) and AUMC (B) derived from in vivo plasma salmon calcitonin concentration-
time profile for the intramuscular administration of salmon calcitonin. The AUC (C) and AUMC (D) 
derived from orally administered salmon calcitonin concentration-time profile for the Oral Ghost Drug 
Delivery device.   
 
 
6.5.4.1. Noncompartmental analysis 
 
The noncompartmental analysis of the in vivo plasma salmon calcitonin concentration-time 
profiles was determine for the I.M. administered salmon calcitonin and orally administered 
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salmon calcitonin in the Oral Ghost Drug Delivery device is shown in Table 6.2. A high 
statistical R2 adjusted for the I.M. administration (0.9819) and oral administration (0.9835), 
respectively. The maximum concentration (Cmax) of salmon calcitonin was determined to be 
2.6 times higher for the I.M. administered salmon calcitonin than the orally administered 
salmon calcitonin. The higher Cmax may induce the noted side effects associated with the 
I.M. administration of salmon calcitonin (e.g. nausea, vomiting, eye pain) because of high 
concentrations may enter the toxic range of the therapeutic range whereas the oral 
formulation has a much lower Cmax. This may reduce the side effects with the 
administration of oral salmon calcitonin but also slightly extend the exposure of the drug 
which may result is better or equivalent treatment therapeutic responses. 
 
Clearly the mean residence time (MRT) will increase between the I.M. and orally 
administered salmon calcitonin formulation as the oral formulation releases salmon 
calcitonin within the small intestine. The MRT increased by ~7.9 fold between the oral and 
IM administration of salmon calcitonin.  The MAT for the oral administration of salmon 
calcitonin was determined to ~116 minutes. 
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Table 6.2. The noncompartmental pharmacokinetic parameters determined from the intramuscular 
(I.M.) administration of salmon calcitonin and the oral administration of salmon calcitonin from the 
Oral Ghost Drug Delivery device. 
 
  I.M. Oral 
Parameter Units Average (SD) Average (SD) 
R
2
  0.991 0.992 
R
2 adjusted
  0.982 0.984 
Correlation XY  -0.998 (±0.0016) -0.998 (±0.0029) 
Number of points for Lamba Z  3 3 
Lamba Z 1/min 0.065 (±0.004) 0.015 (±0.003) 
Lamba Z (lower) min 15 (±0) 126 (±13.416) 
Lamba Z (upper) min 45 (±0) 180 (±0) 
HL Lamba Z min 10.723 (±0.615) 46.77 (±8.967) 
Tlag min  39 (±8.216) 
Tmax Min 0 (±0) 69 (±8.216) 
Cmax pg/mL 245.242 (±8.587) 92.028 (±5.456) 
Cmax Dose pg/mL/mg 7357.328 (257.622) 92.028 (±5.456) 
C0 pg/mL 245.242 (±8.587)  
Tlast min 45 (±0) 180 (±0) 
Clast pg/mL 16.816 (±0.936) 23.09 (±5.097) 
AUClast min.pg/mL 6883.609 (±188.385) 7145.957 (±492.204) 
AUCall min.pg/mL 7010.02 (±192.03) 7838.652 (±415.011) 
AUCINF Observed min.pg/mL 7149.039 (±188.476) 8755.055 (±533.135) 
AUCINF Dose Observed min.pg/mL/mg 214473.311 
(5654.342) 
8755.055 (±533.135) 
AUC % Extrapolated Observed % 5.934 (±0.583) 18.214 (±6.454) 
AUC % Back Extrapolated 
Observed 
% 0 (±0)  
Vz Observed L 73.427 (±10.391)  
Cl Observed mL/min 4662.585 (323.148)  
Vz F Observed L  8683.581 (±1224.886) 
Cl F Observed mL/min  114551.6 (±6819.484) 
AUCINF predicted min.pg/mL 7143.134 (±185.758) 8735.278 (±541.132) 
AUCINF dose predicted min.pg/mL/mg 214296.152 
(5572.796) 
8735.278 (±541.132) 
AUC % Extrapolated predicted % 5.805 (0.685) 18.033 (6.339) 
AUC % Back Extrapolated 
predicted 
% 0 (±0)  
Vz predicted L 73.487 (±10.277)  
Cl predicted mL/min 466.439 (318.863)  
Vz F predicted L  7702.965 (±1238.49) 
Vz F predicted mL/min  114823.5 (±6973.627) 
AUMClast min
2
.pg/mL 111597.503 
(±2592.511) 
757968.9 (±35626.86) 
AUMCINF Observed min
2
.pg/mL 131703.316 
(±3148.244) 
1162597 (±194881.6) 
AUMC % Extrapolated 
Observed 
% 22.113 (±1.922) 33.556 (±9.767) 
AUMCINF predicted min
2
.pg/mL 131256.005 
(3156.683) 
1157618 (±193098.2) 
AUMC % Extrapolated 
predicted 
% 21.7047 (±2.264) 33.3009 (±9.612) 
MRTlast min 13.419 (0.144) 106.3517 (±6.739) 
MRTINF Observed min 16.215 (±0.4421) 132.364 (±16.815) 
MRTINF pred min 16.155 (±0.487) 132.109 (±16.644) 
Vss Observation L 85.897 (7.085)  
Vss predicted L 85.746 (7.282)  
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6.5.4.2. Compartmental analysis 
 
The compartmental analysis of salmon calcitonin was conducted to determine if recirculation 
and exchange of the drug between “grouped tissue types” had affected the derived 
pharmacokinetics of the noncompartmental analysis utilizing the Gauss-Newton method.  
The classical one compartment IV bolus, no lag time, 1st order elimination model was applied 
to the obtained in vivo plasma salmon calcitonin concentration-time profile after IM 
administration of salmon calcitonin, is shown in Figure 6.10, and obtained an extremely high 
correlation of 0.99, as indicated in Table 6.3. Additionally, the classical one compartment, 1st 
order elimination, initial time lag, 1st order elimination model was applied to the obtained in 
vivo plasma salmon calcitonin-time profile after oral administration of the salmon calcitonin 
loaded Oral Ghost Drug Delivery Device, is shown in Figure 6.11, and once again obtained 
an extremely high correlation of ≥0.98, as indicated in Table 6.3.  
 
The one compartment model was utilized for both the intramuscular and oral administration 
of salmon calcitonin whereby the body is defined as a single central compartment. The 
distribution of salmon calcitonin throughout the central compartment is rapid and equally 
distributed throughout the tissues, within the limits of observable detection for the 
intramuscular administration. The one compartment model illustrates that the plasma drug 
concentration is only primarily influenced parameter by the drug elimination from the system. 
Thus, the model is simply characterised by the volume of the system, dosage of drug, and 
plasma drug concentration within the system for the intramuscular administration. The oral 
administration of salmon calcitonin is slightly different from that of the intramuscular 
administration. The main difference lies in the inclusion of absorption phase whereby salmon 
calcitonin was released within the small intestine and distributed in the intraluminal fluids, 
then underwent the process of absorption. The good correlation of the one compartmental 
model for the orally administered salmon calcitonin, indicates that once the obsorption phase 
was completed, salmon calcitonin distributed throughout the body in a rapid and uniform 
manner.  
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Figure 6.10: The one compartment IV-bolus, no lag time, 1
st
 order elimination of intramuscular 
administration of salmon calcitonin.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: The one compartment 1
st
 order, initial lag time, 1
st
 order elimination of oral administration 
of salmon calcitonin in the Oral Ghost Drug Delivery device.  
 
 
 
 
 
 
 
 
K10 
 
K01 
1 0 
      
 
       
  
         
                        
Where: C(t) is concentration with respect to time, D is 
administered dose, K01 is the rate of absorption, K10 is the rate 
of elimination and V is the volume of distribution 
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Where: C (t) is concentration with respect to time, D is administered 
dose, K10 is the rate of elimination, and V is the volume of distribution 
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Table 6.3. The statistical analysis of the compartmental pharmacokinetic parameters determined from 
the intramuscular administration of salmon calcitonin and the oral administration of salmon calcitonin 
from the Oral Ghost Drug Delivery device for each pig utilized. 
 
 Pig 1 Pig 2 Pig 3 Pig 4 Pig 5 
 IV Oral IV Oral IV Oral IV Oral IV Oral 
CSS 
(Obs) 
58206 15686 64373 16153 61635 12657 67856 14101 56275 13827 
           
SSR 193.47 330.63 237.12 280.04 659.99 129.8 366.17 281.42 166.51 274.9 
           
S 
(DF) 
4.398 
(10) 
6.42 
(8) 
4.869 
(10) 
5.91 
(8) 
8.12 
(10) 
4.02 
(8) 
6.051 
(10) 
5.93 
(8) 
4.08 
(10) 
5.86 
(8) 
           
Corr 
(Obs, 
Pred) 
0.99 0.98 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 
           
AIC 
criteria 
67.18 77.61 69.62 75.61 81.91 66.39 74.83 75.67 65.38 75.39 
           
SBC 
criteria 
68.15 79.55 70.59 77.55 82.87 68.33 75.80 77.61 66.35 77.33 
CSS (Obs): Corrected sum of squared observations 
SSR: Sum of squared residuals 
S (DF):  Standard error of weighted residuals  and the Degrees of freedom (observations minus the number of 
zero weights) 
Corr(Obs, Pred): Correlation of observed and predicted 
AIC criteria: Akaike information criterion 
SBC criteria: Schwarz Bayesian information criterion 
*Pig 6 was removed from the study before administration procedures due to illness 
 
The compartmental analysis of plasma salmon calcitonin concentration-time profile that had 
been I.M. administered generated AUC/AUCINF and Cmax values that were almost identical 
to that obtained within the noncompartmental analysis, indicating that during the I.M. 
administration recirculation exchange mechanism did not induce a significant alteration of 
drug distribution. Whereas the compartmental analysis of salmon calcitonin concentration-
time profile, that had been orally administered with the utilization of the Oral Ghost Drug 
Delivery device, also had a very similar Cmax and AUC/AUCINF, which indicated that 
recirculation and exchange of salmon calcitonin had not affected the noncompartmental 
pharmacokinetic analysis of the salmon calcitonin. The noncompartmental pharmacokinetic 
analysis is based on alibragic analysis that does not take into account recirculation and 
exchange of a drug compound between tissue layers. Compartmental analysis is based on 
linear or nonlinear differential equations which takes into account the recirculation and 
exchange of drug compounds. If the calculated pharmacokinetic parameters form the same 
plasma concentrations-time points results in slightly different values, recirculation and 
exchange of the drug compound could account for these slight differing values. The 
compartmental analysis of salmon calcitonin from the I.M. and oral administration can be 
reviewed in Table 6.4. 
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Table 6.4. The compartmental pharmacokinetic parameters determined from the intramuscular 
administration of salmon calcitonin and the oral administration of salmon calcitonin from the Oral 
Ghost Drug Delivery device. 
 
Parameter Unit I.M.  Oral  
AUC min.pg/mL 6853.234 (±222.6873) 8796.044 (±406.2473) 
AUMC min
2
.pg/mL 191651.972 (±371.129)  
K10 1/min 0.03576 (±0.0032)  
K01 Half Life Min  9.207 (±0.9141) 
K10 Half Life Min 19.384 (±1.732) 40.844 (±1.474) 
Clearance pg/mL 4863.397 (±412.8633)  
Clearance Fraction mL/min  113687.477 (±5619.986) 
Tmax Min  84.611 (±7.5616) 
MRT Min 27.965 (±5427.105)  
Vss L 136.005 (±4.7592)  
Cmax pg/mL 245.063 (±8.8633) 96.763 (±4.22) 
 
6.5.5. Unit Impulse Response 
 
The generation of a unit impulse response is a pivotal process during the development of an 
in vitro-in vivo correlation because it measures the absorption-time scale between the orally 
administered formulation and the 100% bioavailable parenteral administration of the drug. 
The Unit Impulse Response (UIR) is independent of the dissolution of salmon calcitonin from 
the Oral Ghost Drug Delivery device and is therefore identical for all the in vitro-in vivo 
correlations. The generation for the UIR can be reviewed in Figure 6.12 whereby the fitted 
plasma salmon calcitonin concentration-time profile for the oral administration has been 
overlaid with fitted plasma salmon calcitonin concentration-time points. These points are 
compared with the 100% bioavailable formulation plasma drug concentration-time profile to 
generate an input rate-time profile. Thereafter a cumulative input-time profile is generated 
that represents the “ideal” dissolution profile from the observed plasma salmon calcitonin 
concentration-time profile that was orally administered. 
 
6.5.6. In vitro-in vivo correlation  
 
The in vitro-in vivo correlation is generated through the process of deconvolution whereby 
the “ideal” dissolution profile is generated through the process of convolution and thereafter 
the in vitro dissolution is compared with this “ideal” profile. This correlation also utilized to 
generate an absorbance scale-time profile (AbsScale-time) and a time scale-time profile 
(Tscale-time).  The fractional dissolution (Fdiss) and factional absorption (FAbs) is correlated 
by comparing the in vitro dissolution and the in vivo absorption with respect to each other at 
each fitted time point. These parameters are fitted to the in vitro-in vivo correlation model, as 
shown in Equation 6.11: 
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                                                                                               (Eqn. 6.11) 
 
Where Fab is the fractional absorption in the in vivo environment, AbsScale is the absorption 
scale generated through deconvolution, Fdiss is the factional dissolution in the in vitro 
environment, Tscale is the time scale generated through deconvolution and Tvivo is the time 
in the in vivo environment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12: The generation of a Unit Impulse Response (UIR) where the fitted plasma salmon 
calcitonin concentration-time profile (A), the input rate-time profile (B) and the cumulative input-time 
profile (C) was generated from the 100% bioavailable intramuscular administration of salmon 
calcitonin and orally administered salmon calcitonin in the Oral Ghost Drug Delivery device utilizing 
Winnonlin (Pharsight, Version 5.1). 
 
 
 
Time (min)
0 50 100 150 200 250 300
P
re
d
ic
te
d
 P
la
s
m
a
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
L
)
0
20
40
60
80
100
120
 
Time (min)
0 50 100 150 200 250 300
In
p
u
t 
R
a
te
 (
m
g
/m
in
)
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
0.0012
0.0014
 
Time (min)
0 50 100 150 200 250 300
C
u
m
u
la
ti
v
e
 I
n
p
u
t 
(m
g
)
0.00
0.01
0.02
0.03
0.04
0.05
 
Observed 
Fitted 
 Observed 
Fitted 
 
Observed 
Fitted 
 
A B 
C 
180 
 
The in vitro-in vivo correlation parameters that were generated through the process of 
convolution and deconvolution that was derived from the isolated porcine gastrointestinal 
fluid and the FaSSGF-FeSSIF V2 dissolution fluid set is shown in Figure 6.13 and Figure 
6.14, respectively. The in vitro-in vivo correlation, unlike the generation of the UIR in this 
study, is dependent of the in vitro dissolution environment and will generate unique 
parameters for the in vivo-in vitro correlation model. Therefore an in vitro-in vivo correlation 
had to be conducted for each dissolution fluid set and the unique convolution-deconvolution 
parameters for USP pH 1.2-USP pH 6.8, FaSSGF-FaSSIF V2 and FaSSGFc pH 1.5-
FaSSGFc pH 7.5 can be reviewed in Appendix 9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: The in vitro-in vivo correlation generated from the dissolution of salmon calcitonin from 
the Oral Ghost Drug Delivery device within isolated porcine gastrointestinal fluids (fasted state). The 
fitted dissolution of salmon calcitonin concentration-time profile (A) and the Fractional Absorbed-
Fractional Dissoluted profile (B) were generated from the deconvolution of the observed plasma 
salmon calcitonin concentration-time profile that was obtained in the in vivo administration of the Oral 
Ghost Drug Delivery device. The blue line in (B) represents an ideal correlation and red circles in (B) 
represent the measured FDiss:FAbs correlation. 
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Figure 6.14: The in vitro-in vivo correlation generated from the dissolution of salmon calcitonin from 
the Oral Ghost Drug Delivery device within FaSSGF-FeSSIF V2 dissolution set. The fitted dissolution 
of salmon calcitonin concentration-time profile (A) and the Fractional Absorbed-Fractional Dissoluted 
profile (B) were generated from the deconvolution of the observed plasma salmon calcitonin 
concentration-time profile that was obtained in the in vivo administration of the Oral Ghost Drug 
Delivery device. The blue line in (B) represents an ideal correlation and red circles in (B) represent the 
measured FDiss:FAbs correlation. 
 
6.5.7. In vitro-in vivo correlation validation 
 
The in vitro-in vivo correlation validation is the final step whereby the in vitro-in vivo 
correlation utilized to generate in vivo noncompartemental pharmacokinetic parameters from 
a dissolution profile. The in vivo noncompartemental pharmacokinetic parameters that were 
generated from the in vitro dissolution of salmon calcitonin from the Oral Ghost Drug 
Delivery device in isolated porcine gastrointestinal fluids and the FaSSGF-FeSSIF V2 
dissolution set is shown in Table 6.5. The in vitro-in vivo correlation validation derived from 
the USP pH 1.2-USP pH 6.8, FaSSGF-FaSSIF V2 and FaSSGFc pH 1.5-FaSSIFc pH 6.8 
can be reviewed in Appendix 9.  
 
The FaSSGF-FaSSIF V2 dissolution set generated the tightest in vitro-in vivo correlation 
from the dissolution media. USP pH dissolution generated the poorest in vitro-in vivo 
correlation with respect to Cmax, AUClast and MDTlast. Interestingly, isolated 
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gastrointestinal fluids from the porcine model did not generate the tightest correlation but did 
perform better than the USP dissolution fluid set. There could be many explanations for this 
occurrence such as destabilization of the bile salt components, variance in pH and ionic 
concentration during the dissolution profiling. The control of the physicochemical and 
physicomechanical properties of within designed dissolution fluids are controlled to a far 
higher degree than can be achieved within a pooled sample of biological fluids. This may 
translate into a cumulative reduced performance of the isolated gastrointestinal fluids with 
respect to the biorelevant dissolution fluids.  
 
The observed and fitted plasma salmon calcitonin concentration-time profile that was derived 
from the in vitro dissolution of salmon calcitonin from the Oral Ghost Drug Delivery device 
can be reviewed in Figure 6.15. The unique convolution and deconvolution parameters 
utilized to generate the fitted in vivo salmon calcitonin concentration-time profile can be 
reviewed in Figure 6.15. Additionally, the AUC and AUMC for the observed and fitted 
plasma salmon calcitonin concentration-time profile can also be reviewed in Figure 6.15. 
The AUC and AUMC profiles are utilized to determine the time periods at which the fitted 
plasma salmon calcitonin-time profile overestimates or underestimates the plasma 
concentration of salmon calcitonin with respect to the observed plasma salmon calcitonin-
time profile.  As indicated previously, the AUC and AUMC are utilized to determine the MRT 
for both the fitted and observed pharmacokinetic parameters. The in vitro-in vivo correlation 
validation profiles are presented for the dissolution within isolated porcine gastrointestinal 
fluids is also shown for the FaSSGF-FeSSIF V2 in Figure 6.16. Additionally, these profiles 
are presented for the USP pH 1.2-USP pH 6.8, FaSSGF-FaSSIF V2 and FaSSGFc pH 1.5-
FaSSIFc pH 7.5 dissolution fluid sets in Appendix 9. According to the fitted error 
calculations the Cmax was best correlated by the FaSSGF-FeSSIF V2 dissolution set 
(followed by isolated porcine gastrointestinal fluid set, FaSSGF-FaSSIF V2 set, USP pH 1.2-
USP pH 6.8 set and lastly FaSSGFc pH 1.5-FaSSIFc pH 7.5). The AUClast was best 
correlated by the FaSSGF-FaSSIF V2 dissolution set (followed by FaSSGF-FeSSIF V2 set, 
isolated gastrointestinal fluid set, FaSSGFc pH 1.5-FaSSIFc pH 7.5 and lastly USP pH 1.2-
USP pH 6.8 set). 
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Figure 6.15: The in vitro-in vivo correlation validation generated from the dissolution of salmon 
calcitonin from the Oral Ghost Drug Delivery device within isolated porcine gastrointestinal fluids 
(fasted state). The fitted and observed in vivo plasma salmon calcitonin concentration-time profile (A) 
and the fitted and observed Fractional Absorbed-time profile (B). Additionally, the observed and fitted 
AUC-time and the observed and fitted AUMC-time profiles (C) were generated from in vitro-in vivo 
correlation process. 
 
Finally, the MDTlast achieved the highest correlation for the FaSSGF-FaSSIF V2 (followed 
by FaSSGF-FeSSIF V2 set, isolated porcine gastrointestinal fluid set, FaSSGF pH 1.5-
FaSSIFc pH 7.5 and lastly USP pH 1.2-USP pH 6.8). The utilization of biorelevant 
dissolution fluid should be, as indicated by Verzoni et al., (2004) should be utilized for the 
most optimized dosage form due to the expense and time required to conduct these 
dissolution procedures (Verzoni et al., 2004). But the significant benefit is the potential 
illustration of the physicomechanical and physicochemical properties of the drug delivery 
Time (min)
0 100 200 300 400 500 600
C
o
n
v
o
lu
ti
o
n
 (
(p
g
/m
L
).
p
g
/m
L
)
0
20
40
60
80
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
S
a
lm
o
n
 C
a
lc
it
o
n
in
 i
n
 p
la
s
m
a
(p
g
/m
L
)
0
20
40
60
80
100
 Time (min)
0 50 100 150 200 250 300
S
a
lm
o
n
 C
a
lc
it
o
n
in
 A
b
s
o
rb
e
d
 (
p
g
/m
L
)
0.00
0.01
0.02
0.03
0.04
0.05
 
Time (min)
0 50 100 150 200 250 300
A
U
C
 (
m
in
.p
g
/m
L
)
0
2000
4000
6000
8000
10000
A
U
M
C
 (
m
in
2
.p
g
/m
L
)
0.0
2.0e+5
4.0e+5
6.0e+5
8.0e+5
1.0e+6
1.2e+6
 
Fitted AUMC 
Observed 
AUMC 
Fitted AUC 
Observed AUC 
Observed Absorbed  
Fitted Plasma Concentration 
 Observed Plasma 
Concentration Fitted Absorbed 
A B 
C 
184 
 
device or system that may not have occurred in USP dissolution fluid and to which degree 
these properties are altered.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: The in vitro-in vivo correlation validation generated from the dissolution of salmon 
calcitonin from the Oral Ghost Drug Delivery device within the FaSSGF-FeSSIF V2 set. The fitted and 
observed in vivo plasma salmon calcitonin concentration-time profile (A) and the fitted and observed 
Fractional Absorbed-time profile (B) were generated. Additionally, the observed and fitted AUC-time 
and the observed and fitted AUMC-time profiles (C) were generated from in vitro-in vivo correlation 
process. 
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Table 6.5. The noncompartmental pharmacokinetic parameters determined form the in vitro-in vivo 
correlation generated from the dissolution analysis of salmon calcitonin from the Oral Ghost Drug 
Delivery device in isolated porcine gastrointestinal fluids (fasted state) and the FaSSGF-FeSSIF V2 
dissolution set.  
 
Parameter Units In Vivo  Fitted from 
 isolated 
 gastrointestinal  
fluids (fasted 
state) 
Fitted from 
 FaSSGF-FeSSIF V2 
dissolution set 
R2  0.9919 0.9947 1 
R2 adjusted  0.9838 0.9895 1 
Correlation (X,Y)  -0.9959 -0.9974 -1 
Number points 
lambda Z 
 3 3 4 
Lambda Z 1/min 0.0123 0.0307 0.0356 
Lambda Z lower min 135 150 135 
Lambda Z upper min 180 240 240 
Half Life Lambda z min 56.1973 22.6133 19.4602 
Tlag min 45 0 0 
Tmax min 75 105 105 
Cmax pg/mL 93.8674 74.3135 107.2579 
Cmax D pg/mL/mg 93.8674 74.3135 107.2579 
Tlast min 180 240 240 
Clast pg/mL 28.3373 3.2087 1.4398 
AUClast min*pg/mL 7281.047 8300.917 7926.316 
AUCall min*pg/mL 8131.166 8300.917 7926.316 
AUCINF observed min*pg/mL 9578.508 8405.597 7966.737 
AUCINF D observed min*pg/mL/mg 9578.508 8405.597 7966.737 
AUC %Extrap 
observed 
% 23.9856 1.2454 0.5074 
Vz F observed mL 8664317 3881231 3524039 
CL F observed mL/min 104400.4 118968.4 125521.9 
AUCINF predicted min*pg/mL 9556.405 8409.718 7966.856 
AUCINF D predicted min*pg/mL/mg 9556.405 8409.718 7966.856 
AUC %Extrap 
predicted 
% 23.8098 1.2938 0.5089 
Vz F predicted mL 8483894 3879329 3523986 
CL F predicted mL/min 104641.9 118910.1 125520 
AUMClast min*min*pg/mL 808258.7 958581 895149 
AUMCINF observed min*min*pg/mL 1408070 987119.4 905985 
AUMC %Extrap 
observed 
% 42.5981 2.8911 1.196 
AUMCINF predicted min*min*pg/mL 1402299 988242.9 906016.8 
AUMC %Extrap 
predicted 
% 42.3619 3.0015 1.1995 
MRTlast min 111.0086 115.4789 112.9338 
MRTINF observed min 147.003 117.436 113.721 
MRTINF predicted min 146.7392 117.512 113.7233 
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6.6. Concluding remarks 
 
The in vivo oral administration of salmon calcitonin from the Oral Ghost Drug Delivery device 
in porcine model animal has demonstrated that the oral peptide therapeutic delivery can be 
achieved with this device. Additionally, the administration of this device was achieved 
without abdominal surgery within an animal model that has the closest non-primate 
gastrointestinal physiology with that of humans. The implementation of biorelevant 
dissolution fluids will become more pertinent as advances in oral drug delivery technology 
become more sensitive to innate physiological or biochemical properties of the 
gastrointestinal tract. For instance, the Oral Ghost Drug Delivery device relies on the 
presence of a steep pH profile within the gastrointestinal tract to achieve the desired 
targeted release. As demonstrated previously, the Trigger Mechanism that induces the 
displacement of the mini-pellet entities from the device is sensitive to the ionic concentration 
of the aqueous environment but may also be sensitive to the presence of bile acids. These 
physicochemical properties of the aqueous environment will clearly have an impact on the 
physicomechanical performance of the Trigger Mechanism within the device. These 
impacting principles can be extended to the optimized mini-pellet formulations. With the 
significant social pressure for reduced experimental studies conducted on animal models, 
the evaluation and refinement of in vitro procedures that can meet these goals should be 
aggressively pursued. This study successfully attempts to bridge the gap between in vitro-ex 
vivo-in vivo experimentation in a way that can be utilized to reduce animal experimentation in 
future work.  
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CHAPTER 7 
Conclusions and Recommendations 
 
7.1. Conclusions  
 
The development of peptide therapeutics as highly potent, effective and selective treatment 
options for chronic conditions will continue to grow exponentially with each year. The 
pharmaceutical industry is investing billions in life science research that ranges from gene 
therapy and cancer biology to neurological and osteological biochemical profiling. Many of 
the potential therapeutic agents derived from these research areas are of a 
biopharmaceutical identity. The development of patient friendly means to administer these 
compounds should be aggressively pursued to fully maximize the benefits of these 
therapeutics.  
 
The Oral Ghost Drug Delivery device attempts to overcome many of the issues pertaining to 
the oral administration of peptide therapeutics. The device attempts to be highly targeted 
within the gastrointestinal tract due to the extremely high cost of this peptide therapeutics. 
This is achieved with a combination of a Eudragit® cap and a pH responsive hydrogel. The 
second change is the localization of the solid dosage form within the small intestine to 
facilitate an effective drug concentration that promotes the absorption of the peptide 
therapeutic. This is achieved with a mini-pellet formulation that incorporated trimethyl 
chitosan, a known mucoadhesive, excipient. The absorption of the peptide therapeutic is an 
additional challenge that was overcome with a dual action approach. The inclusion of EDTA 
within the in situ hot melt dispersion mini-pellet and within the drug carrier mini-pellet was 
aimed at reducing the monovalent and divalent ionic concentration load within a located 
environment. This has been suggested to induce the opening of tight junctions located within 
the epidermal layer of the small intestine. Additionally, the inclusion of EDTA has been 
indicated to reduce the effectiveness of intestinally located peptidase enzymes. A reduction 
in the peptidase enzyme activity increases the effect amount of active peptide therapeutic for 
absorption. Thus, the promotion of the peptide therapeutic transport via the paracellular 
transport mechanism and the reduction in peptidase enzyme activity increase the plasma 
drug concentration of the peptide therapeutic. Trimethyl chitosan has also been indicated to 
increase the paracellular transport of peptide therapeutics by opening the tight junctions 
which can augment the effect of EDTA within a localized environment. All of these 
mechanisms have been unified and incorporated within one device to ensure that a peptide 
therapeutic can achieve successful absorption within the gastrointestinal tract. 
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The administration frequency of the OGDD device will be highly dependent of the disease 
state of the patient, the peptide therapeutic that is being administered and the achievable 
pharmacokinetic parameters through customization of the OGDD device. The customization 
of the OGDD device can be achieved in two unique processes whereby the pH responsive 
hydrogel can be synthesized to swell faster or be more sensitive to a pH profile and the 
Avicel®-EDTA-mPEG in situ hot melt dispersion can be modified to administer greater 
amounts of chelatory compounds within the localized environment. Additionally, the length 
and width of the non-responsive shell component can be easily adjustable to the needs of a 
specific application.  
 
The oral administration of salmon calcitonin from the Oral Ghost Drug Delivery device was 
successfully achieved with a Cmax of ~94pg/mL, AUClast of ~7280min.pg/mL and MTDlast 
of 111min. The in vitro-in vivo correlation of salmon calcitonin was achieved at the highest 
degree when the FaSSGF-FaSSIF V2 dissolution set. This was a significantly better 
improvement over the utilization of USP pH 1.2-USP pH 6.8 dissolution set.  
 
7.2. Recommendations 
 
The in vivo Cmax is much lower than the parentally administered salmon calcitonin of 
~245pg/mL which can be overcome by increasing the loaded salmon calcitonin dosage in 
the Oral Ghost Drug Delivery device. The utilization of biorelevant dissolution fluid to 
generate tighter in vitro-in vivo correlations when analysing novel or innovative drug delivery 
systems should be pursued to increase the predictability of the drug delivery system within 
the in vivo environment. Additionally, it should be noted that there is substantial differences 
within the gastrointestinal environment across animal species and these differences should 
be characterized as fully as possible, in order to reduce the usage of animals for in vivo 
analysis.  
 
An in situ hot melt dispersion of a thermally stable drug within mPEG 2000 is a novel method 
for obtaining an easy to prepare homogenously distributed dosage form. A metal chelatory 
compound was utilized in this work because a non-specific metal chelatory can enhance the 
paracellular transport of a peptide therapeutic and reduce the activity of intraluminal small 
intestine peptidases. A variety of metal chelators, that are thermostable and chelate specific 
ions could be utilized instead of EDTA to achieve a more specific inhibition of a peptidase 
subspecies. Or specific chelatory compound that has demonstrated significant potential to 
open tight junctions can also be included within the hot melt dispersion. A hot melt 
189 
 
dispersion is highly desirable within the industrial setting because a more homogenous 
distribution of a drug entity can be achieved and a reduction in solvents are employed. An 
extension of this novel approach could be the inclusion of a specific thermal stable 
compound, that is not chelatory in nature, which can reduce the presystemic metabolism of 
the peptide therapeutic, could offer significant benefit to this application. The advantage of 
including Avicel® with these formulations is the enhancement of the physicomechanical 
properties of the in situ hot melt dispersion as often a polymeric material that can undergo 
melting in a stable manner, does not produce a solid dosage form that can be resilience to 
handling or transportation. The physicomechanical influence of including alternative 
chelatory or peptidase inhibitory compounds should be investigated before applying the 
approaches because the alternative API could alter the physicomechanical properties 
significantly. Lastly, alternative polymeric materials that can undergo stable melting should 
be investigated that may enhance the dissolution of the chelatory compound within the small 
intestinal tract in some beneficial manner. This could either be a more localized dissolution 
of the chelatory compound or a more advantageous dissolution profile of the chelatory 
compound. 
 
The inclusion of trimethyl chitosan within the OGDD device did convey significant 
advantages to the oral absorption of the peptide therapeutic. An extension of this approach 
could be the further modification of trimethyl chitosan to include a covalently bonded specific 
chelatory compound that has the potential to reduce the activity of a peptidase subspecies 
that is particularly active against the administered peptide therapeutic entity. This would 
increase the effective amount of active peptide therapeutic within a localized environment. If 
this approach is pursued, the formulation scientist should be very vigilant that the significant 
benefits of this polymeric material are not lost during the modification reaction. The peptide 
therapeutic could also be entrapped within nanosized particles and then suspended within a 
matrix of trimethyl chitosan. The nanonized particles could increase the absorption of the 
peptide therapeutic within the in vivo environment and enhance the half life of the peptide 
therapeutic within the systemic circulation, hence augmenting the pharmacological 
properties of the peptide therapeutic. The generation of an solid oral dosage form that 
utilizes nanonized particle may cause the nanonized particles to be disrupted and facilitate a 
limited advantage. Additionally, the greater the processing that a peptide therapeutic is 
subjected to, the greater probability that the peptide therapeutic will loss activity due to the 
highly sensitive nature of these compounds.     
 
Lastly, the inclusion of an additional small molecular weight drug within the swellable trigger 
mechanism of the OGDD device could be utilized to enhance the treatment of a chronic 
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condition or enhance the treatment of comorbidity. The main issue of this approach is 
ensuring that the inclusion of a small molecular weight drug does not induce significant or 
unexpected physicomechanical alternations to the swellable trigger mechanism. Altered 
physicomechanical properties of the swellable trigger mechanism could cause the device to 
fail in its primary purpose of delivering a peptide therapeutic within a targeted location in the 
small intestine. Additionally, the small molecular weight drug should not cause a drug-drug 
interaction or negatively influence the abilities of the chelatory compound. Often, small 
molecular weight drugs are stabilized as a salt variant which could increase the availability of 
monovalent or divalent metal ions within the targeted drug location. This may cause a 
reduced chelatory potential and by causal effect allow the peptidase enzymes to retain full 
activity or reduce the paracellular transport rate of the peptide therapeutic within the 
systemic circulation. These issues could be overcome with the utilization of specific 
chelatory compounds or by exploiting a small molecular weight drug that has not been 
stabilized with a metal ion. 
   
7.3. Future Outlook 
 
The OGDD device is a significant step to administering peptide therapeutics to the oral route 
without utilizing intra-abdominal surgery during in vivo studies. With further refinement, the 
device could easily be translated into human subjects after careful examination of any 
potential toxicity and significant clinical trial data. The device offers the patient an alternative 
to parenteral administration that may benefit the therapeutic outcome of chronic conditions 
or acute conditions (e.g. administration of vaccines). The OGDD device has a high 
customizable potential that could be augmented to achieve the successful oral 
administration of many biopharmaceuticals within targeted locations in the gastrointestinal 
tract. This will become increasingly important as greater quantities and variants of 
biopharmaceuticals become clinically certified for treatment of human conditions.  
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Appendix 2 
Punch and Die Mechanism Part Schematics 
The punch and die mechanism was manufactured as a specialised tooling to produce mini-
pellets with a diameter of 4cm and a variable length. In addition, the specialised mini-pellet 
punch and die mechanism allowed for variable compression force to be applied to the pellets 
which could be monitored using the hydraulic force gauge which was utilised to generate 
mini-pellets under a uniform pressure. The punch and die mechanism was manufactured 
from stainless steel so that the mechanism could be cleaned easily. The punch and die 
mechanism contains seven parts that assemble into a complete unit that can be used with 
any table top tableting press. Each part is represented within the schematics below with the 
appropriate size.   
 
Punch and Die Mechanism 
Part and schematic Function 
 
Stainless steel funnel 
 
 
 
 
 
 
Stainless steel funnel was designed and 
manufactured to allow accurately weighted 
powders to be dispensed within the die. 
 
Stainless steel base plate 
 
 
 
 
 
Stainless steel base plate was designed and 
manufactured to allow stabilisation of the 
bottom punch after the punch and die 
mechanism had been assembled 
 
 
Stainless steel bottom sheath 
 
 
 
 
 
 
Stainless steel bottom sheath was designed 
and manufactured to allow stabilisation of the 
bottom punch and die after the punch and 
die mechanism had been assembled 
Stainless steel top sheath 
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Stainless steel top sheath was designed and 
manufactured to allow stabilisation of the top 
punch and die after the punch and die 
mechanism had been assembled 
 
Stainless steel die 
 
 
 
 
Stainless steel die was designed and 
manufactured to allow production of mini-
pellets at varying lengths. 
 
 
Stainless steel bottom punch 
 
 
 
 
 
Stainless steel bottom punch was designed 
and manufactured to allow production of 
mini-pellets at varying lengths. 
 
 
Stainless steel top punch 
 
 
 
 
 
Stainless steel top punch was designed and 
manufactured to allow production of mini-
pellets at varying lengths. 
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The punch and die mechanism was assembled as represented in the schematics below. 
Each part was precisely cut and measured so that each component fitted within the the 
assembly to generate an air tight seal (prevention of contaminatnes once the punch and die 
mechanism was assembled). The punch and die parts were first aligned [A]. The bottom 
sheath was placed on top of the base plate as the structural support for the mechanism [B]. 
The bottom punch was inserted into the base plate and bottom sheath which effectively 
“locked” the components together [C]. The die was fitted over the bottom punch and within 
the bottom sheath [D]. The punch and die at this point would be ready for the addition of a 
powder formulation that was poured through the funnel to prevent the loss of any powder [E]. 
The funnel would be removed and the top punch inserted into the die [F]. Finally the top 
sheath would be fitted over the die to generate an airtight seal and to stabilise the top punch 
agaist the compression force excerted by the tableting press [G]. The punch and die 
mechanism would be placed within a table press, exposed to the desired compression 
(under 1 metric tonns) and the mini-pellet would thereafter be retrieved by disassembling the 
punch and die. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] [B] [C] 
[D] [E] [F] 
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[G] 
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Appendix 3 
Powdered X-Ray Diffraction of Hydrogel Formulations 
 
Hydrogel Formulation 1 
 
Hydrogel Formulation 2 
 
Hydrogel Formulation 3 
 
Hydrogel Formulation 4 
 
Hydrogel Formulation 5 
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Hydrogel Formulation 6 
 
Hydrogel Formulation 7 
 
Hydrogel Formulation 8 
 
Hydrogel Formulation 9 
 
Hydrogel Formulation 10 
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Hydrogel Formulation 11 
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Appendix 4 
Gravimetric swelling studies of the stimuli responsive hydrogel in biorelevant media 
 
Hydrogel Formulation 2 
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Red dots: USP pH 1.2 
Blue dots: USP pH 6.8 
Pink dots: Millipore
®
 water 
 
Red dots: FaSSIF V2 
Blue dots: FeSSIF V2 
Pink dots: FaSSGF pH 1.6 
 
Red dots: FaSSGFc pH 6.5 
Blue dots: FaSSIFc pH 7.5 
Pink dots: FaSSGFc pH 1.5 
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Hydrogel Formulation 6 
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Hydrogel Formulation 8 
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Red dots: USP pH 1.2 
Blue dots: USP pH 6.8 
Pink dots: Millipore
®
 water 
 
Red dots: FaSSGFc pH 6.5 
Blue dots: FaSSIFc pH 7.5 
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Red dots: USP pH 1.2 
Blue dots: USP pH 6.8 
Pink dots: Millipore
®
 water 
 
Red dots: FaSSIF V2 
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Red dots: FaSSGFc pH 6.5 
Blue dots: FaSSIFc pH 7.5 
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Appendix 5 
 Distance-Time Studies of the Stimuli Responsive Hydrogel against a Constant Force 
of 0.01 N 
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Appendix 6 
Drug Dissolution of 4-Aminosalcylic Acid within Biorelevant Dissolution Fluid and 
USP Dissolution Fluid 
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Appendix 7 
Dissolution Modeling of the Stimuli Responsive Hydrogel 
 
4-Aminosalcylic acid 
Model Equation R
2 adjusted
 
USP pH 1.2 
Peppas-Sahlin               0.9944 
USP pH 6.8 
Weibull 
           
        
         
0.9971 
FaSSGF pH 1.6 
Weibull 
           
 
               
       
 
  
0.9985 
FaSSIF V2 
Weibull 
            
 
                 
      
 
  
0.9985 
FeSSIF V2 
Weibull 
            
 
                 
      
 
  
0.997 
FaSSGFc pH 1.5 
Weibull 
            
        
         
0.989 
FaSSGFc pH 6.5 
Weibull 
            
        
        
0.9982 
FaSSIFc pH 7.5 
Weibull 
           
        
        
0.9844 
 
Ciprofloxacin 
Model Equation R
2 adjusted
 
Isolated gastric fluids 
Peppas-Sahlin                    0.9906 
Isolated intestinal fluids 
Weibull 
             
                 
          
0.9943 
USP pH 1.2 
Weibull 
           
        
          
0.9991 
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FaSSGF 
Gompertz 
           
                     
 
0.9943 
FaSSGFc pH 1.6 
Logistic 
        
                     
                         
 
0.9851 
 
Indomethacin 
Model Equation R
2 adjusted
 
USP pH 1.2 
Weibull 
            
 
               
     
 
  
0.9996 
USP pH 6.8 
Weibull 
            
 
                
       
0.9972 
FaSSGF pH 1.6 
Gompertz                  
                0.9845 
FaSSIF-V2 
Weibull 
            
        
         
0.9987 
FeSSIF 
Makoid-Banakar                           0.9935 
FaSSGFc pH 1.5 
Gompertz                   
                0.9845 
FaSSGFc pH 6.5 
Weibull 
            
        
         
0.998 
FaSSIFc pH 7.5 
Weibull 
            
        
         
0.9966 
 
Metronidazole 
Model Equation R
2 adjusted
 
USP pH 1.2 
Peppas-Sahlin               0.9911 
USP pH 6.8 
Logisitic 
        
                    
                        
 
0.9974 
FaSSGF pH 1.6 
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Peppas-Sahlin               0.999 
FaSSIF V2 
Probit                               0.996 
FeSSIF V2 
Weibull 
           
        
        
0.9967 
FaSSGFc pH 1.5 
Gompertz                    
                0.9809 
FaSSGFc pH 6.5 
Logisitic 
        
                   
                       
 
0.9942 
FaSSIFc pH 7.5 
Weibull 
           
        
        
0.9927 
 
Sulfamethoxazole 
Model Equation R
2 adjusted
 
USP pH 1.2 
Gompertz                    
               0.9965 
USP pH 6.8 
Weibull 
          
 
                   
               
 
 
0.9893 
FaSSGF 
Weibull 
            
        
              
0.9957 
FaSSIF 
Weibull 
            
 
                 
       
 
  
0.9961 
FeSSIF V2 
Gompertz                   
                0.9971 
FaSSGFc pH 1.5 
Weibull 
            
 
                 
            
 
  
0.9881 
FaSSGFc pH 6.5 
Weibull 
            
 
               
       
 
  
0.9976 
FaSSIFc pH 7.5 
Weibull 
            
       
         
0.9917 
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Zidovudine 
Model Equation R
2 adjusted
 
USP pH 1.2 
Makoid-Banakar                          0.9934 
USP pH 6.8 
Weibull 
           
        
        
0.9951 
FaSSGF 
Makoid-Banakar                           0.9967 
FaSSIF V2 
Probit                               0.9838 
Theophylline 
Model Equation R
2 adjusted
 
Isolated gastric fluids 
Peppas-Sahlin                           0.9993 
Isolated intestine fluids 
Logistic 
         
                      
                         
 
0.9954 
USP pH 1.2 
Peppas-Sahlin              0.9983 
USP pH 6.8 
Weibull 
           
       
        
0.9989 
FaSSGF 
Makoid-Banakar                           0.9949 
FaSSIF V2 
Weibull 
           
        
        
0.9983 
FeSSIF V2 
Weibull 
            
        
        
0.9914 
FaSSGFc pH 1.5 
Makoid-Banakar                          0.9873 
FaSSGFc pH 6.5 
Probit                               0.9967 
FaSSIFc pH 7.5 
Peppas-Sahlin               0.9958 
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FeSSIF 
Weibull 
           
        
         
0.9967 
FaSSGFc pH 1.5 
Peppas-Sahlin               0.9976 
FaSSGFc pH 6.5 
Weibull 
           
        
         
0.9956 
FaSSIFc pH 7.5 
Weibull 
           
        
        
0.996 
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Appendix 8  
Fitted Regression Curves of Insulin Formulations Generated From Box-Benkin Design 
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Formulation 1 Formulation 2 
Formulation 3 Formulation 4 
Formulation 5 Formulation 6 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9957) 
Makoid-Banakar (R
2 adjusted
:0.9918) 
Logistic (R
2 adjusted
:0.974) 
Peppas-Sahlin (R
2 adjusted
:0.9921) 
Weibull (R
2 adjusted
:0.9918) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9942) 
Makoid-Banakar (R
2 adjusted
:0.9866) 
Weibull (R
2 adjusted
:0.9855) 
Weibull (R
2 adjusted
:0.9925) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9939) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.992) 
Makoid-Banakar (R
2 adjusted
:0.9936) 
Weibull (R
2 adjusted
:0.995) 
Weibull (R
2 adjusted
:0.9944) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.977) 
Makoid-Banakar (R
2 adjusted
:0.9771) 
Weibull (R
2 adjusted
:0.9918) 
Weibull (R
2 adjusted
:0.9944) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9718) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9742) 
Makoid-Banakar (R
2 adjusted
:0.9609) 
Weibull (R
2 adjusted
:0.9991) 
Weibull (R
2 adjusted
:0.9989) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9955) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.983) 
Makoid-Banakar (R
2 adjusted
:0.9242) 
Weibull (R
2 adjusted
:0.9983) 
Weibull (R
2 adjusted
:0.9989) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9879) 
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Formulation 7 Formulation 8 
Formulation 9 Formulation 10 
Formulation 11 Formulation 12 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9921) 
Makoid-Banakar (R
2 adjusted
:0.9905) 
Weibull (R
2 adjusted
:0.9872) 
Weibull (R
2 adjusted
:0.9847) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9141) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9925) 
Makoid-Banakar (R
2 adjusted
:0.9117) 
Weibull (R
2 adjusted
:0.9624) 
Weibull (R
2 adjusted
:0.9357) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9901) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9557) 
Makoid-Banakar (R
2 adjusted
:0.9803) 
Weibull (R
2 adjusted
:0.9817) 
Weibull (R
2 adjusted
:0.9812) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9904) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9674) 
Makoid-Banakar (R
2 adjusted
:0.9461) 
Weibull (R
2 adjusted
:0.9996) 
Weibull (R
2 adjusted
:0.9996) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.991) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9898) 
Makoid-Banakar (R
2 adjusted
:0.9609) 
Weibull (R
2 adjusted
:0.9655) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9879) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9872) 
Makoid-Banakar (R
2 adjusted
:0.9222) 
Weibull (R
2 adjusted
:0.9374) 
Peppas-Sahlin with Tlag (R
2 adjusted
:0.9825) 
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Formulation 13 Formulation 14 
Formulation 15 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9769) 
Makoid-Banakar (R
2 adjusted
:0.9241) 
Weibull (R
2 adjusted
:0.9365) 
Peppas-Sahlin (R
2 adjusted
:0.9845) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9841) 
Makoid-Banakar (R
2 adjusted
:0.9305) 
Weibull (R
2 adjusted
:0.9432) 
Peppas-Sahlin (R
2 adjusted
:0.9876) 
Makoid-Banakar with Tlag (R
2 adjusted
:0.9963) 
Makoid-Banakar (R
2 adjusted
:0.9778) 
Weibull (R
2 adjusted
:0.967) 
Peppas-Sahlin (R
2 adjusted
:0.9964) 
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Appendix 9 
In vitro-in vivo correlation of salmon calcitonin 
 
Fasted State Simulated Gastric Fluid to Fasted State Simulated Intestinal Fluid – 
Version 2 
Dissolution fitting 
 
 
 
 
 
 
 
 
 
Correlation 
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Statistical Analysis of the Predicted Dissolution Profile 
Corrected Sum of Squared Observations: 0.269796E-01 
Sum of Squared Residuals: 0.125408E-02 
S=0.355914E-02 with 99 Degrees of Freedom 
Correlation (Observed, Predicted): 0.9771 
AIC criteria: -670.81692 
SBC criteria: -665.58668 
AUC (0 to last time) by trapezoidal rule: 5.87088 
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 Fitted Salmon Calcitonin profile 
Salmon Calcitonin observations  
R
e
le
a
s
e
 P
e
rc
e
n
t 
(%
) 
FaSSIF-V2 
Observed Fractional Release 
Fitted Fractional Release 
MDT=2.397804 (SE: 0.004302) 
B=8.09257 (SE: 0.15108) 
Corrected Sum of Squared Observations: 2.1045 
Sum of Squared Residuals: 0.256114E-03 
S: 0.565811E-02 with 8 degrees of freedom 
Correlation (Observation, Predicted): 1.00 
AIC Criteria: -78.69889 
SBC: -78.09372 
AUC (0 to last time) by trapezoidal rule: 8.00488 
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Correlation validation 
Noncompartmental Analysis Derived Fasted State Simulated Intestinal Fluid Version 2 
human model 
Parameter Units In Vivo  Fitted In Vivo 
R2  0.9919 0.9999 
R2 adjusted  0.9838 0.9999 
Correlation (X,Y)  -0.9959 -1 
Number points lambda Z  3 6 
Lambda Z 1/min 0.0123 0.0356 
Lambda Z lower min 135 105 
Lambda Z upper min 180 240 
Half Life Lambda z min 56.1973 19.4763 
Tlag min 45 0 
Tmax min 75 105 
Cmax pg/mL 93.8674 129.7717 
Cmax D pg/mL/mg 93.8674 129.7717 
Tlast min 180 240 
Clast pg/mL 28.3373 1.0802 
AUClast min*pg/mL 7281.047 7669.539 
AUCall min*pg/mL 8131.166 7669.539 
AUCINF observed min*pg/mL 9578.508 7699.892 
AUCINF D observed min*pg/mL/mg 9578.508 7699.892 
AUC %Extrap observed % 23.9856 0.3942 
Vz F observed mL 8664317 3649184 
CL F observed mL/min 104400.4 129872 
AUCINF predicted min*pg/mL 9556.405 7700.1 
AUCINF D predicted min*pg/mL/mg 9556.405 7700.1 
AUC %Extrap predicted % 23.8098 0.3969 
Vz F predicted mL 8483894 3649086 
CL F predicted mL/min 104641.9 129868.4 
AUMClast min*min*pg/mL 808258.7 848370.1 
AUMCINF observed min*min*pg/mL 1408070 856507.5 
AUMC %Extrap observed % 42.5981 0.9501 
AUMCINF predicted min*min*pg/mL 1402299 856563.3 
AUMC %Extrap predicted % 42.3619 0.9565 
MRTlast min 111.0086 110.6155 
MRTINF observed min 147.003 111.2363 
MRTINF predicted min 146.7392 111.2405 
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USP Simulated Gastric Fluid (pH 1.2) to USP Simulated Intestinal Fluid (pH 6.8) 
 
Dissolution Fitting 
 
 
 
 
 
 
 
 
 
Correlation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation Validation 
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USP pH 6.8 
Observed Fractional Release 
Fitted Fractional Release 
MDT=3.767223 (SE: 0.256742) 
B=2.048134 (SE: 0.303964) 
Corrected Sum of Squared Observations: 1.74497 
Sum of Squared Residuals: 0.379873E-01 
S: 0.689087E-01 with 8 degrees of freedom 
Correlation (Observed, Predicted): 0.9895 
AIC criteria: -28.70503 
SBC criteria: -28.09986 
AUC (0 to last time) by trapezoidal rule: 7.00278 
 
 
Corrected Sum of Squared Observations: 0.269844E-01 
Sum of Squared Residuals: 0.973580E-03 
S=0.313594E-02 with 99 Degrees of Freedom 
Correlation (Observed, Predicted): 0.9861 
AIC criteria: -696.38757 
SBC criteria: -691.15732 
AUC (0 to last time) computed by trapezoidal rule: 5.78141 
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Noncompartmental Analysis of USP Simulated Gastric Fluid to USP Simulated 
Intestinal Fluid pH 6.8 
Parameter Units In Vivo  Fitted In Vivo 
R2  0.9919 0.9912 
R2 adjusted  0.9838 0.9823 
Correlation (X,Y)  -0.9959 -0.9956 
Number points lambda Z  3 3 
Lambda Z 1/min 0.0123 0.0202 
Lambda Z lower min 135 150 
Lambda Z upper min 180 240 
Half Life Lambda z min 56.1973 34.2679 
Tlag min 45 0 
Tmax min 75 105 
Cmax pg/mL 93.8674 61.9825 
Cmax D pg/mL/mg 93.8674 61.9825 
Tlast min 180 240 
Clast pg/mL 28.3373 7.7879 
AUClast min*pg/mL 7281.047 8421.629 
AUCall min*pg/mL 8131.166 8421.629 
AUCINF observed min*pg/mL 9578.508 8806.647 
AUCINF D observed min*pg/mL/mg 9578.508 8806.647 
AUC %Extrap observed % 23.9856 4.3719 
Vz F observed mL 8464317 8664317 
CL F observed mL/min 104400.4 113550.6 
AUCINF predicted min*pg/mL 9556.405 8819.605 
AUCINF D predicted min*pg/mL/mg 9556.405 8819.605 
AUC %Extrap predicted % 23.8098 4.5124 
Vz F predicted mL 8483894 5605479 
CL F predicted mL/min 104641.9 113383.8 
AUMClast min*min*pg/mL 808258.7 981275.3 
AUMCINF observed min*min*pg/mL 1408070 1092714 
AUMC %Extrap observed % 42.5981 10.1984 
AUMCINF predicted min*min*pg/mL 1402299 1096465 
AUMC %Extrap predicted % 42.3619 10.5055 
MRTlast min 111.0086 116.5185 
MRTINF observed min 147.003 124.0783 
MRTINF predicted min 146.7392 124.3213 
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Fasted State Simulated Gastric Fluid Canine Model (pH 1.6) to Fasted State Simulated 
Intestinal Fluid Canine Model (pH 7.5) 
 
Dissolution Fitting 
 
 
 
 
 
 
 
 
Correlation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicted fitted profile 
Predicted observations  
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FaSSIFc pH 7.5 
Observed Fractional Release 
Fitted Fractional Release 
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MDT: 3.230728 (SE: 0.183034) 
B: 2.423116 (SE: 0.339031) 
Corrected Sum of Squared Observations: 1.82847 
Sum of Squared Residuals: 0.257965E-01 
S: 0.567852E-01 with 8 Degrees of Freedom 
Correlation (observed, Predicted): 0.9934 
AIC criteria: -32.57516 
SBC criteria: -31.96999 
AUC (0 to last time) by trapezoidal rule: 7.40712 
 
Statistical Analysis of the Predicted Dissolution Profile 
Corrected Sum Squared Observations: 0.269851E-01 
Sum of Squared Residuals: 0.638932E-03 
S: 0.254045E-02 with 99 Degrees of Freedom 
Correlation (Observed, Predicted): 0.9906 
AIC criteria: -738.92689 
SBC criteria: -733.69665 
AUC (0 to last time) by trapezoidal rule: 5.87147 
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Correlation validation 
Noncompartmental Analysis of Fasted State Gastric Fluid to Fasted State Simulated 
Intestinal Fluid Canine Model 
Parameter Units In Vivo  Fitted In Vivo 
R2  0.9919 0.9921 
R2 adjusted  0.9838 0.9842 
Correlation (X,Y)  -0.9959 -0.9961 
Number points lambda Z  3 3 
Lambda Z 1/min 0.0123 0.0269 
Lambda Z lower Min 135 150 
Lambda Z upper Min 180 240 
Half Life Lambda z Min 56.1973 25.7408 
Tlag Min 45 0 
Tmax Min 75 105 
Cmax pg/mL 93.8674 69.0159 
Cmax D pg/mL/mg 93.8674 69.0159 
Tlast Min 180 240 
Clast pg/mL 28.3373 4.4692 
AUClast min*pg/mL 7281.047 8359.044 
AUCall min*pg/mL 8131.166 8359.044 
AUCINF observed min*pg/mL 9578.508 8525.014 
AUCINF D observed min*pg/mL/mg 9578.508 8525.014 
AUC %Extrap observed % 23.9856 1.9469 
Vz F observed mL 8664317 4356143 
CL F observed mL/min 104400.4 117301.9 
AUCINF predicted min*pg/mL 9556.405 8532.059 
AUCINF D predicted min*pg/mL/mg 9556.405 8532.059 
AUC %Extrap predicted % 23.8098 2.0278 
Vz F predicted mL 8483894 4352546 
CL F predicted mL/min 104641.9 117205 
AUMClast min*min*pg/mL 808258.7 968563.9 
AUMCINF observed min*min*pg/mL 1408070 1014560 
AUMC %Extrap observed % 42.5981 4.5336 
AUMCINF predicted min*min*pg/mL 1402299 1016513 
AUMC %Extrap predicted % 42.3619 4.717 
MRTlast Min 111.0086 115.8702 
MRTINF observed Min 147.003 119.0098 
MRTINF predicted Min 146.7392 119.1404 
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Appendix 10 
Front Pages of Publications 
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